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Abstract 
Keloids are fibroproliferative scars that form in response to abnormal healing processes. The 
extracellular matrix (ECM) remodelling of the dermis in the maturation phase of normal wound 
healing is insufficient in keloids, leading to excessive ECM proteins being deposited in the 
granulation tissue. Keloid scars are unique to humans, and show increased prevalence in 
darker skin types. Current treatments rarely lead to permanent regression, and despite decades 
of study, the key molecular processes responsible for keloid scarring are still largely elusive. 
The research presented in this thesis aims to investigate markers of keloid scars, and to 
examine the impact of both the dermis and epidermis in keloid pathogenesis. 
 
Histological examination of the keloid scars showed a thickened epidermis and densely 
collagenous dermis, both of which demonstrated a higher level of cell proliferation and 
myofibroblast expression, as compared to normal skin. Differences between the central and 
marginal regions of the scars were also noted. Protein expression patterns of Matrix 
Metalloproteinases (MMPs) 1, 2, 13 and 14 were examined in formalin fixed paraffin embedded 
biopsies from the same keloids (n=10) and healthy skin (n=9). MMPs 2 and 14 showed a 
distinct pattern of protein expression across the central, marginal, and adjacent non-keloid 
regions of the scar. In the dermis, MMP2 and 14 were most evident at the leading edge, 
whereas the epidermis revealed a strong but variable pattern along all regions. This was in 
contrast to healthy skin, where expression in both epidermis and dermis was much lower 
overall, and showed a more uniform pattern across the tissue. 
 
Gene expression levels of key ECM and adhesion molecules, as well as select target genes 
across 10 signal transduction pathways, were analysed through Real-Time qPCR in keloid 
scars and healthy control skin from unaffected individuals (n=5). MMPs 1, 13 and 14 gene 
expression levels were significantly increased by 52, 24, and 3-fold respectively in keloid, 
compared to normal tissue. SPP1 and SPARC were also upregulated by 29.6 and 9.2-fold 
respectively, in keloid tissue. Hedgehog and Wnt pathway target genes were significantly 
altered in keloid tissue, with WISP1 and VEGFA being overexpressed by 10 and 2-fold 
respectively, and BMP2 and BMP4 underexpressed by 5 and 3.7-fold respectively. 
 
Eighteen of the most altered of these 168 genes were examined further in primary cultured 
fibroblasts (n=6) and keratinocytes (n=4), from both keloid and healthy control skin. Gene 
expression profiles appeared complementary between fibroblast and keratinocyte cell-types, 
either of which did not necessarily match the gene expression profiles demonstrated earlier in 
whole tissue. This might be due to the epidermal and dermal cells being in isolation from each 
other, and therefore 3D culture containing both cell-types would be more representative of the 
original tissue environment. SPP1 was the only gene that consistently showed significant over-
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expression in whole tissue and primary keloid cells. Protein expression levels of SPP1 
appeared increased in keloid tissue compared to normal skin, particularly in the basal epidermis 
and edge dermis of the keloid scars. 
 
In summary, a high level of inter-patient variability was observed throughout all biomarker 
investigations, though the leading edge of all keloids consistently appeared to be the most 
active region. The consistent detection of changes in expression SPP1 indicates a potential role 
for osteogenic-linked signalling in the fibrotic nature of keloid scarring. 
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1.1 Human Skin 
The skin is a large, complex organ consisting of 17% of the body’s weight, which 
provides an essential barrier for the body against the environment, giving 
protection against mechanical stress and invasion of pathogens (Farage et al., 
2010, Simpson et al., 2011). Skin protects the body from water loss and 
temperature change, as well as providing sensory roles, vitamin D synthesis, 
immune surveillance and excretion of wastes through sweat glands (Farage et al., 
2010). The two major compartments in skin are the epidermis, and the dermis 
(Figure 1-1).  
 
1.1.1 Epidermis 
The epidermis is a multi-layered epithelium consisting of a terminally 
differentiated stratified squamous epithelium, which has to maintain equilibrium 
between cell proliferation and death. Keratinocytes are the main cell type in the 
epidermis, making up 95% of the skin’s cell population. Other cell types within the 
epidermis include melanocytes which provide pigmentation to skin and hair, 
Langerhans cells which function immunologically, and Merkel cells which are 
sensory receptor cells (Farage et al., 2010). 
 
The epidermis consists of five specialized layers: the stratum basale (basal layer), 
and the suprabasal layers incorporating the stratum spinosum (spinous layer); 
stratum granulosum (granular layer); stratum lucidum (clear cell layer); and the 
outermost layer stratum corneum (cornified layer) (Figure 1-1). Keratinocytes 
proliferate and form a stratified squamous epithelium made of flattened 
(squamous) epithelial cells which migrate from the undifferentiated basal epithelia 
to the terminally differentiated stratified squamous of the external layer of the 
skin. During this process called keratinisation, the keratinocytes increase in size 
and then flatten, as they differentiate out (Farage et al., 2010, McGrath et al., 2004). 
The basal layer keratinocytes synthesise keratins K5 and K14, whereas the 
intermediate suprabasal layers express K1 and K10, allowing for clear 
differentiation between the two populations (Markey et al., 1992, Leigh et al., 
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1993, Blanpain and Fuchs, 2006, Fuchs, 1990). In the granular layer, keratinocytes 
begin to lose their nuclei, and dense cytoplasmic granules form, containing 
profilaggrin – the precursor to the interfilamentous protein filaggrin. Loricrin and 
involucrin are additional proteins expressed in this epidermal layer (Fuchs, 1990, 
McGrath et al., 2004). The stratum lucidum is a thin layer of clear cells, 
transluscent under a microscope. This layer functions as a waterproof layer 
between the two most differentiated epidermal layers (McGrath et al., 2004). Once 
cells transition to granular cells, they collapse into a flattened shape, and express 
filaggrin. 
 
Epidermal stem cells reside in the basal layer of the epidermis, as well as the bulge 
region of hair follicles, where they maintain homeostasis in skin, by regenerating 
and repairing hair and the epidermis post-injury (Alberts, 2008, McGrath et al., 
2004). The stem cells in the hair follicle can give rise to the eight differentiated cell 
types within the hair follicle: Outer Root Sheath (ORS), Companion layer of the 
ORS, Henle, Huxley layers of the Inner Root sheath (IRS) plus the IRS Cuticle, 
Cortex of the hair fibre and hair fibre cuticle and finally hair follicle germinative 
epithelium (Owens and Watt, 2003, Youssef et al., 2010). 
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Figure 1-1 Structure of human skin 
Human skin is composed of the epidermis, the dermis, and adipose tissue. Within the 
epidermis, there is the basal layer and four suprabasal layers of keratinocytes. The 
suprabasal layers include the spinous layer, granular layer (stratum granulosum), 
stratum lucidum (clear cell layer – not visible here), and the stratum corneum 
(cornified layer). The dermis is made up of extracellular matrix (ECM) molecules, 
lymphatic and blood vessels, immune cells and fibroblasts.  Adapted from (Pasparakis 
et al., 2014). 
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1.1.2 Dermis  
The dermis, also known as the stromal tissue, is mainly made up of connective 
tissue containing various extracellular matrix (ECM) components, immune and 
inflammatory cells, as well as fibroblast cells.  The dermis is traversed by blood 
and lymphatic vessels as well as nerves (Rinn et al., 2006). The dermal-epidermal 
junction (or basement membrane) is undulating with epidermal ridges, rete ridges, 
projecting into the dermis. This provides not only mechanical support for the 
epidermis, but also is a barrier against the exchange of molecules and cells 
(McGrath et al., 2004).  Below the dermis, but not strictly part of the skin, is a fatty 
layer of adipose, the subcutaneous layer. 
 
There are three major components to the dermis ECM: collagen, elastin and 
hyaluronic acid (hyaluronan; HA) (Farage et al., 2010). Dermal fibroblasts can 
synthesise components of the ECM and basement membrane proteins such as 
collagen, fibronectin, laminin and elastin. Epithelial cells depend on this stroma for 
their organisation (Farage et al., 2010, Ghaffari et al., 2009a, Bremnes et al., 2011). 
Within the dermis and adipose tissue there is also a number of appendages, 
including hair follicles, sebaceous glands, sweat glands and nails. Each of these 
contribute to a number of critical functions of the skin (Farage et al., 2010). 
 
1.1.2.1 Fibroblasts 
Fibroblasts are mesenchymal cells and a member of the connective tissue family of 
cells.  They are non-vascular, non–epithelial and non-inflammatory cells.  
Fibroblasts were first described in the late 19th century based upon their location 
and morphology (Kalluri and Zeisberg, 2006).  They play a vital role during 
development of organs such as skin, eyes, lungs, and then later play a supportive 
and structural role in the body.  Fibroblasts are important in maintaining 
homeostasis of adjacent epithelium through the secretion of growth factors.  
During processes such as wound healing, fibroblasts are activated and produce 
matrix degrading enzymes, cytokines and epithelial growth factors. Collagen types 
I, III, IV and V, fibronectin, and MMPs are some of the constituents of the ECM that 
fibroblasts are responsible for producing (Kalluri and Zeisberg, 2006, Bierie and 
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Moses, 2006).  Fibroblasts are consistently spindle shaped even when the cells 
originate in different anatomical sites (Chang et al., 2002, Krtolica and Campisi, 
2002).  Despite their morphological similarities, fibroblasts originating from these 
independent sites all have diverse gene expressions (Rinn et al., 2006, Kalluri and 
Zeisberg, 2006).  However, as members of the connective tissue family of cells they 
are characterised by the expression of the intermediate filament Vimentin. 
 
1.1.2.2 Collagens: Fibril forming  
The collagens are a large family of 28 ECM triple helical proteins that are 
distributed across many tissue types in the body (Ricard-Blum, 2011, Söderhäll et 
al., 2007). Depending on the development stage, and the tissue type, collagen fibril 
lengths range between 12nm and over 500nm (Kadler et al., 2007). They have a 
wide range of functions including providing tissue structure, aiding cell adhesion 
and migration, angiogenesis, tissue repair, and tissue remodelling (Gordon and 
Hahn, 2010, Kadler et al., 2007, Ricard-Blum, 2011). Based on their 
supramolecular assemblies (as observed through electron microscopy), collagens 
have been categorized into subfamilies: fibril-forming, fibril-associated with 
interrupted triple helices (FACITs), beaded filaments, anchoring fibrils, 
transmembrane collagens, and network-forming (Ricard-Blum, 2011, Kadler et al., 
2007). 
 
Fibril-forming collagens have a primary role in contributing to the architecture 
and mechanical properties of tissues, and are synthesized as procollagens with N- 
and C-propeptides at either end of the triple helical region (Kadler et al., 2007, 
Ricard-Blum, 2011). Specific pro-collagen proteinases cleave off the N- and C-
propeptides, revealing telopeptides (non-triple helical extensions of the protein 
chains). This enables fibrillogenesis, via binding sites within the telopeptides to 
form covalent cross-links with residues in the triple helix domain (Ricard-Blum, 
2011, Prockop and Fertala, 1998). Most collagen fibrils consist of multiple collagen 
types, lending the term “heterotypic”. The most abundant collagen is fibril-forming 
collagen I, making up more than 90% of bone mass, and providing crucial 
biomechanical properties including tensile strength and torsional stiffness(Gelse et 
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al., 2003). Collagen I is also the major collagen in a range of other tissues including 
tendons, skin, cartilage, ligaments, and the cornea (Gelse et al., 2003). Collagen I is 
usually formed as a heterotrimer (two identical α1(I)-chains and one α2(I)-chain), 
though it can be found as a homotrimer (three α1(I)-chain) (Gelse et al., 2003, 
Ricard-Blum, 2011). In normal skin, collagen triple helical fibrils are usually part of 
composite fibres containing type III collagen, whereas in cartilage the common 
combinations are types II with XI and IX, or type II with III (Ricard-Blum, 2011, Wu 
et al., 2010, Bruckner, 2010, Fleischmajer et al., 1990). In bone, tendon or the 
cornea, collagen I as well as collagen III can be found to incorporate into fibres 
containing collagen type V (Gelse et al., 2003, Niyibizi and Eyre, 1989). Non-
collagenous macromolecules such as fibronectin, proteoglycans, or integrins, as 
well as other collagens containing large non-collagenous domains such as collagen 
V, are thought to help regulate fibrillogenesis by influencing collagen assembly and 
growth (Ricard-Blum, 2011, Wenstrup et al., 2004, Kalamajski and Oldberg, 2010, 
Gelse et al., 2003, Fessler et al., 1985).  
 
1.1.2.3 Collagens: Fibril-Associated with Interrupted Triple Helices (FACIT)  
Fibril-Associated Collagens with Interrupted Triple helices, or FACITs, such as 
collagens IX, XII and XIV, are shorter collagens and do not form fibrils on their own. 
The collagenous domains of these structures are interrupted with short non-
helical domains, and are associated with the surfaces of other collagen fibrils 
(Gelse et al., 2003). Collagens XII and XIV covalently crosslink to collagen I-
containing fibrils, whereas collagen IX covalently links to collagen II-containing 
fibrils (Ricard-Blum, 2011, Amenta et al., 2005, Olsen, 1997). One unique FACIT, 
collagen XVI, can integrate itself into distinct suprastructural aggregates, 
depending on the tissue context. In the papillary dermis of the skin for example, it 
crosslinks with and integrates into specialised microfibrils containing fibrillin-1 
(Kassner et al., 2003). Whereas in cartilage, collagen XVI does not integrate into 
fibrillin-1 containing microfibrils, but instead crosslinks with weakly banded 
collagen fibrils containing collagens II and XI (Kassner et al., 2003, Ricard-Blum, 
2011). 
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1.1.2.4 Collagens: Beaded filaments and anchoring fibrils 
Collagen VI forms beaded filaments, making structural links with cells. Collagen VI 
monomers crosslink into tetramers which then assemble into long microfibrils, 
leading to the appearance of a beaded repeat every 105nm (Kadler et al., 2007). 
Together with collagen VII anchoring fibrils, collagen VI connects the epidermis to 
the dermis, playing an important role in the basement membrane (Ricard-Blum, 
2011, Gordon and Hahn, 2010). 
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1.2 Normal cutaneous wound healing 
Cutaneous wound healing is a complex response to injury, which aims to restore 
skin integrity and function as efficiently as possible.  It is a highly organised and 
dynamic process of interactions between numerous cell-types, extracellular matrix 
and signalling molecules. Four precisely and highly programmed phases are 
observed (Figure 1-2 and 1-3) (Guo and Dipietro, 2010, Mathieu et al., 2006): 
haemostasis (immediately post-injury) (Guo and Dipietro, 2010); inflammation (2-
5 days) (Guo and Dipietro, 2010, Gosain and DiPietro, 2004, Broughton et al., 
2006a, Campos et al., 2008); proliferation and re-epithelialisation (2 days – 3 
weeks) (Campos et al., 2008, Guo and Dipietro, 2010, Gosain and DiPietro, 2004); 
and tissue remodelling (3 weeks to 2 years or more) (Guo and Dipietro, 2010, 
Wolfram et al., 2009). Increasingly, these phases of wound healing are thought to 
be overlapping, and not necessarily distinct from each other (Figures 1-2 and 1-
3). 
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Figure 1-2 The phases of wound healing 
Three of the four main phases in wound healing are shown here: after hemostasis, the 
inflammatory phase, proliferation and re-epithelialisation phase, and the maturation 
or tissue remodelling phase. These three phases are often overlapping, and not always 
distinct from each other. Adapted from (Darby et al., 2014) 
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Figure 1-3 Normal wound healing phases 
Normal wound healing comprises of three stages after the initial hemostasis. (a) Clot 
formation and inflammatory infiltration occurs from 2 days post-injury. (b) Granulation 
tissue formation and re-epithelialisation during the proliferation phase, occurs 2-10 
days post-injury. (c) Once integrity of the epithelial layer is restored, the granulation 
tissue matures into a scar. Tissue remodelling can last for up to 2 years post-injury. 
Adapted from (Gurtner et al., 2008b) 
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1.2.1 Haemostasis and inflammation 
After the initial bleeding, vascular constriction occurs, followed by blood 
coagulation and platelet aggregation. These lead to the formation of a temporary 
clot and restoration of haemostasis (Guo and Dipietro, 2010, Broughton et al., 
2006b). Potent vasoconstrictors thromboxane A2 and prostaglandin 2-α are 
released shortly after injury, after which the clotting cascade is activated. The clot 
that forms is made up of collagen, platelets, thrombin and fibronectin which all 
together initiate an inflammatory response (Witte and Barbul, 1997). The clot also 
protects against invasion of microorganisms and provides a substrate for 
migration of fibroblasts, monocytes, neutrophils, and endothelial cells to infiltrate 
this temporary scaffolding (Broughton et al., 2006b, Kurkinen et al., 1980). Pro-
inflammatory factors are released at this stage, to initiate the inflammatory 
response (Broughton et al., 2006b). Platelet migration is promoted by the release 
of EGF (epidermal growth factor), PDGF (platelet derived growth factor), and TGF-
β (transforming growth factor); macrophages infiltration is stimulated by the 
release of FGF (fibroblast growth factor), ILs (interleukins) 1, 2, 6 and 8, PDGF, 
TNF (tumour necrosis factor), and TGF-α; and fibroblasts and keratinocytes are 
attracted by IFNs (interferons) α, β, and γ, KGF (keratinocyte growth factor), as 
well as TGF- α and β (Broughton et al., 2006b, Henry and Garner, 2003, Lawrence 
and Diegelmann, 1994). 
 
Infiltrating neutrophils help to clear up any invading microbes and cellular debris 
(Guo and Dipietro, 2010, Gosain and DiPietro, 2004, Broughton et al., 2006a, 
Campos et al., 2008). Then macrophages and leukocytes infiltrate the area to 
prepare the wound bed for the next phase of healing. Macrophage activation is 
important as these cells mediate angiogenesis, fibroplasia and synthesise nitric 
oxide (Witte and Barbul, 2002). They also release numerous cytokines which then 
stimulate fibroblast infiltration and further wound debridement (Broughton et al., 
2006b). 
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1.2.2 Proliferation and re-epithelialisation 
Re-epithelialisation, angiogenesis, collagen deposition, and granulation tissue 
formation are the key events in the later stages of wound healing. If the basement 
membrane has been destroyed, epithelial cells at the edges of the wound begin 
proliferating and migrating, thereby causing wound contraction and eventually re-
establishing the protective barrier (Lawrence and Diegelmann, 1994, Grotendorst 
et al., 1989). TNF-α stimulates endothelial cell migration and capillary formation. 
Angiogenesis is critical to supply oxygen, nutrients and circulating growth factors, 
required for local cellular metabolism. Without this, the granulation tissue will not 
form properly, and can result in chronically unhealed wounds. Local fibroblasts 
synthesise and secrete KGF and IL-6 which further stimulate neighbouring 
keratinocytes to migrate to the wound area, proliferate and differentiate into a 
newly formed epidermis (Smola et al., 1993, Xia et al., 1999, Broughton et al., 
2006b). 
 
For granulation tissue formation, fibroblasts and keratinocytes are recruited to the 
wound area where, alongside more mature immune cells, they secrete growth 
factors such as TGF-beta and EGF, and synthesize temporary ECM components. 
These include fibronectin, vitronectin, laminin, and collagen (mainly type III) 
(Campos et al., 2008, Guo and Dipietro, 2010, Gosain and DiPietro, 2004). 
Fibroblasts already located in the wound site begin to be activated into 
myofibroblasts, as they acquire smooth muscle cell characteristics, and express α-
SMA (Darby et al., 2014). These myofibroblastic cells show contractile properties, 
with α-SMA being present in microfilament bundles and stress fibers. Other 
related proteins have also been found to be expressed in myofibroblasts, including 
desmin, cytoglobin, and transgelin, however α-SMA is thought to be the most 
reliable marker for this cell type (Tomasek et al., 2002). The main function of 
myofibroblasts is to synthesise ECM components, in order to eventually replace 
the temporary matrix of the granulation tissue, and begin the remodelling phase of 
wound healing (Hinz and Gabbiani, 2003).  
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1.2.3 Tissue remodelling 
In the final scar maturation stages, which can last between a few days and up to 2 
years post-injury, there is an attempt to recover normal tissue structure. The ECM 
is re-organised through the replacement of less resilient ECM proteins with 
stronger components. Collagen type III is replaced by collagen type I, 
proteoglycans, and glycosaminoglycans are deposited, and vascular density 
regresses to normal levels. Physical contraction is ongoing throughout the wound 
healing process, in which myofibroblasts appear to have a central role. Crucially, 
amongst all the new ECM synthesis, there is also great complexity in regulated 
ECM degradation through proteases such as matrix metalloproteases (MMPs), 
their inhibitors – tissue inhibitors of metalloproteases (TIMPs), and the 
plasminogen activator system (PA). Once tissue remodelling is coming to an end 
and tissue integrity has been restored, vascular cells and myofibroblasts are lost 
through apoptosis (Desmoulière et al., 1995). The balance between ECM synthesis 
and degradation is essential to the resulting architecture of the tissue. The ultimate 
normal scar will contain collagen bundles running in parallel to the surface (Guo 
and Dipietro, 2010, Wolfram et al., 2009). 
 
1.3 Aberrant scarring 
Deregulation of any of the stages described above can lead to insufficient or 
excessive healing activities, resulting in a whole range of conditions, including 
ulcers, hypotrophic scars, hypertrophic scars, or keloids. It is thought that an 
extended proliferation phase is key to keloid scar development, where many 
proliferation factors, which are up-regulated during normal granulation tissue 
formation, remain enhanced and do not undergo degradation once tissue integrity 
is restored (Jumper et al., 2015). The keloid epidermis shows a flattened but 
thickened epidermis, with a highly collagenous dermis (Lee et al., 2004). As there 
are no definitive biomarkers established for keloid scarring, a combination of 
clinical appearance and histopathology is used in order to differentiate between 
keloid scarring and other forms of cutaneous fibrosis (Jumper et al., 2015). Table 
1-1 summarises some of the key histological features that keloids have with other 
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dermal fibroses. Figure 1-4 demonstrates differences between hypertrophic and 
keloid scar formation, as well as clinical images from keloid patients. 
 
1.3.1 Hypertrophic scarring 
Hypertrophic scars are very similar to keloids, which often makes it difficult to 
distinguish between the two clinically. Both tend to be raised, pruritic, 
erythematous, and painful, however hypertrophic scars remain within the 
boundaries of the original wound, and can spontaneously regress over time. 
Keloids, on the other hand, infiltrate the surrounding healthy tissue, and continue 
to develop over time, without a quiescent or regressive phase (Guo and Dipietro, 
2010, Wolfram et al., 2009, Le et al., 2008) (Figure 1-4). After surgical excision, 
hypertrophic scars do not usually recur, though are more associated with 
contractures than keloids (Mustoe et al., 2002, Jumper et al., 2015). 
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Figure 1-4 Hypertrophic and keloid scarring 
Top panel depicts spectrum of normal to abnormal wound healing, resulting in keloid 
scar formation, adapted from (Shih et al., 2010a). Bottom panel presents clinical 
images of three keloid patients. The smaller scars were initiated by ear piercing, the 
enlarged bulbous scars in the far right image were instigated by childhood smallpox.  
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1.3.2 Other dermal fibroses 
Dermatofibrosarcoma protuberans (DFSP) could easily be confused with keloids, 
especially in the early stages of development. It is a slow-growing sarcoma of the 
skin, not usually found on the hands and feet, found to be at a higher rate of 
incidence in darker skinned individuals, may recur post-surgical excision, and 
usually occurs between the ages of 20-50 years (Criscione and Weinstock, 2007, 
Sabater-Marco et al., 2006). One key histological feature of DFSP is that it shows a 
honeycomb pattern when the fibrous stroma extends into the underlying adipose 
tissue (Sabater-Marco et al., 2006). Non-polarised collagen (Barr et al., 1986) and  
positive CD34+ staining (Aiba et al., 1992) have been used to discriminate DSFP 
against other cutaneous scarring, though parts of the keloid margin have also 
shown to express CD34+, where it may inversely correlate with collagen I 
production (Aiba et al., 1992, Jumper et al., 2015). 
 
Another condition, distinct from keloid and DSFP, though with features in 
common, is dermatofibroma. Like keloid scarring, dermatofibromas have a 
hyperplastic epidermis, are hyperkeratotic, and show hyalinised collagen in the 
dermis (Alves et al., 2014, Jumper et al., 2015). It differs from keloid scarring, as it 
tends to be a more uniform, scaly lesion, and does not recur post-excision. The 
epidermis shows increased rete ridges, and the hair follicle structures are also 
increased (Luzar and Calonje, 2010). Dermatofibroma is easily distinguished from 
DSFP, as histological examination shows a CD34- and factor XVIIIα positive stain 
for dermatofibroma, though a CD34+ and factor XVIIIα negative stain for DSFP 
(Altman et al., 1993). 
 
Cutaneous scleroderma (or morphea) can also resemble dermatofibroma or keloid. 
It is characterized by a thickened dermis, which occasionally presents dense 
nodules, and a lack of appendages. Histologically, morphea lesions have a lower 
level of cellularity compared to keloids (Rencic et al., 2003), though they express 
similar proteins to keloid scars, including diffuse TNC (tenascin) (Lacour et al., 
1992), and COMP (cartilage oligomeric matrix protein) (Moinzadeh et al., 2013). 
They have flattened rete ridges, as in keloids, increased collagen in the dermis, and 
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increased immune cell infiltration (Buechner et al., 1993). The key difference in 
this cutaneous fibrosis is that scleroderma is a systemic disease, therefore clinical 
assessment must first rule out any signs of systemic sclerosis (Jumper et al., 2015). 
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Table 1-1 Cutaneous fibroses with similarities to keloid scarring 
Adapted from (Jumper et al., 2015). DSFP = Dermatofibrosarcoma protuberans 
Type of fibrosis 
In common with 
Keloids 
Different from keloids 
Markers 
used 
Hypertrophic 
scarring 
Raised scar; thickened 
collagen nodules; 
increased cellularity 
Non-flattened epidermis; 
organised collagen fibres; 
no recurrence 
H&E, α-SMA 
DSFP Raised, pigmented 
skin; recurrence post-
excision 
Honeycomb pattern in 
dermis; non-polarising 
collagen fibres 
Vimentin, α-
SMA, CD34+, 
factor XVIIIα- 
Dermatofibroma Thickened epidermis; 
hyperkeratosis; 
hyalinised collagen 
Scaly lesions; no 
recurrence; reduced 
cellularity 
CD34-, factor 
XVIIIα+ 
Cutaneous 
scleroderma  Pigmented; flattened 
rete ridges 
Reduced cellularity; 
organised collagen fibres; 
systemic features 
CD34-, CD1a, 
CD3, CD8, 
CD25, CD20+, 
CD57+ 
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1.4  Keloid Scarring  
1.4.1 Clinical aspects 
One of the most defining features of fibrosis, and indeed keloid scarring, is the high 
accumulation of ECM, particularly collagen type I. The structure and distinct 
organisation of keloidal collagen is one of the clearest histopathological differences 
between keloids and other forms of cutaneous fibroses. In normal skin, collagen is 
contained within distinct bundles which are mostly organised in parallel to the 
epidermis, yet randomly connected to each other. Hypertrophic scars show flat 
collagen fibers organised in a wavy pattern, usually in parallel to the epithelial 
surface. In contrast, the collagen fibers in keloids tend to be haphazardly 
organised, with some lying in parallel to the epidermis and some not. Keloids also 
show dense, acellular bundles of collagen fibres, particularly in the central region 
(Atiyeh et al., 2005, Jumper et al., 2015). The ratio of collagen type I to type III is 
higher in keloid scars than in normal skin, and the highest expression of these 
collagens has been observed in the marginal region of the keloid (Syed et al., 
2011). 
 
Aside from the aesthetic issues most patients face, these fibroproliferative scars 
can lead to disfigurement, possible obstruction to movement, and debilitating 
psychological strain (Stucker and Shaw, 1992, Le et al., 2008). Keloid pathogenesis 
has been studied for several decades, but is still poorly understood. They have only 
been observed in humans, and so the lack of reliable animal models has hindered 
progress in this area of research (Le et al., 2008, Chang et al., 2009). Some in vitro 
models are becoming increasingly reliable, especially with the advancement in 3D 
culture technologies, though there is still little consistency between research 
groups. The fibrotic lesion is known to be induced by skin trauma, but forms in 
predisposed individuals. Skin trauma can be as major as a surgical wound, or as 
minor as a body piercing or acne. Most keloids develop within 3 months of injury, 
though it can take up to 1 year to appear (Le et al., 2008, Rohde et al., 2009). One 
theory involves the constant forces of tension as a contributing factor to keloid 
development, as they are more likely to form across joints and skin that creases at 
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a right angle – with the exception of earlobe keloids (Rudolph, 1987, Rohde et al., 
2009).  
 
Keloid scarring occurs in all ethnicities, with the highest prevalence observed in 
darker skin types, such as in African and Asian populations, estimated up to 16% 
of the population (Jagadeesan and Bayat, 2007, Shih and Bayat, 2010b, Brown et 
al., 2008a). Prevalence in Caucasian populations are reported to be no more than 
1%. A slight predominance in females has also been noted, though this could be 
linked to a higher rate of earlobe piercing in females (Le et al., 2008, Zips et al., 
2008). Keloids can occur at any age, though they more often develop between the 
ages of 11 and 30 years (Le et al., 2008, Aarabi et al., 2008).  This has been 
explained by the fact that younger individuals more frequently injure themselves, 
and their skin is more elastic than in older persons (Wolfram et al., 2009, Gurtner 
et al., 2008a). Furthermore, keloid formation has also been associated with 
endocrine factors. Menopause prompts the recession of keloids, whereas women 
report keloid onset or enlargement during pregnancy (Wolfram et al., 2009, Curry 
and Osteen, 2003). 
 
1.4.2 Clinical management of keloids 
As keloid pathogenesis is so complex and still unclear to date, clinical management 
is varied, and there is no “golden standard”. There are numerous reports on 
retrospective, uncontrolled studies with small sample sizes, meaning that 
statistical significance is usually hard to evaluate. Other than study design, other 
factors such as patient selection, patient treatment history, and long-term follow-
up is inconsistent between clinical studies. This makes interpretation confusing, 
and the variety of therapies being investigated shows just how little is understood 
about the disorder (Broughton et al., 2006b). Prevention of injuries is the obvious 
solution, though highly impractical. If it is known a certain individual is prone to 
keloid scarring, any surgical wounds should be closed with minimal tension, 
avoiding incisions across joint spaces, and following skin creases where possible 
(Wolfram et al., 2009, Rudolph, 1987, Lim et al., 2002a, Boyce et al., 2002). Total 
keloid excision with no adjuvant therapy stimulates further fibrogenesis, and can 
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lead to the quick recurrence of larger scars. Recurrence rates range from 45% to 
100% (Wolfram et al., 2009, Smiley et al., 2005, Broughton et al., 2006b). Surgical 
intervention is usually performed intralesionally so as to “de-bulk” larger scars, 
and always in combination with another therapy such as pressure therapy, 
chemotherapy, radiotherapy, or steroid injections (Wolfram et al., 2009, 
Broughton et al., 2006b). Less common is extralesional surgical excision, 
principally performed in more recent clinical trials, in combination with 
chemotherapy or radiotherapy. If the lesion is particularly large, a partial thickness 
skin graft may be used to close the wound with as little tension as possible. 
 
1.4.2.1 Pharmacologic therapies 
The first-line treatments for keloids are corticosteroids, the most common of 
which is triamcinolone acetonide (TA). These are commonly administered 
intralesionally (within the margins of the keloid) into the upper layers of the 
dermis, and function as a global anti-inflammatory agent, which inhibits cell 
growth and proliferation (Petratos et al., 2002). Vasoconstriction is increased, and 
the inflammatory infiltrate is reduced, meaning effective phagocytosis and 
collagenase production by macrophages and polymorphonuclear neutrophils in 
the wound bed is also reduced (Broughton et al., 2006b, Rudolph, 1987, Wolfram 
et al., 2009, Rohde et al., 2009, Menon et al., 2012). Inhibition of both fibroblast 
and keratinocyte proliferation has been observed in culture, with fibroblasts from 
different regions of the keloid even showing differential response to the 
glucocorticoids (Smith et al., 2008). It appears that the subset of fibroblasts 
residing in the reticular dermis of the central scar nodules, where TGF-β signalling 
is increased, are more resistant to glucocorticoids than fibroblasts from the 
superficial dermis or adjacent normal tissue (Smith et al., 2008). In the clinical 
setting, if effects such as tissue atrophy, hypopigmentation, or telangiectasia 
develop during treatment, it is halted (Wolfram et al., 2009, Veleirinho et al.). 
 
Immunomodulators such as imiquimob and interferon-α2b, induce cytokine and 
interferon release at the site of application, which in turn act to deactivate 
fibroblasts from producing excessive collagen fibrils. There has been limited 
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success with these therapies, showing up to a 54% recurrence rate, compared with 
15% when using TA (Wolfram et al., 2009, Rudolph, 1987).  
 
The chemotherapy 5-Fluorouracil (5-FU) is well known in the oncology field, 
where it has been in use for over 50 years (Philandrianos et al.). It works by 
targeting rapidly proliferating cells, which in the case of the keloids, would be the 
fibroblasts. It has also been shown to interfere with TGF-β signalling, and to reduce 
gene expression of Type I Collagen in keloid fibroblasts (Wolfram et al., 2009, 
Zigrino et al.). Intralesional injection of 5-FU has been used with some success, 
particularly when in combination with corticosteroids, and even more so when 
administered after extralesional excision (inclusive of a small margin of the 
adjacent healthy skin) (Huang et al., 2013b). A combination of low-dose 5-FU, with 
triamcinolone on cultured keloid fibroblasts led to reduced cell proliferation (due 
to the corticosteroid), followed by cell-cycle arrest and apoptosis (due to the 5-FU). 
Collagen I production and TGF-β signalling was reduced, while MMP2 expression 
was induced, all to a statistically significant level (Huang et al., 2013b). This is a 
promising route for keloid treatment, nevertheless 5-FU can demonstrate side 
effects such as ulceration, pain, and hyperpigmentation (Wolfram et al., 2009, 
Rudolph, 1987). 
 
1.4.2.2 Other therapies 
Occlusive dressings, including silicone and non-silicone gel sheeting, have been 
increasingly used over the last 20-30 years in the treatment of abnormal scars, 
with reasonable success. Reports have shown occlusive dressings to soften scars 
and reduce their size, erythema, pruritis and pain (Le et al., 2008, Bagabir et al., 
2012). Keloid prevention was noted in up to 80% of cases post-excision (Le et al., 
2008, Jin et al.).  The mechanism of action is unclear, however the theory is that 
occlusion provides hydration and increased temperature to the scar, thereby 
affecting local keratinocytes to alter growth factor secretion, and as a result 
influence fibroblast regulation (Wolfram et al., 2009, Bagabir et al., 2012, Li et al., 
2012a, Li et al., 2012b).  
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Radiotherapy is most successfully used as an adjunct to surgical excision, with 
reports of around 30% recurrence rate. Although radiotherapy technologies are 
ever evolving, using lower effective doses and increasing the specificity of their 
action, there are still major risks for the patient. Postoperative complications 
include impaired wound healing, fibrosis, and the potential for malignancy in the 
surrounding healthy tissues (Le et al., 2008). 
Cryotherapy has shown good outcomes in patients with smaller lesions, and in 
fair-skinned individuals. It involves the use of a freezing medium to ablate the 
targeted lesions. Intralesional cryosurgery has shown higher success rates 
compared with contact cryotherapy, as well as causing less pain – the major factor 
for lack of compliance to the full course of treatment by patients (Le et al., 2008, 
Chung et al., 2007). 
 
1.4.3 Genetics of keloid scarring 
Keloid formation has been described in individuals with other connective-tissue 
genetic disorders, including Rubinstein-Taybi syndrome (Siraganian et al., 1989), 
Ehlers-Danlos syndrome (Pope et al., 1977, Char, 1971), pachydermoperiostosis 
(Hambrick and Carter, 1966), and Dupuyten’s disease (González-Martínez et al., 
1995, Shih and Bayat, 2010b). Rubinstein-Taybi syndrome is characterised by 
abnormalities such as developmental delay, mental retardation, broad thumbs, and 
distinctive facial features (Mishra et al., 2015). One study reported a 5% 
occurrence rate of keloids in individuals with Rubinstein-Taybi syndrome, though 
there was no conclusive evidence that the two are necessarily associated, as the 
keloid occurrence rate was not calculated in the control patient group (Siraganian 
et al., 1989). The observation of keloid formation in Ehlers-Danlos syndrome 
patients was interesting as this genetic disorder displays a collagen type III 
deficiency (Pope et al., 1975).  
 
Most keloids occur sporadically, but some cases are hereditary. Over the relatively 
small number of studies on the genetics of familial keloids, the most commonly 
reported mode of inheritance is autosomal dominant with incomplete penetrance 
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and variable expression (Shih et al., 2010a, Marneros et al., 2001). While there 
have been several studies on keloid inheritance and on isolating responsible genes 
for keloid scarring, select genes have not yet been verified. So far, genome-wide 
studies have been performed on Japanese and Chinese families (Nakashima et al., 
2010a, Marneros et al., 2004b), but only small-scale studies have been performed 
on the highest prevalent ethnicities, such as African-Caribbean (Shih and Bayat, 
2010a, Bella et al., 2011). An African-American family showed linkage to the 7p11 
locus, where EGFR might be affected, and in a Japanese family, a keloid 
susceptibility locus was mapped to 2q23, where TNFAIP6 (tumour necrosis factor, 
alpha induced protein 6) may be of interest (Marneros et al., 2004b, Shih and 
Bayat, 2010b). In a large Chinese family spanning five generations, the linkage 
locus 18q21.1 was thought to be important – a region where SMADs 2, 4, and 7 
(mothers against decapentaplegic homologs) and PIAS2 (protein inhibitor of 
activated signal transducer and activator of transcription 2) are coded for (Shih 
and Bayat, 2010b, Yan et al., 2007). The SMAD genes are involved in the TGF-β 
pathway, which has been associated with fibrosis, and will be discussed below 
(section 1.4.5).  
 
A number of genes within the TGF-β pathway, as well as other factors such as 
EGFR, p53, and RUNX3 (Runt-related transcription factor 3), have been 
investigated for polymorphisms and mutations. As with much of keloid research, 
the results are often conflicting and inconsistent in use of methodologies. To date, 
no polymorphisms or mutations have been identified in TGF-β ligands TGF-β1, 2, 
and 3, or in their receptors TGF-βRI, II and III, or in SMADS 3, 6 and 7 (Bayat et al., 
2004, Bayat et al., 2005, Brown et al., 2008b, Saed et al., 1998). Similarly, although 
p53 mutations were found in cultured keloid-derived fibroblasts, these were non-
existent in the original tissues, meaning the mutations were likely to be acquired 
during the cell culture process (Saed et al., 1998). Zhang et al. found a higher rate 
of gene mutations in TNF receptor II in keloid tissue, compared to the same 
patients’ venous blood control (Zhang et al., 2008). 
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1.4.4 ECM remodelling in keloids 
The balance of ECM protein production and degradation is clearly deregulated in 
keloid scarring, and numerous studies have shown how this deregulation can be 
seen in all phases of wound healing (Shih et al., 2010a). In the inflammatory phase, 
fibronectin and fibrinogen form a temporary matrix to allow cells to migrate 
through the wounded area. At this stage, fibronectin and collagen type I levels are 
increased, along with a decrease in fibrin degradation (Babu et al., 1989, Kischer 
and Hendrix, 1983, Shih et al., 2010a, Friedman et al., 1993, Tuan et al., 1996). 
Elevated levels of hyaluronic acid has been debated over a number of studies, not 
agreeing to whether it’s due to increased production in early wound healing, or a 
lack of degradation in the later phases of healing (Meyer et al., 2000, Alaish et al., 
1995). The proliferative phase is where ECM production increases momentum in 
normal wound healing, and in keloid scarring even more so. Arguably, keloids 
never fully end their proliferative phase, as they continue expanding over time. As 
growth factors are recruited to the wound bed, neovascularisation, collagen 
deposition, granulation tissue formation and wound contraction take place (Shih et 
al., 2010a). 
As the wound enters the later stages of repair, enzymes such as collagenases, 
gelatinases, and elastases ensure initial ECM structures are digested and 
replenished with more stable versions, until the injury has been reconstituted to 
its original state (O'Kane and Ferguson, 1997, Shih et al., 2010a). The major 
enzymes in this complex, yet delicately balanced, process include the matrix 
metalloproteinases (MMPs), plasminogen activator (PA)-plasmin, and a disintegrin 
and metalloproteases (ADAMs). PA converts plasminogen into plasmin, which 
consecutively breaks down fibrin (Toriseva and Kahari, 2009), and activates 
procollagenase to breakdown collagen (Tuan and Nichter, 1998). Several factors 
have been suggested as inhibitors of ECM breakdown, including interferon-γ (IFN-
γ). In normal wound healing, IFN-γ inhibits fibroblast proliferation, decreases 
synthesis of collagen types I, II and III, and increases collagenase synthesis 
(Adelmann-Grill et al., 1987, Jimenez et al., 1984, Shih et al., 2010a). IFN-γ has been 
reported as reduced in keloids, where collagen synthesis is increased and 
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collagenase activity appears ineffective in degrading the fibrotic scar tissue (Shih 
et al., 2010a, McCauley et al., 1992). 
It is accepted that α-SMA-expressing fibroblasts in granulation tissue signifies the 
presence of ECM-producing myofibroblasts (Darby et al., 2014, Darby et al., 1990, 
Jumper et al., 2015). When local populations of fibroblasts are not available or 
sufficient for granulation tissue remodelling, alternative sources of myofibroblasts 
have been reported to be mesenchymal stem cells (Jahoda et al., 2003), circulating 
bone marrow derived cells (Pittenger et al., 1999, Opalenik and Davidson, 2005), 
as well as differentiated cells undergoing epithelial- or endothelial-to-
mesenchymal transition (Darby et al., 2014, Nakamura and Tokura, 2011). During 
prolonged wound healing processes, myofibroblasts are implicated with excessive 
scarring, where they fail to undergo cell death once the granulation tissue has 
matured and tissue remodelling is underway (Desmoulière et al., 1995, Darby et 
al., 1990). In fact, it was suggested that α-SMA expression is present in 
hypertrophic scars but not in keloid scars, making it a potential marker for 
differentiating between these two histologically similar formations (Ehrlich et al., 
1994). Since then however, α-SMA expression has been observed in both keloids 
and hypertrophic scarring (Lee et al., 2004, Lee et al., 2012), with increased 
intensity surrounding the thickened collagenous nodules characteristic of keloid 
scars (Santucci et al., 2001, Jumper et al., 2015). Understandably, the potential 
regulation of myofibroblast disappearance through apoptosis is of increasing 
interest in terms therapeutics (Hinz and Gabbiani, 2003). 
 
Along with the myofibroblasts normally present in many fibrotic diseases, 
mesenchymal stem cell (MSC) populations have been identified in keloid dermis, at 
an elevated level compared to healthy control skin. Iqbal et al support that there is 
in fact a hybrid haematopoietic/ mesenchymal cell population, called fibrocytes, 
present as a distinct population alongside the MSCs (Iqbal et al., 2012). 
 
1.4.4.1 Structural ECM proteins in keloids 
The abundant structural protein collagen type I accounts for the majority of the 
fibrotic scar tissue seen in the keloid dermis. It is generally accepted that thickened 
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collagen I fibres are organized in a haphazard manner, termed as “keloidal 
collagen” (Lee et al., 2004).  They have a glassy appearance, are hyalinised, 
oesinophilic, and can form acellular nodules in parts of the reticular dermis 
(Ehrlich et al., 1994). The ratio of collagen I/ collagen III is also increased in 
keloids (Abergel et al., 1985, Kischer and Brody, 1981, Lee et al., 2004). In normal 
skin the ratio is approximately 6, whereas in keloid scars the collagen type I/III 
ratio is close to 17 (Friedman et al., 1993, Shih et al., 2010a). It has not been 
concluded whether this effect is due to the lack of collagenase activity (particularly 
for type III), or an increased production of both collagen types (Niessen et al., 
1999, Abergel et al., 1985, Shih et al., 2010a). It is likely that both actions 
contribute to the problem. Collagens V and VI have also been found to be 
overexpressed in keloids (Shih and Bayat, 2010b), which may indicate changes to 
the basement membrane integrity, where these collagens reside (Gordon and 
Hahn, 2010, Ricard-Blum, 2011). 
 
Fibronectin is a key glycoprotein of the ECM, which binds to integrins and other 
ECM-related molecules, forming an early granulation tissue (Martino et al., 2011). 
It has shown increased expression in keloids compared to normal skin (Kischer 
and Hendrix, 1983), especially at the dermal-epidermal junction, and co-localised 
with fibroblasts located between the thickened collagen nodules (Sible et al., 
1994). Fibronectin can also be stimulated by the growth factor TGF-β1 (Lee et al., 
2013, Jumper et al., 2015).  
 
Hyaluronan, an essential glycosaminoglycan of the ECM, has shown a unique 
expression pattern in keloid tissue. It has shown minimal expression in the 
papillary dermis, with intense expression in the subrabasal layers of the epidermis. 
In contrast, hypertrophic scars have shown a stronger expression in the papillary 
dermis, and very low expression in the epidermis (Hellström et al., 2014), making 
this protein a potential useful marker for differentiating between hypertrophic 
scars and keloids (Sidgwick and Bayat, 2012). HA is thought to be important in 
effective epithelialization, and well as for regulating fibroblast cell morphology 
(Tan et al., 2011). 
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Elastin and fibrillin were found to be disorganised in keloid lesions, as compared 
to normal skin. Fibrillin-1 was decreased across the whole tissue, whereas elastin 
showed no expression in the papillary dermis, and a significantly increased level in 
the reticular dermis (Amadeu et al., 2004). 
 
More recently, molecules such as dermatopontin, periostin, and tenascin have been 
linked to keloid histopathology (Jumper et al., 2015, Sidgwick and Bayat, 2012). 
Dermatopontin has shown a decreased level of both gene and protein expression 
in keloids compared to normal skin (Russell et al., 2010, Catherino et al., 2004). In 
keloids, periostin has shown increased expression in the dermis and epidermis, 
compared to normal skin, as well as strong co-localisation with CD31, suggesting 
periostin may affect blood vessel density (Zhang et al., 2015). In hypertrophic 
scars, dermal fibroblast proliferation and differentiation were enhanced (Crawford 
et al., 2015). 
 
1.4.5 Fibrogenic Signalling Pathways 
There is growing evidence that epithelial-mesenchymal cross talk has a significant 
impact in wound healing and fibrotic disorders (Tuan et al., 1996, Ashcroft et al., 
1997a). During wound healing, keratinocytes stimulate fibroblasts to produce 
growth factors as well as ECM proteins, which then stimulate keratinocyte 
proliferation in a double paracrine manner (Werner et al., 2007). In keloids, a 
similar pattern has been reported in numerous studies, though the extended effect 
on the keratinocytes has not been thoroughly examined (Ashcroft et al., 1997a, 
Wachsstock et al., 1987, Rasp et al., 1987, Adelmann-Grill et al., 1987, Shih et al., 
2010a). Co-culturing keloid keratinocytes with normal fibroblasts resulted in an 
enhanced TGF-β-induced collagen production by the fibroblasts (Ashcroft et al., 
1997a, Ashcroft et al., 1997b, Freneaux et al., 2000). Also, increased differentiation 
of fibroblasts was noted when treated with conditioned media from co-cultured 
cells, compared to when treated with conditioned media from single layer cultures 
(Freneaux et al., 2000).  
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When grown under co-culture conditions, keratinocytes and fibroblasts have 
shown to produce increased levels of TGF-β – also shown to induce α-SMA 
expression in the fibroblasts. The increased fibroblast differentiation is noted by 
increased cell contractility (Werner et al., 2007). Other than TGF-β, overexpression 
of other cytokines and growth factors, such as IGF, PDGF, and TNF-α in keloids 
show there is a lack of control of the wound healing signals (Wolfram et al., 2009, 
Diegelmann et al., 1979, Niessen et al., 1999, Blackburn and Cosman, 1966, Ehrlich 
et al., 1994, Rohde et al., 2009, Zips et al., 2008, Aarabi et al., 2008). PDGFR-α is at 
least four times enhanced in keloid fibroblasts (Shih et al., 2010a, Haisa et al., 
1994), which could be due to TGF-β1 action (Shih et al., 2010a, Messadi et al., 
1998), compared to healthy control skin fibroblasts.  
 
Moreover, there is an apparent imbalance between proliferative and apoptotic 
pathways, thought to be due to a combination of increased myofibroblast 
proliferation, and a downregulation of apoptotic related genes (Chipev et al., 2000, 
Luo et al., 2001, Ladin et al., 1998, Akasaka et al., 2001, Shih and Bayat, Syed et al., 
2011). Though more recently, evidence is growing that levels of apoptosis and 
proliferation vary between regions within the keloid lesion, with the central part of 
the scar showing increased levels of apoptosis, and the marginal region showing 
the highest level of proliferation.  
 
1.4.5.1 TGF-β/SMAD signalling in keloids 
The TGF-β system is a superfamily of proteins that regulate several different 
processes, including morphogenesis, embryonic development, adult stem cell 
differentiation, immune regulation, wound healing and inflammation. TGF-β uses 
protein kinase receptors and SMAD mediators to transduce signals (Derynck and 
Zhang, 2003), and any deregulation of the pathways can contribute to pathologies 
such as cancer, cardiovascular issues, fibrosis, and congenital disorders. In fibrotic 
conditions, abnormal TGF-β regulation has been linked to pulmonary fibrosis, liver 
cirrhosis, congestive heart failure, rheumatoid arthritis, Marfan syndrome, 
hypertrophic scars, systemic sclerosis, as well as keloids (Santibañez et al., 2011, 
He et al., 2010, Varga and Pasche, 2008, Fujiwara et al., 2005a). More specifically, 
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TGF-β1 has been established as an important fibrogenic factor that promotes ECM 
production and fibrosis in tissues, including in keloids (He et al., 2010, Leask and 
Abraham, 2004, Fujiwara et al., 2005a). Keloid fibroblasts are believed to express 
increased levels of TGF-β1, which induces collagen overproduction in the dermis. 
Additionally, CTGF expression is induced by TGF-β, which encourages fibroblast 
differentiation into myofibroblasts, and eventually collagen synthesis (Santibañez 
et al., 2011). The TGF-β receptors (TGF-βR) I and II and some of their intracellular 
signalling mediators, SMAD2, SMAD3 and the SMAD2/3/4 complex, have been 
shown to be elevated in keloids compared to normal skin (Phan et al., 2005, He et 
al., 2010).  The SMADs also interact with the mitogen-activated protein kinase 
(MAPK) pathway, which in combination with JNK promotes cell invasion and ECM 
synthesis through mesenchymal cell activation (He et al., 2010, Furukawa et al., 
2003, Matsuzaki and Okazaki, 2006). TGF-β1–induced SMAD2/3 phosphorylation 
at the linker region serves as a cross-talk platform for phosphorylation by the 
MAPK pathway, making TGF-β1 a key factor in keloid pathogenesis (He et al., 
2010). 
 
TGF-β1/SMAD signalling (Fig 1-5) is achieved when the appropriate SMAD 
complexes translocate to the nucleus to propagate transcription. Phosphorylated 
SMAD2/3 link with SMAD4 to form a complex, and together with the ERK and JNK 
pathways translocate to the nucleus (Shi and Massague, 2003, He et al., 2010, 
Derynck and Zhang, 2003). From there, gene expression for proteins crucial to 
ECM regulation are targeted. One example is plasminogen activator inhibitor-1 
(PAI-1), an important factor in cell invasion and ECM deposition, and has increased 
activity in keloids (Yang et al., 2008, Tuan et al., 2003, He et al., 2010). He et al 
demonstrated that ERK, JNK and p38 inhibitors significantly suppressed TGF-β1-
induced PAI-1 expression, meaning that these pathways also play a role in PAI-1 
transcription (He et al., 2010). SMAD7 acts as an inhibitor of the SMAD2/3 
complex, through its interaction with activated TGF-βRI, thus preventing SMAD2/3 
phosphorylation, and as a result decreasing fibrogenic proteins. In keloid 
fibroblasts, SMAD7 appeared significantly reduced, and even more so when the 
cells are treated with TGF-β1 (Nakao et al., 1997, Kopp et al., 2005, Yu et al., 2006). 
This could explain the lack of a negative feedback loop in keloids, which would 
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ordinarily keep ECM production in balance. He et al showed that inhibiting p38 in 
keloid fibroblasts reversed the SMAD7 reduction, which supports their hypothesis 
that the p38 pathway is involved in regulating fibrogenesis in keloids (He et al., 
2010). 
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Figure 1-5 The TGF-β/ SMAD signalling pathway 
Once bound to its ligand, the TGF-β receptor kinases induce phosphorylation of the R-
SMADs (receptor-activated SMADs 2 and 3), which then form a complex with co-SMAD 
(SMAD4). The SMAD 2/3/4 complex is then translocated to the nucleus to regulate 
transcription of target genes. SMAD6 or 7 along with Smurf1/2 inhibit this process, by 
blocking R-SMADs from forming a complex, and therefore contribute to a negative 
feedback to TGF-β action. Image adapted from (Derynck and Zhang, 2003). 
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1.4.5.2 Other signalling pathways, growth factors and cytokines in keloids 
The Wnt pathway has long been implicated in fibrosis, though only a small number 
of studies have shown its role in keloid scarring (Igota et al., 2013). There are two 
main pathways to Wnt signalling: β-catenin-dependent, which leads to 
downstream transcription of genes related to cell proliferation and growth; and β-
catenin-independent, linked to cell polarity and migration (Niehrs, 2012). There is 
also a third pathway involving Ca2+, where calceneurin induces NFAT (nuclear 
factor of activated T-cells), leading to effects on cell migration and cell fate (see 
Figure 1-6) (Niehrs, 2012). Igota et al. demonstrated Wnt5a was overexpressed in 
keloid fibroblasts compared to normal fibroblasts, due to the β-catenin-dependent 
Wnt activation (Igota et al., 2013). In hypertrophic and keloid scar tissue, 
histological examination demonstrated TGF-β-induced activation of the β-catenin-
dependent Wnt signalling pathway (Sato, 2006). In isolated keloid fibroblasts, a 
range of IGF-(insulin growth factor) binding proteins were found to be 
overexpressed, compared to normal fibroblasts, whereas expression of Wnt 
pathway inhibitors DKKs (dickkopf homolog) 1 and 3, and SFRP1 (secreted 
frizzled related protein 1) were decreased. JAG-1 (jagged-1), an effector of the 
Notch pathway and a target of Wnt signalling, was also over-expressed in keloid 
fibroblasts (Smith et al., 2008).  When comparing the central and marginal regions 
of the keloid scar separately, apoptosis-inducing genes were found to be over-
expressed in the central region, whereas apoptosis inhibitor AVEN was increased 
in the keloid edge, supporting the notion that the keloid margin is expanding 
whereas the centre is regressive (Seifert et al., 2008) 
 
Another signalling pathway known to impact on fibrosis is the Notch pathway, 
which requires cell-cell contact for activation, and is important in regulating 
several processes including proliferation, differentiation and apoptosis (He and 
Dai, 2015). In systemic sclerosis and scleroderma, Notch activation appeared to 
impact on myofibroblast activation (Dees et al., 2011). Very little has been 
reported on Notch signalling in keloids, though Syed et al. observed a significant 
up-regulation of Notch receptors and ligand Jagged-1 (JAG-1) in keloid scars 
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compared to both adjacent normal skin to the keloids and external control skin 
(Syed and Bayat, 2012). 
 
During the proliferative phase, neovascularisation helps to form an initial 
granulation tissue, where nutrient and oxygen transfer is enabled. Keloids 
demonstrate increased neovascularisation, with VEGF signalling playing a major 
role (Shih et al., 2010a, Beer, 2005, Gira et al., 2004). PDGF, CTGF (connective 
tissue growth factor), EGF, and IGF are among the cytokines shown to impact on 
fibrogenesis, and have been reported as increasing the proliferative response in 
keloids (Shih et al., 2010a). 
EGF action in keloids is inconclusive at present, with reports of increased, 
decreased and no significant difference in expression levels in keloids (Shih et al., 
2010a, Harper, 1989, Satish et al., 2004). Aside from re-epithelialisation, CTGF 
plays an important role in ECM production and tissue remodelling in the later 
stages of wound healing (Shih et al., 2010a, Abreu et al., 2002). In keloid epidermis, 
CTGF shows increased expression at the basal layer. Co-culturing keloid 
keratinocytes and fibroblasts leads to increased secretory CTGF and decreased 
endogenous CTGF, together suggesting that keratinocytes secrete CTGF into the 
dermis and from there promotes fibrogenesis (Shih et al., 2010a, Khoo et al., 2006). 
CTGF also impacts on TGF-β signalling (Abreu et al., 2002, Shih et al., 2010a), 
discussed earlier on. IGF-I also encourages keloid fibrogenesis through TGF-β1 
signalling. Keloid tissues and fibroblasts demonstrate increased levels of IGF-I 
receptor (IGF-IR), which could partly explain the proliferative, anti-apoptotic, 
invasive nature of keloids (Shih et al., 2010a, Ishihara et al., 2000). 
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Figure 1-6 Wnt signalling pathways 
Schematic of the main pathways involved in Wnt signalling. (a) The β-catenin-
independent pathway: PCP (planar cell polarity) signalling is primarily involved in 
regulating cell polarity and motility. (b) In the β-catenin-dependent pathway, when 
Wnt ligand is present, the destruction complex (comprising of GSK3, APC, Axin and 
CKIα) is inactivated. This allows β-catenin to be translocated to the nucleus and 
activate gene transcription. (c) The Wnt-Ca2+ pathway leads to activation of NFAT 
(nuclear factor of activated T cells) which once translocated to the nucleus, triggers 
transcription of genes regulating cell fate and migration. 
Adapted from (Niehrs, 2012) 
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1.5 Research aims and objectives  
1.5.1 Research aim 
In the current literature, it becomes clear that there is a high degree of variability 
reported in a large proportion of keloid scars. Whether in relation to the disorder’s 
histopathology, genetic analysis, or signalling processes taking place, it is difficult 
to reach firm conclusions on the cause of keloid scarring. The prevailing 
inconsistencies in methodologies applied, experimental design, source materials 
used, as well as control material used, make it even more challenging to establish a 
causative link to keloids.  
 
The overall aim of my research was, as far as possible, to identify a marker of 
keloid scarring, in a uniform as possible group of clinical samples, so that this 
could be used to further elucidate keloid pathogenesis. I examined the keloid scars 
as a whole entity, inclusive of the epidermis and dermis, containing the central, 
marginal, and adjacent normal sites of the scars.  
1.5.2 Objectives 
 To characterise the keloid scar and control skin biopsies, by assessing their 
tissue morphology, cell proliferation, and fibroblast activation. Also, to 
investigate protein expression patterns of MMPs 1, 2, 13, and 14 in the same 
tissues. 
 To explore gene expression alteration in whole keloid tissues, using a 
focused approach. Real Time qPCR arrays were used to examine 84 genes 
linked to the ECM, and a further 84 genes linked to 10 of the most well 
known signalling pathways. 
 To validate the gene expression results in whole tissue, as well as in 
primary cultured keratinocytes and fibroblasts from the same cohort of 
specimens.  
 To conclude with an identified biomarker for future investigations in keloid 
biology. 
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2 Materials and Methods 
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2.1 Patient samples 
Keloid specimens were received from The Royal London Hospital in Whitechapel, 
London. Ethical approval for these has been made under the ethical registration 
number 2011-000626-29. The nature of keloid scarring is such, that it is deemed 
unethical to harvest matched control healthy skin biopsies from keloid patients, as 
this would lead to a new keloid forming. Therefore, healthy control skin samples 
were retrieved from unaffected patients undergoing routine procedures within the 
plastic surgery department of The Royal London Hospital, where there was excess 
unwanted skin. Most of the available normal skin came from Caucasian individuals, 
however African-Caribbean skin was collected wherever possible, so as to at least 
match the keloid scars by ethnicity. Full patient consent was collected in all cases. 
Refer to Tables 2-1 and 2-2 for detailed information relating to all patient samples 
used in this thesis. 
 
All keloids were extralesionally excised, including a margin of the adjacent normal 
tissue. Almost all the keloids showed vertical growth, with only K36 and K42 
showing a “butterfly” appearance, where the central part of the keloid is flattened 
and only the edges protrude vertically.  
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Table 2-1 Patient information for keloid, normal and hypertrophic scars used throughout thesis. 
NB: ECM PCR (Extracellular matrix and adhesion molecules qPCR array – see section 2.3.2); STP PCR (signal transduction pathway finder qPCR array – 
see section 2.3.2); IHC (Immunohistochemistry – see sections 2.2.1-2.2.3) 
Keloid Sample 
ID 
Gender Ethnicity Body location IHC 
ECM PCR 
array 
STP PCR 
array 
Primary 
Fibroblasts 
Primary 
Keratinocytes 
Chapter ref.    3 4 4 5 5 
NSc F 
 
African-Caribbean Neck X     
HSc Unknown Caucasian Unknown X     
K20 Unknown African-Caribbean Unknown    X X 
K26 Unknown African-Caribbean Earlobe - Recurrence X     
K28 F African-Caribbean Abdomen  X X   
K32 M Asian Ear X     
K34 F African-Caribbean Post-auricular X X X X  
K35 M African-Caribbean Scapula X X X   
K36 F African-Caribbean Breast (butterfly) X X X X X 
K40 M African-Caribbean Cheek X X X   
K42 F Caucasian Abdomen (butterfly) X     
K51 M African-Caribbean Sternum X   X X 
K55 M African-Caribbean Nape of neck X   X X 
K70 M Caucasian Post-auricular X   X  
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Table 2-2 Patient information of healthy control tissues used throughout thesis. 
NB: ECM PCR (Extracellular matrix and adhesion molecules qPCR array – see section 2.3.2); STP PCR (signal transduction pathway finder qPCR array – 
see section 2.3.2); IHC (Immunohistochemistry – see sections 2.2.1-2.2.3) 
Normal Skin 
Sample ID 
Gender Ethnicity Body location IHC ECM array STP array Primary 
Fibroblasts 
Primary 
Keratinocytes 
Chapter ref.    3  4 4 5 5 
NS4 F Caucasian Unknown X   X  
NS6 F African-Caribbean Breast X X X X X 
NS7 F Caucasian Facelift  X    
NS8 F Caucasian Breast    X X 
NS9 F African-Caribbean Breast X X    
NS14 F Caucasian Breast  X X   
NS16 F Caucasian Breast X X X   
NS17 F African-Caribbean Abdomen X  X   
NS18 M Caucasian Thigh X     
NS21 F African-Caribbean Breast X  X   
NS22 F African-Caribbean Abdomen X     
NS24 F African-Caribbean Breast    X  
NS25 F African-Caribbean Breast X     
NS29 F Caucasian Abdomen     X 
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2.1.1 Tissue fixation and wax embedding 
Clinical samples were cut with a disposable surgical scalpel (cat. SCA-310-030K, 
Fisher) into approximately 5-20mm3 pieces and incubated in 4% (v/v) 
formaldehyde (diluted from 37 wt% solution in water, stabilized with 5-15% 
methanol; cat. 119690010, Acros Organics, Fisher Scientific UK) or 10% Neutral 
Buffered Formalin (cat. HT501128-4L, Sigma Life Science, Poole, UK) for 16-48hrs 
at room temperature, then transferred to 70% (v/v) ethanol (made up with 
≥99.8% Ethanol, absolute; cat. E/0650DF/17, Fisher Scientific) until embedding in 
paraffin (cat. 36114 4V, VWR Chemicals) within 2-7 days. The system used for 
embedding the tissues in paraffin is the Tissue-Tek VIP 5 Vaccuum Infiltration 
Processor (Sakura). The system processes the tissue samples in graded alcohols 
(70% (v/v), 80% (v/v), 95% (v/v), and 100% (v/v) Ethanol), Xylene, and Paraffin. 
The tissue samples are held in the processing chamber in solution under pressure. 
The graded alcohols dehydrate the tissue, the xylene removes the alcohol from the 
tissue, and the paraffin interpenetrates the tissue. See Table 2-3 for the processing 
program used. 
 
Formalin-fixed paraffin-embedded tissues were sectioned using a HM 325 Rotary 
Microtome (cat. 902100, Thermo-Fisher Scientific) and Low-profile Tissue-Tek 
Accu-Edge disposable microtome blades (cat. 25608-964, Sakura Finetek, supplied 
by VWR Chemicals), to cut sections at 3-4μm thick, and placed on Superfrost Plus 
Micro glass slides (cat. 48311-703, VWR Chemicals). Before carrying on with any 
chosen staining procedure described below, tissue sections were placed in an oven 
at 57°C for 30min, to allow sections to fully adhere to the glass slides. 
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Table 2-3 Processing schedule for paraffin embedding of fixed human tissue. All steps 
were carried out under vaccuum conditions, while mixing. 
Step Solution Time (min) Temperature (°C) 
1 70% Ethanol 60 Room Temperature 
2 90% Ethanol 60 Room Temperature 
3 95% Ethanol 60 Room Temperature 
4 100% Ethanol 60 Room Temperature 
5 100% Ethanol 60 Room Temperature 
6 100% Ethanol 60 Room Temperature 
7 Xylene 90 Room Temperature 
8 Xylene 90 Room Temperature 
9 Paraffin wax 90 60° C 
10 Paraffin wax 90 60° C 
11 Paraffin wax 60 60° C 
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2.1.2 Snap-freezing fresh tissue 
After thoroughly washing with PBS containing 1% (v/v) antibiotic/ antimycotic 
(containing 10,000 units penicillin, 10mg streptomycin, and 25μg amphotericin B 
per mL in 0.9% (w/v) NaCl; cat. P11-002, PAA Laboratories GmbH, Austria), 
clinical samples were cut into approximately 2-5mm3 pieces, placed into 2mL 
cryovials (cat. 430488, Corning Incorporated) and fully immersed for at least 5 
seconds in liquid nitrogen. These were then stored at -80C, and were later 
homogenized for either protein or RNA extraction (see below). 
 
2.2 Protein assays  
2.1.1 Haematoxylin and Eosin (H&E) 
The Varistain Gemini ES Slide Stainer (Shandon) was used to carry out the 
Haematoxylin and Eosin (H&E) stain on paraffin-embedded tissue sections. The 
slides were submerged in xylene for 2min, then again in xylene twice for 1min. 
Next the slides are submerged in IMS alcohol (Industrial Methylated Spirit; cat. 
302434C, VWR Chemicals) for 2min, and again in alcohol twice for 1min, before 
washing in tap water for 30sec. The sections are incubated in Mayer’s 
Haematoxylin solution (cat. 72804, Thermo Scientific) for 12min, washed with tap 
water for 3min, differentiated in 0.3% Acid alcohol (concentrated HCl in 70% 
Ethanol) for 10sec, and washed again for 3min. Next, the sections are placed in 
Eosin solution (cat. 10061830, Fisher Scientific) for 2min, and washed in tap water 
for 90sec. Finally, the slides are dehydrated in alcohol once for 2min and twice for 
3min, then cleared in xylene twice for 2min and once for 1min, before mounting 
coverslips onto the slides with DPX mountant (cat. 360294H, VWR Chemicals). 
 
2.1.2 Herovici’s special stain  
2.1.2.1 Solutions for Herovici’s special stain 
Celestine Blue: 50g Iron Alum (Ammonium iron (III) sulphate 12-hydrate; cat. 
10021, VWR Chemicals) was stirred into 1000mL cold distilled water until fully 
 62 
dissolved.  5g Celestine Blue (cat. HD1240, TCS Biosciences Ltd) was added and the 
mixture boiled for a few minutes. After cooling, the solution was filtered and 
140mL Glycerol (cat. 10118, VWR Chemicals) added. 
 
Mayer’s Haemalum: 1g Haematein (cat. 34036, VWR Chemicals) was dissolved in 
50mL 90% (v/v) Ethanol, with a gentle heat. 1000mL distilled water was added 
and the solution brought to boil. When the colour deepened, 50g Potassium Alum 
(Aluminium potassium sulphate 12-hydrate; cat. 10009, VWR Chemicals) was 
added. The mixture was cooled and filtered before using. 
 
Van Gieson: 100mL Saturated Aqueous Picric Acid (Trinitrophenol; cat. 10192, 
VWR Chemicals) were mixed with 10mL 1% (w/v) Aqueous Acid Fuchsin (Acid 
magenta; cat. 34031, VWR Chemicals). 
Herovici’s stain: 50mL Van Gieson was added to 50mL 0.05% (w/v) Aqueous 
Methyl Blue (cat. M6900, Sigma-Aldrich, Poole, UK). Once well mixed, 10mL 
glycerol was added, before adding 0.5mL Saturated Aqueous Lithium Carbonate 
(cat. 10329, VWR Chemicals). 
 
2.1.2.2 Herovici protocol 
Tissue sections were de-waxed by soaking in xylene twice for 3min each, then 
soaking in IMS alcohol twice for 3min. The sections were rehydrated by soaking in 
distilled water for at least 5min. Sections were covered with Celestine Blue 
solution for 2min, the solution was tipped off, then Mayer’s Haemalum was added 
for 2min. Slides were washed in distilled water for 5min, before differentiating in 
1% (v/v) Acid Alcohol for a few seconds. After washing in distilled water for a 
further 5min, sections were covered with Herovici’s stain for 2min, briefly rinsed 
in distilled water, then differentiated in 1% (v/v) Acetic Acid (ethanoic acid; cat. 
10498, VWR Chemicals) for 2min. Finally, slides were rinsed in distilled water, 
dehydrated by rinsing in IMS alcohol, cleared by rinsing in xylene, and mounted 
with DPX. With this special stain, young collagen (type III) will show up in blue, 
mature collagen (type I) in red, muscle in yellow, and nuclei blue/ black. 
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2.2.1 3,3’-Diaminobenzidine (DAB) Immunohistochemistry (IHC) 
Tissue sections were de-waxed by soaking in xylene twice for 3min each, then 
soaking in IMS alcohol twice for 3min. The sections were rehydrated, by soaking in 
distilled water for at least 5min. For antigen retrieval, the tissue sections were 
placed in a plastic slide rack and then submerged in the appropriate antigen 
retrieval buffer (see Table 2-4) within a plastic container. The container with the 
slides was placed in the microwave at 850W for 35min, then removed from the 
microwave and allowed to cool for 5min. The slide rack was then removed and 
submerged in tap water for at least 5min. The antigen retrieval conditions and 
concentrations used for each primary antibody examined here are shown in Table 
2-4. After antigen retrieval, sections were dabbed dry and the Dako DAB 
Peroxidase Substrate kit (Vector Laboratories) was used for subsequent steps. 
Sections were incubated with 3% (v/v) hydrogen peroxide solution for 15min, and 
washed twice with Dako wash buffer for 3min, before incubating with normal 
horse serum for 20min. The primary antibody was appropriately diluted in Dako 
wash buffer (see Table 2-4) then added to the tissue sections for 40min, before 
washing with Dako wash buffer twice for 3min. Anti-mouse and anti-rabbit 
secondary antibody solution was added for 30min, sections were washed with 
Dako wash buffer twice for 3min once more, then were incubated in ABC reagent  
for 30min. Finally, sections were washed with Dako wash buffer twice for 3min, 
and DAB solution [1 drop DAB solution per 1mL substrate buffer] was added and 
left for exactly 5min. The sections were washed in tap water for at least 5min 
before counterstaining using the Varistain Gemini ES Slide Stainer (as in section 
2.2.1). Slides were submerged in haematoxylin for 2min, washed in tap water for 
3min, then differentiated in acid alcohol for 10sec before washing in tap water for 
3min. Finally, the stained tissue sections were dehydrated in alcohol once for 2min 
and twice for 3min, then cleared in xylene twice for 2min and once for 1min, 
before mounting coverslips onto the slides with DPX. 
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Table 2-4 List of antibodies used for immunohistochemistry 
Protein 1ary antibody supplier 
(product code) 
1ary antibody description 1ary antibody 
concentration for IHC 
Antigen retrieval method 
for IHC 
Ki67 Novocastra (NCL-L-Ki67-MM1) Mouse monoclonal IgG1 61.2mg/mL used at pH6, microwave, 35min 
α-SMA Dako (M0851) Mouse monoclonal IgG2a kappa Used at 1:100 pH6, microwave, 35min 
MMP1 Protein Tech (17873-1-AP) Rabbit polyclonal IgG 0.5mg/mL used at 1:100 pH6, microwave, 35min 
MMP2 Abcam (ab37150) Rabbit polyclonal IgG 1mg/mL used at 1:100 pH8.1, microwave, 35min 
MMP13 Protein Tech (18165-1AP) Rabbit polyclonal IgG 0.7mg/mL used at 1:100 pH6, microwave, 35min 
MMP14 Abcam (ab88618) Rabbit polyclonal IgG 1mg/mL used at 1:100 pH8.1, microwave, 35min 
SPP1  Proteintech (22952-1-AP) Rabbit polyclonal IgG 0.36mg/mL used at 1:50 pH6, microwave, 10min 
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2.2.2 Immunofluorescence 
For immunofluorescent detection, the same antigen retrieval methods were used 
for each antibody described in the previous section (see Table 2-4), though 
blocking was carried out for 1hr using 5% (v/v) normal goat serum (cat. 50-197Z, 
Invitrogen) diluted in PBS. Tissue sections were incubated for 1hr at room 
temperature with primary antibody diluted as in Table 2-4 in PBST [PBS 
containing 0.1% (v/v) Tween (Polyoxyethylene-sorbitan monolaurate; cat. P-1379, 
Sigma Life Sciences, Poole UK)]. Sections were washed thoroughly, then incubated 
with Alexa Fluor 568 Goat-anti-Rabbit secondary antibody (cat. A11011, Life 
Technologies) diluted in the same buffer as for the primary, at a dilution ratio of 
1:500, for 1hr at room temperature, in the dark. After washing thoroughly once 
more, sections were mounted with ProLong Gold antifade reagent containing DAPI 
(4’, 6-diamidino-2-phenylindole; cat. P-36931, Life Technologies). 
 
2.2.3 Protein sample preparation 
2.2.3.1 Tissue homogenisation 
Two similar methods were used for tissue homogenization, according to the 
equipment available throughout the duration of this project. In the first one, snap 
frozen tissue samples of 20-50mg were ground in a stainless steel pestle and 
mortar, previously cooled on dry ice to ensure the tissue remained frozen and 
broke up into a powder. The frozen powdered sample was then scraped out into a 
nuclease-free 1.5mL microfuge tube (cat. AM12400, Ambion), 100µL of lysis RIPA 
buffer containing protease inhibitors (see Table 2-5 - contains inhibitors of serine, 
cysteine and acid proteases, and aminopeptidases in DMSO; cat. P8340-1ML, 
Sigma-Aldrich, Poole UK) and phosphatase inhibitors (see Table 2-5 - contains 
inhibitors of serine, threonine and tyrosine phosphatases; cat. 5870S, Cell 
Signalling) was added, and kept on ice until the next step.  
 
The alternative method involved using the Tissue Lyser LT (cat. 85600, QIAGEN, 
Germany). Here, one or two 7mm stainless steel beads (cat. 69990, QIAGEN) were 
pre-cooled in a 2mL microfuge tube on dry ice, to which 20-50mg of snap frozen 
 66 
tissue were added. 100µL of RIPA protein lysis buffer containing protease and 
phosphatase inhibitors as above were added to the tube, before placing in the 
Tissue Lyser LT and oscillating at a frequency of 50Hz, 3 times for 3min. After each 
3min the tubes were inspected for sufficient tissue lysis, and if the mixture began 
to warm to room temperature, the sample was cooled for 2min on dry ice before 
oscillating for a further 3min. Once the tissue was sufficiently homogenized, the 
mixture was carefully removed and placed into a fresh 1.5mL microfuge tube. The 
tube containing the bead was then washed with a further 50µL of lysis buffer, 
which was then carefully removed and added to the rest of the mixture. After the 
first part of mechanical homogenization, an electric pestle (cat. K749510-1500, 
Fisher Scientific) was used to help lyse the sample further, before continuing with 
protein extraction. 
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Table 2-5 Constituents of protease and phosphatase inhibitor mixes, used in protein 
extraction methods. 
Reagent 
Groups of enzymes 
targeted by inhibitors 
Inhibitor names 
(stock concentration) 
Protease Inhibitor 
Cocktail (100x) 
P8340-1ML, Sigma 
Serine proteases  
(e.g. trypsin, chymotrypsin, 
and plasmin) 
AEBSF (104mM), 
Aprotinin (80μΜ), 
Leupeptin (2mM) 
Aminopeptidases Bestatin (4mM) 
Cystein proteases 
E-64 (1.4mM), 
Leupeptin (2mM) 
Acid proteases Pepstatin A (1.5mM) 
Phosphatase Inhibitor 
Cocktail (100x) 
5870S, Cell Signalling 
Serin/ threonine and acidic 
phosphatases 
Sodium fluoride 
Serin/ threonine 
phosphatases 
Sodium pyrophosphate 
β-glycerophosphate 
Tyrosine and alkaline 
phosphatases 
Sodium orthovanadate 
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2.2.3.2 Protein extraction from tissues and cells 
Homogenised tissue samples were put through 2-3 freeze/ thaw cycles to further 
break up the fibrous tissue, before overnight incubation at 4C on rotation (SB3 
Rotator, Stuart Equipment, UK). Samples were then centrifuged at 13,000rpm 
(Heraeus Fresco 17 Microcentrifuge, cat. 75002420, Thermo Scientific, Germany), 
at 4C for 10 min, and the supernatant collected. The insoluble pellet was re-
suspended in 50µL of RIPA protein lysis buffer containing protease and 
phosphatase inhibitors as before, then centrifuged again at 13000rpm, 4C for 
10min, before collecting the supernatant. This process was followed a total of 
three times, and all three supernatants were collated into one sample. During 
optimization steps, it was found that around 90-95% of the total protein from the 
fibrous tissue samples is collected within the first three fractions.  
For cultured cells, protein extraction was completed when the cells reached close 
to 70% confluency. The conditioned media was reserved for other assays 
described below, before thoroughly washing the cells with cold tissue culture-
grade PBS (Dulbecco’s Phosphate Buffered Saline; cat. D8537, Sigma Life Sciences, 
Poole, UK). The PBS was aspirated, and then cold RIPA protein lysis buffer, 
containing protease and phosphatase inhibitors as described above, was added to 
the cells. For 0.5 x 106 cells 100µL of the RIPA protein lysis buffer was used, to 
ensure as high a final protein concentration as possible. Once the RIPA protein 
lysis buffer was added, the cells were scraped and collected into a 1.5mL microfuge 
tube, and stored at -80C until the next step. Cell lysates were then incubated on 
ice for 0.5-2hrs, with agitation by vortexing for 10sec every 15-20min, before 
being spun down at 13,000rpm, at 4C for 10min. The supernatants were collected, 
and any remaining pellets discarded. 
 
2.2.3.3 Protein quantification assay 
Protein quantification was carried out using the DC Protein Assay Kit II (cat. 500-
0112, Bio-Rad, UK). First of all, a 1:5 dilution of each sample was made for the 
assay. If samples appeared highly concentrated, a 1:10 or 1:20 dilution was used, 
to ensure the sample concentration values were within the linear range of the 
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standard curve. Seven dilutions of the protein standard Bovine Serum Albumin 
(BSA) containing from 0mg/mL to 1.2mg/mL protein, were prepared in the same 
RIPA protein lysis buffer used for tissue or cell lysis. For the assay, at least 
duplicates of 5μL of each diluted sample or standard were placed in a clear flat-
bottomed 96-well microplate (cat. 353075, Falcon, Fisher Scientific), followed by 
25μL of solution A’. Solution A’ consists of 20μL of reagent S (surfactant solution) 
to every 1mL of reagent A (alkaline copper tartrate solution). Finally, 200μL of 
reagent B (dilute Folin reagent) was added per well. The plate was gently shaken, 
while avoiding the formation of bubbles, and incubated at room temperature for a 
minimum of 15min, though the reaction is stable for upto 2hrs. Absorbance levels 
were measured at 750nm using the Synergy HT microplate reader (cat. 12926527, 
Bio-Tek Instruments, Thermo Fisher Scientific, UK), before estimating the 
individual protein concentrations. 
 
2.2.4 Western Blotting 
Western blotting was used to detect the expression of specific proteins in cell 
lysates. The isolated protein samples are first denatured, then separated according 
to size, by sodium-dodecyl sulphate (SDS) gel electrophoresis. The SDS applies a 
negative charge to positive ions on the proteins, allowing the proteins to be 
transferred to a nitrocellulose membrane by electrophoresis. Specific proteins can 
then be detected using a primary antibody, to which a secondary antibody binds. 
The secondary antibody is coupled to horseradish peroxidase (HRP), which upon 
the addition of ECL (enhanced chemiluminescent) reagent, a chemical reaction 
occurs and becomes luminescent. The resulting light emission is finally detected 
using autoradiography film. 
 
2.2.4.1 Sodium dodecyl sulphate (SDS) – polyacrylamide gel electrophoresis 
(PAGE) 
Protein lysates were diluted with 4x NuPAGE LDS Sample Buffer (cat. NP0008, 
Invitrogen Life Technologies) containing 10% (v/v) β-mercaptoethanol as a 
reducing agent, then heated at 95-100°C for 3-5 min. 12-well or 15-well Bis-Tris 
precast gels (cat. NP0336BOX, Invitrogen Life Technologies) were secured in the 
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gel electrophoresis tank (XCell SureLock Electrophoresis Mini-Cell; cat. EI0001, 
Invitrogen Life Technologies), before loading samples into the gels: 8µL of protein 
ladder (cat. 161-0374, PrecisionPlus Dual Color Protein Standards, BIORAD) and 
20µL of each sample (10-20µg per well). NuPAGE 20x MOPS SDS running buffer 
(cat. NP0001, Invitrogen Life Technologies) was diluted 1:20 with distilled water, 
and added to the gel electrophoresis tank. Electrophoresis was achieved at a 
current of 60v, 200mA, 100-200W for 15-20mins, then increased to 200v for a 
further 45-60min.  
 
2.2.4.2 Protein transfer and immunoblotting 
The proteins separated on the gels were then transferred onto nitrocellulose 
membranes (Hybond-C Extra Nitrocellulose 0.45μm; cat. RPN303E, GE Healthcare 
Life Sciences), using the Hoefer TE22 Mighty Small transfer tank (cat. TE22, 
Hoefer, supplied by GE Healthcare Life Sciences), and 1x Transfer Buffer [200mL 
Methanol + 700mL water + 100mL 10x Transfer Buffer; see Table 2-6]. The 
current was set at 39mA, 400v for 2hrs.  
 
Any background signal on the membranes was then blocked with 5% (w/v) 
Blocking Buffer [5% (w/v) non-fat dry milk in TBST [Tris-buffered saline (see 
Table 2-6)] containing 0.1% (v/v) Tween], at room temperature for 1hr, under 
agitation. Primary antibody incubation followed, diluting the antibody at the 
appropriate concentration in 3% (w/v) Blocking buffer [3% (w/v) non-fat dry 
milk in TBST; see Table 2-6] and incubating at room temperature for 1hr, under 
agitation. See Table 2-7 for antibody details. MMPs 2 and 14 show 2 expected 
product sizes, as the smaller one represents the active form of the proteins, and the 
larger one represents the inactive form. 
 
The membranes were thoroughly washed with TBST 3 times for 5min, before 
incubating with the appropriate HRP immunoglobulins diluted in 3% (w/v) 
Blocking buffer for 1hr, at room temperature, under agitation. For primary 
antibodies raised in mouse, the Goat-anti-Mouse HRP immunoglobulins (cat. 
P0447, Dako, Agilent Technologies) was used an appropriate dilution optimized 
for each assay (see Table 2-7); whereas for primary antibodies raised in rabbit, 
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the Goat-anti-Rabbit HRP immunoglobulins (cat. P0448, Dako, Agilent 
Technologies) was used (see Table 2-7). Finally, the membranes were thoroughly 
washed 3 times with TBST, and once with TBS before development. 
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Table 2-6 Constituents of buffers used in Western Blotting 
Buffer Constituents Amount Product details Notes 
10x TBS  
(pH7.6) 
Tris-Base 24g cat. T1503-1KG; Sigma-Aldrich For 1L TBST: 100mL 10x TBS + 
899mL distilled water + 1mL Tween  
NaCl 88g cat. S7653-1KG; Sigma-Aldrich 
Distilled water 1000mL Millipore filtered water 
10x Transfer 
Buffer 
Tris-Base 30.35g cat. T1503-1KG; Sigma-Aldrich For 1L 1x Transfer buffer: 100mL 
10x Transfer Buffer + 200mL 
Methanol + 700mL distilled water 
Glycine 144g cat. G8898-1KG; Sigma-Aldrich 
Distilled water 1000mL Millipore filtered water 
Blocking 
Buffer 
Non-fat milk powder 5g (Block) or 
3g (Antibody) 
Marvel dried skimmed milk; Marvel 5% used for blocking membranes, 
whereas 3% used for diluting 
primary and secondary antibodies 
TBST 100mL 1:10 dilution of 10x TBS in distilled 
water plus 0.1% Tween 
Stripping 
Buffer 
(pH6.7) 
Tris-Base 5.75g cat. T1503-1KG; Sigma-Aldrich Used for stripping membranes of 
antibody probing, in order to blot 
for a different protein on the same 
samples 
SDS 10g cat. 23500.260; VWR International 
β-Mercaptoethanol 3.47mL cat. M-3148; Sigma Life Sciences 
Distilled water 500mL Millipore filtered water 
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Table 2-7 Primary and secondary antibodies used for Western Blotting. 
Protein 1ary antibody supplier 
(product code) 
1ary antibody 
(dilution used) 
2ary antibody (dilution used) Expected 
product size 
MMP2 Abcam (ab37150) Rabbit polyclonal IgG  
(1:1000 dilution) 
HRP Rabbit Immunoglobulins; 
cat. P0448, Dako; (1:30.000) 
66/72 kDa 
MMP14 Abcam (ab88618) Rabbit polyclonal IgG  
(1:1000 dilution) 
HRP Rabbit Immunoglobulins; 
cat. P0448, Dako; (1:10.000) 
58/65 kDa 
β-Actin 
 (loading control) 
Sigma (A2228) Mouse monoclonal IgG  
(1:50.000 dilution) 
HRP Mouse Immunoglobulins; 
cat. P0447, Dako; (1:50.000) 
42 kDa 
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2.2.4.3 Image capture and quantification 
The western blots were developed using the Amersham ECL Prime Western 
Blotting reagent (cat. RPN2232, GE Healthcare), containing a luminol solution and 
a peroxide solution. These two solutions were first brought to room temperature, 
before mixing an aliquot of the solutions at a 1:1 ratio (taking care not to cross-
contaminate the bottles of solution). Each membrane was blotted to remove excess 
liquid, then placed on a plastic sheet, and roughly 1mL of the mixture was placed 
per 10cm2 membrane, and incubated at room temperature for 5min. The 
membrane was then enclosed in the plastic sheeting, any excess liquid blotted, and 
stabilized with some tape inside a 18 x 24cm autoradiography Hypercassette (cat. 
RPN13642, Amersham, GE Healthcare). Development then continued in a dark 
room, where a sheet of Amersham Hyperfilm ECL was carefully placed on the 
membrane and incubated for 5sec to 30min in the dark, depending on the strength 
of the signal. The films were then developed using the Xograph Film Autoprocessor 
(Xograph). 
 
The developed films from the western blots were captured on the CanoScan 
LiDE220 flatbed scanner (Canon). Quantification was achieved using ImageJ 1.49v. 
The scanned images were first converted to 8-bit gray-scale images, before 
rectangles of equal size were drawn around each lane of bands to be quantified. 
Next, the profile plot of all the lanes was created via ImageJ, and a straight line was 
drawn across the bottom of each peak, so as to remove any background noise from 
the calculations. The area and size of each peak (representing each band) was then 
measured automatically, and the relative values of band density plotted in Excel. 
To take into account any human error at the time of running the SDS-PAGE gel, the 
values obtained from the protein of interest were corrected with the values 
obtained from the loading control (β-Actin). Finally, the relative difference in band 
density was measured between the normal and keloid samples, representing the 
relative difference in levels of expression for the proteins analysed. 
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2.3 Nucleic acid assays 
2.3.1 RNA extraction from tissue 
Before starting any nucleic acid work, all surfaces and pipettes were first cleaned 
with 70% (v/v) ethanol, then with RNase AWAY solution (cat. 7002, Thermo 
Scientific), and finally with nuclease-free water, to ensure all nucleases and 
contaminants had been removed. Tissue homogenization prior to total RNA 
extraction was carried out in exactly the same way as described in section 2.2.5.1. 
The key difference was the type and volume of lysis buffer used: here, 300-600µL 
in total of Buffer RLT Plus (from the RNeasy Fibrous Tissue Mini Kit; cat. 74704, 
QIAGEN) containing 0.01% (v/v) β-Mercaptoethanol (cat. M-3148, Sigma Life 
Sciences, Poole, UK) was used. As above, an electric pestle was used to help lyse 
the sample further, before continuing with the method for the RNeasy fibrous 
tissue kit.  
 
All samples were treated with proteinase K (from the RNeasy Fibrous Tissue Mini 
Kit) for 10min at 55°C, before centrifuging the samples at ≥10,000rpm for 3min. 
The supernatant was removed and placed in a fresh microtube, to which an equal 
volume of 70% (v/v) ethanol was added and thoroughly mixed. The mixture was 
transferred to the RNeasy spin columns in 700μL aliquots, and centrifuged at 
≥10,000rpm for 30sec, while discarding the flow-through each time. At this stage, 
the RNA in the sample had bound to the column membrane, and so it was washed 
once by adding 350μL of Buffer RW1 to the column, centrifuging at ≥10,000rpm 
for 30sec, and discarding the flow-through. Next, 10μL of DNase stock solution 
mixed with 70μL of Buffer RDD were added to each RNeasy membrane for removal 
of any DNA contamination, and incubated for 15min at room temperature. The 
columns were washed with a further 350μL of Buffer RW1, centrifuged at 
≥10,000rpm for 30sec, and the flow-through discarded. This was followed by 2 
washes with 500μL of Buffer RPE, centrifuging at ≥10,000rpm for 30sec-2min, and 
discarding the flow-through. The RNeasy columns were then placed in fresh 
collection tubes, and centrifuged at ≥10,000rpm for a further 1min to ensure all 
remnants of ethanol and wash buffer constituents had been completely removed 
from the RNeasy membranes. Finally, the bound RNA was eluted from the 
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membranes with 20-40µL of nuclease-free water (cat. BP2484-100, Fisher 
BioReagents, Fisher Scientific). The concentrations were subsequently calculated 
by measuring absorbance levels at 260nm, using the NanoDrop 1000 
spectrophotometer (Thermo Scientific).  
 
In order to ensure the RNA samples were of acceptable purity for use in 
downstream applications described below, the ratio of absorbance levels at 260nm 
and 280nm was used to assess the purity of RNA. A 260/280 ratio of 
approximately 2.0 was considered to be a pure RNA sample, with values near 1.8 
considered to be contaminated with DNA, and values lower than ≈1.8 to be 
potentially contaminated with protein, phenol or other chemical contaminants 
(NanoDrop, 2012, NanoDrop, 2007). 
 
2.3.2 Real Time quantitative Polymerase Chain Reaction (qPCR) RT2 
Profiler arrays  
Two different RT2 Profiler Real Time qPCR arrays were used to examine 5 keloid 
and 5 normal skin samples (Tables 2-1 and 2-2): the Human Extracellular Matrix 
and Adhesion Molecules (ECM) array (cat. 330231 PAHS-013ZA, QIAGEN); and the 
Human Signal Transduction Pathway Finder (STP) array (cat. 330231 PAHS-
014ZA, QIAGEN). A full description of the genes tested in each array is presented in 
Appendices A and B. 
 
2.3.2.1 Reverse transcription and qPCR run for arrays 
The RT2 Profiler Real Time qPCR arrays are provided in 96-well plates containing 
the primer assays for 84 pathway-focused genes, 5 reference genes, 1 gDNA 
(genomic DNA) control, 3 reverse transcripting (RT) controls, and 3 positive PCR 
controls. cDNA synthesis by RT was performed using the RT2 First Strand kit (cat. 
330401, Qiagen). First of all, 1μg RNA was mixed with 2μL of Buffer GE and made 
up to a total of 10μL with non-DEPC treated nuclease-free water, to eliminate any 
remaining gDNA. This gDNA mix was incubated at 42°C for 5min, then placed on 
ice for at least 1min. The reverse transcription mix was made up of 4μL 5x Buffer 
BC3, 1μL Control P2, 2μL RE3 Reverse Transcriptase Mix, and 3μL of nuclease-free 
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water per sample. This 10μL reverse transcription mix was combined with the 
10μL of gDNA elimination mix, before incubating at 42°C for 15min, and 95°C for 
5min to stop the reaction. A further 91μL of nuclease-free water were added to the 
RT reaction mixture, and thoroughly mixed by pipetting. The cDNA synthesis 
reactions were kept on ice until proceeding. 
For the RT2 Real Time qPCR arrays, 102μL of cDNA synthesis reaction was mixed 
with 1350μL of 2x RT2 SYBR Green Mastermix. This was thoroughly mixed by 
pipetting, and then 20μL was aliquoted in each well of the array plates. The PCR 
reaction was performed on the ABI 7500 standard system (Applied Biosystems), 
with the following thermal profile: 10min at 95°C, and 40 cycles of 30sec at 95°C 
and 60sec at 60°C. Data was then analysed using the ∆∆CT method, using the 
predesigned excel template provided by Qiagen 
(www.SABiosciences.com/pcrarraydataanalysis.php.) 
 
2.3.2.2 Statistical analysis for qPCR arrays 
Calculations were carried out as follows. In each sample, Ct values for each gene 
were firstly normalized against the average of the 5 reference genes (this gives the 
ΔCt values). Next, the ΔCt values were converted to the log scale, making the 
assumption that all assays were close to 100% efficient. This was achieved using 
the formula 2–ΔCt. For each gene, the average log scale value of the three control 
samples (AVGctrl) was calculated, and ∆∆CT was estimated by dividing the log scale 
value of each of the 10 samples by the AVGctrl. The resulting data shows the fold-
change in gene expression in each sample, relative to the average of the 5 controls. 
Fold-change of 1 or over was considered as gene up-regulation, whereas a fold-
change of less than 1 was considered as gene down-regulation. For statistical 
analysis to test whether keloid expression was significantly different to control, a 
student’s t-test was applied (p<0.05), with no consecutive correction for multiple 
comparisons. 
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2.3.3 Real Time qPCR by relative standard curve method  
2.3.3.1  Reverse transcription and qPCR run 
Complementary DNA (cDNA) synthesis was achieved using the SuperScript VILO 
cDNA synthesis kit (cat. 11754-050, Invitrogen Life Technologies). Per reaction, 
4µL of 5x VILO Reaction Mix and 2µL 10x SuperScript Enzyme Mix were added to 
1-1.5µg of RNA, according to yield of RNA extraction from each batch of samples. 
The final reaction volume was made up to 20µL with nuclease-free water, and 
gently mixed by pipetting. The RT reaction was carried out in a thermal cycler 
(peqSTAR 2X double block thermocycler; cat. PEQL95-07002, VWR), incubating at 
25°C for 10min, then 42°C for 60min, and terminated at 85°C for 5min. Synthesised 
cDNA was diluted 1:30 for use in Real Time qPCR reactions described below. 
 
Forward and reverse primer pairs were designed and tested for specificity in silico 
using the NCBI Primer-BLAST function 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Alternatively, the 
PrimerBank (http://pga.mgh.harvard.edu/primerbank/) was used to select 
previously tested primer sets. All selected primer oligos were then synthesized by 
Sigma. In certain cases where primer optimization proved unsuccessful, off-the-
shelf QuantiTect primer assays were used (QIAGEN). See Table 2-8 for oligo 
sequences and associated melting temperatures optimised for the qPCR reactions. 
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Table 2-8 Real Time qPCR primer sequences and assay melting temperatures used.  
Gene Sense Primer sequence Anti-sense Primer sequence Tm (°C) 
BCL2 AGGCTGGGATGCCTTTGTGG TTTGTTTGGGGCAGGCATGT 64 
BMP2 ACTACCAGAAACGAGTGGGAA GCATCTGTTCTCGGAAAACCT 64 
COL1A1 ACTTGCTTGAAGACCCATGC GGTGTTTGAGCATTGCCTTT 64 
EGFR TGCACCTACGGATGCACTG CGATGGACGGGATCTTAGGC 64 
GATA3 Hs_GATA3_1_SG (QuantiTect Primer Assay) 62 
HEY1 CGGCTCTAGGTTCCATGTCC GCTTAGCAGATCCCTGCTTCT 62 
MMP1 GAGCAAACACATCTGAGGTACAGGA TTGTCCCGATGATCTCCCCTGACA 64 
MMP2 Hs_MMP2_1_SG (QuantiTect Primer Assay) 62 
MMP3 Hs_MMP3_1_SG (QuantiTect Primer Assay) 62 
MMP13 TCCTGATGTGGGTGAATACAATG GCCATCGTGAAGTCTGGTAAAAT 62 
MMP14 CGAGGTGCCCTATGCCTAC CTCGGCAGAGTCAAAGTGG 62 
SFN GGATCCCACTCTTCTTGCAG CTGCCACTGTCCAGTTCTCA 64 
SORBS1 TGGGCAAGACAAAGACATGGA AGCACTGGAAGAAAGCCTCC 60 
SPARC ACGGCAAGGTGTGCGAGCTG TTGGTGCCCTCCAGGGTGCA 64 
SPP1 ATCACCTGTGCCATACCAGT CTTACTTGGAAGGGTCTGTGG 64 
TNC ACAGCCACGACAGAGGC AGCAGCTTCCCAGAATCCAC 58 
VEGFA Hs_VEGFA_6_SG (QuantiTect Primer Assay) 62 
WISP1 CCAGCCTAACTGCAAGTACAA GGCGTCGTCCTCACATACC 62 
HPRT GAAGAGCTATTGTAATGACC GCGACCTTGACCATCTTTG 62 
B2M GAGGCTATCCAGCGTACTCCA CGGCAGGCATACTCATCTTTT 62 
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The KAPA SYBR FAST qPCR kit (cat. K4602, Kapa Biosystems, supplied by 
Anachem Ltd) was used for making up the qPCR reaction mixtures. For a total 
reaction volume of 10µL per well, 9µL were the qPCR master mix, and 1µL the 
diluted cDNA at approximately 5ng/µL. The qPCR master mix was made up as 
follows: 5µL of 2x KAPA SYBR FAST qPCR Master Mix Universal, 0.2µL of 50x ROX 
Low (reference dye), 0.2µL of 10µM Sense Primer, 0.2µL of 10µM Anti-sense 
Primer, and 3.4µL nuclease-free water. Reactions were performed in triplicate, in 
96-well plates (cat. N8010560, Life Technologies), and sealed with MicroAmp 
Optical Adhesive Films (cat. 4311971, Applied Biosystems). The ABI 7500 
standard system (Applied Biosystems) was used for Real Time qPCR analysis. The 
thermal profile was as follows: 5min at 95°C, 40 cycles of 30sec at 95°C and 60sec 
at 58-64°C (see Table 2-8 for individual assay melting temperatures), followed by 
1 min at 95°C to end the reaction. A consecutive melting curve was acquired at the 
end of the PCR, to ensure reaction efficiency and primer specificity. During assay 
optimization steps, the PCR reactions were carried out on the thermal cycler, and 
the resulting PCR products run on an agarose gel (see below), to establish assay 
specificity.  
 
Data was analysed using the Relative Standard Curve method. For this, a reference 
cDNA synthesized from the Stratagene qPCR Human Reference Total RNA (cat. 
750500, Agilent Technologies) was used to create 1:10 serial dilutions for a 4-
point standard curve. The standard curves were tested for each of the 18 genes of 
interest (GOI) and 2 reference genes tested. The GOI Ct values for each sample 
were normalized against the 2 reference genes (HPRT and B2M), and further 
normalized against each gene’s standard curve. This aimed to take into account 
varying assay efficiencies more accurately. Finally, values obtained for each keloid 
sample was compared against the mean value for the combined normal samples. 
This resulted in gene expression fold-changes being reported, and then adjusted to 
show a positive or negative value, representing an up- or down-regulation 
respectively.  
 
All Real Time qPCR samples destined for comparison against one another were 
processed at the same time. More precisely, their RNA extractions, RT reactions, as 
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well as the final qPCR reactions were performed simultaneously for each group of 
samples being examined. Fold-change values of normalized gene expression levels 
in Keloid vs Normal Skin (control) samples from different groups of samples could 
then be assessed all together.  
 
2.3.3.2 Agarose gel electrophoresis 
A 2% (w/v) agarose/ Tris-acetate ethylediamine-tetra-acetic acid (TAE) gel was 
cast, containing 10μL GelRed (Nucleic Acid Gel Stain 10.000X; cat. 41003, Biotium) 
per 100mL of agarose gel mixture. GelRed is an environmentally safe nucleic acid 
dye, used as an alternative to the highly toxic ethidium bromide. It intercalates 
with DNA, which causes the GELRed to strongly fluoresce when exposed to U.V. 
(ultra violet) light, allowing the location of DNA molecules to be visualized on the 
gel. PCR products resulting from assay optimization steps above were loaded on to 
the gel, mixing 8μL PCR product with 2μL sample loading buffer (5x DNA Loading 
Buffer Blue; cat. BIO-37045, Bioline, London, UK). The samples were run alongside 
10μL DNA ladder (HyperLadder 25bp; cat. BIO-33057, Bioline, London, UK) to 
estimate product size, and separated by electrophoresis at a current of  120V for 
30min. Finally, the PCR products were visualised by U.V. light and the gel 
photographed using a Multi Image Light Cabinet (Alpha Innotech Corporation, San 
Leandro, CA, USA).  
 
2.3.3.3 Statistical analysis of Relative Standard Curve method Real Time 
qPCR data 
Calculations were carried out similar to the qPCR arrays, described in section 
2.3.2.2. The differences were as such: normalization was carried out using the 
average of 2 reference genes, giving the ΔCt values; and assay efficiencies were 
calculated based on the standard curves for each assay. Relative differences in ΔCt 
values for each gene were calculated between the keloid and control group of 
samples, by dividing the average keloid value by the average control value. For 
statistical analysis to test whether keloid expression was significantly different to 
control, a student’s t-test was applied (p<0.05), with no consecutive correction for 
multiple comparisons. 
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2.4 Cell culture methods 
All cell culture was performed in a laminar flow hood under aseptic conditions. All 
sterile disposable culture flasks, plates and dishes, as well as disposable 
strippettes, were from Nunc (Roskilde, Denmark). All centrifuge steps were carried 
out using a Centrifuge 5702 (Eppendorf). All fibroblasts were cultured at 37°C in a 
humidified chamber at 5% CO2/ 95% atmospheric air, whereas all keratinocytes 
were cultured at 10% CO2/ 90% atmospheric air. The difference in CO2 levels were 
adjusted dependent on the sodium bicarbonate concentration present in the 
culture media used, to ensure they buffered to pH7.4. Culture media was changed 
every 2-3 days in all cases. 
 
2.4.1 3T3 mouse fibroblast feeder layer 
NIH/3T3 mouse fibroblast cells (CRL-1658, ATCC, LGC Standards, UK), were 
cultured and expanded in T175 cm2, 3-layer or 5-layer polystyrene culture flasks, 
in Dulbecco’s Modified Eagle’s Medium (DMEM; cat. 21331-046, Gibco, Life 
Technologies), supplemented with 10% (v/v) foetal calf serum (FCS; cat. FCS-
SA/500-50115, Labtech International), 1% (v/v) penicillin/ streptomycin (with 
10000 units penicillin and 10mg streptomycin per mL in 0.9% (w/v) NaCl; cat. 
P0781-100mL, Sigma Life Science, Poole, UK) and 1% (v/v) L-Glutamine (200mM 
stock concentration; cat. G2713, Sigma-Aldrich, St Louis, USA). Culture medium 
was changed every 2-3 days, and the cells were passaged when they became 60-
70% confluent, to avoid transformation.  
 
For cell growth arrest, 3T3 cells at no more than 70% confluency were washed 
with cell-culture grade sterile PBS before incubating in 0.05% (v/v) trypsin/ 
0.02% (v/v) versene (1:10 dilution of 10X solution; cat. 59418C-100ML, Sigma-
Aldrich, UK) for 2-5 min, at 37°C. Once cells had detached fully, at least an equal 
volume of DMEM medium was added to the flask (the serum in the medium 
thereby quenching the enzyme action of trypsin/ versene), the cells were 
resuspended and transferred to a falcon tube. The cells were then centrifuged at 
1000rpm for 5min, the supernatant aspirated off, and the pellet resuspended in 
fresh pre-warmed DMEM medium. This ensured any remaining trypsin/ versene 
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solution was fully removed from the cell mixture. 3T3 fibroblasts resuspended at a 
density of 3-4 x106 cells/ mL of DMEM medium were irradiated with 60 Gy. The 
irradiated 3T3 fibroblasts were counted with a haemocytometer and 
cryopreserved in aliquots of 2-4x106 cells per vial, as described below until 
required. 
 
2.4.2 Primary keratinocyte isolation and culture 
Primary keratinocytes were isolated based on the Rheinwald and Green method 
(Rheinwald and Green, 1977, Rheinwald and Green, 1975). Tissues were washed at 
least 3 times with sterile PBS containing 1% (v/v) antibiotic/ antimycotic solution 
(100X solution of penicillin/ streptomycin/ amphotericin B; cat. 15240-062, Life 
Technologies). Excess fatty tissue was trimmed off the bottom using a disposable 
scalpel to avoid interference in the cell extraction procedure, and the tissue was 
cut into approximately 3-5mm2 pieces. In fibrotic keloid tissues, the majority of the 
dermis was initially removed and kept wet in PBS for later fibroblast extraction, 
and to avoid interference to keratinocyte extraction. The tissue pieces still 
containing the epidermis were then incubated in a 2.5mg/mL Dispase II (cat. 
17105-041, Gibco, Life Technologies) solution diluted with PBS containing 1% 
(v/v) penicillin/ streptomycin, either overnight at 4°C or for 45–90min at 37°C. 
The epidermis was consecutively peeled off the dermis, placed in a falcon tube 
containing 0.25% (v/v) trypsin solution (cat. L11-002, GE Healthcare), and kept at 
37°C in a waterbath for 30-60min. Within this 30-60min timeframe, the falcon tube 
was shaken vigorously every 2-10min, the cloudy solution carefully removed and 
placed in RM+ Medium (see Table 2-9), to quench the trypsin activity. Fresh, pre-
warmed 0.25% (v/v) trypsin was added to the remaining epidermis, and the 
process repeated until no further cells were being released. The cell mixture in 
serum-containing medium was then spun at 800-1000rpm for 10min, the 
supernatant carefully removed and discarded, and the cell pellet re-suspended in 
fresh pre-warmed RM+ culture medium. 
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Table 2-9 Cell culture media compositions used for keratinocyte culture 
SFM (serum-free medium); DMEM (Dulbecco’s Modified Eagle’s Medium); FCS (foetal calf serum); EGF (epidermal growth factor); BPE (bovine 
pituitary extract); P/S (penicillin / streptomycin). 
RM+ Medium SFM Medium 1 SFM Medium 2 SFM Medium 3 
1:1 DMEM and F12 (cat. 21331-020, Gibco, Life 
Technologies) 
KSFM (cat. 17005-
075, Gibco, Life 
Technologies) 
1:1 mixture of DMEM (cat. 
21068-028) and Ham’s F12 
(cat. 21765-029; both 
Gibco, Life Technologies) 
1:1 mixture of SFM 
Medium 1 and SFM 
Medium 2 
Supplements (final 
concentrations) 
Product order info Supplements (final 
concentrations) 
Supplements (final 
concentrations) 
Product order info 
1% (v/v) P/S 
cat. 15140122, Life 
Technologies 
1% (v/v) P/S 1% (v/v) P/S 
cat. 15140122, Life 
Technologies 
5% (v/v) FCS 
cat. FCS-SA/500-50115, 
Labtech International 
EGF 0.2ng/mL  EGF 0.2ng/mL  
cat. 10450-013, Life 
Technologies 
1% (w/v) Adenine (100x stock 
= 0.018M in 0.05M HCl) 
cat. A2786-5G, Sigma-
Aldrich 
BPE 25ng/mL  BPE 25ng/mL  
cat. 13028-014, Life 
Technologies 
1% (v/v) RM+ : 
1. transferrin 5μg/mL 
2. hydrocortisone 0.4μg/mL 
3. cholera toxin 10nM 
4. insulin 5μg/mL  
5. liothyronine 200nM  
6. EGF 10ng/mL 
1. cat. T2252, Sigma-Aldrich 
2. cat. H4881, Sigma-Aldrich 
3. cat. C8052, Sigma-Aldrich 
4. cat. I5500, Sigma-Aldrich 
5. cat. T6397, Sigma-Aldrich 
6. cat. EGF-1, Serotec 
CaCl2 0.4mM CaCl2 0.4mM 
cat. 21115, Sigma-
Aldrich 
 L-Glutamine 2mM 
cat. G7513, Sigma-
Aldrich 
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For cell expansion, 3-4x106 (per T75 flask) irradiated 3T3s were first seeded in 
RM+ DMEM medium (Table 2-9) 2-24 hrs before seeding 3x106 keratinocytes in 
the same flask.  
 
For the experiments presented in Chapter 5, primary keratinocytes were 
expanded in RM+ medium on a 3T3 feeder layer, from the initial extraction 
through to the first 2 or 3 passages, before switching to culturing to serum-free 
keratinocyte media. This consisted of two different serum-free media with slight 
differences in composition, to allow for the different growth factor requirements of 
low and highly confluent cells (Table 2-9). For cells of up to 40-50% confluency, 
“Medium 1” was used. Next, “Medium 2” was assembled, which was then used to 
assemble “Medium 3” for cells above 50% confluency. Medium 3 consisted of a 
1:1 mixture of Medium 1 and Medium 2. 
 
2.4.2.1 Primary keratinocyte passaging 
Once cells reached 60-70% confluency, they were first washed with PBS to remove 
any remnant serum-containing medium, and any cell debris. For keratinocytes 
grown on a feeder layer, the fibroblasts were first detached by adding 0.02% (v/v) 
versene to the culture flask and incubating at 37°C for no longer than 2-3min. The 
flask was given a sharp tap on the side to loosen the feeder cells, which were 
carefully aspirated. The remaining keratinocytes were detached by incubating in 
0.05% (v/v) trypsin/ 0.02% (v/v) versene for 5min. At least an equal volume of 
serum-containing cell culture medium was added to the culture flask, the cell 
mixture well resuspended, then placed in a suitable falcon tube to centrifuge at 
800-1000rpm, for 5min at room temperature. The supernatant was aspirated, the 
cell pellet resuspended in 10mL culture medium, and the cells counted using a 
haemocytometer. Finally, keratinocytes were expanded as described below, 
switched to serum-free media for subsequent experiments, or cryopreserved.  
 
To switch keratinocytes to serum-free media, the pellet of detached keratinocytes 
obtained during the regular procedure for cell passaging was gently resuspended 
in PBS twice, to remove as much of the serum-containing RM+ medium as possible. 
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The washed pellet of keratinocytes was then resuspended in Medium 1, 
centrifuged at 800-1000 rpm to form a pellet again, and finally resuspended in 
Medium 1 to seed in a culture flask (3-4x106 cells per T75 flask). After 1 passage in 
Medium 1, keratinocytes were detached by adding 0.05% (v/v) trypsin/ 0.02% 
(v/v) versene, and incubating for 5min as above. The enzyme action was 
neutralised with Trypsin Neutraliset Solution 1x (cat. R-002-100, Gibco, Life 
Technologies), and the cell mixture centrifuged at 800-1000rpm to form a pellet. 
The keratinocytes were either seeded for experiments, or cryopreserved. 
 
2.4.3 Primary fibroblast isolation and culture 
The remaining dermis from the primary keratinocyte isolation procedure was 
scraped and roughly sliced into 3-5mm2 pieces, before incubating in 0.5-
0.75mg/mL Collagenase D solution (activity at 0.180 U/mg lyophilized enzyme; 
cat. 11088866001, Roche Diagnostics, Germany) diluted in serum-free DMEM cell 
culture medium (1% (v/v) penicillin/ streptomycin, 1% (v/v) L-Glutamine), 
overnight at 37°C. The falcon tubes containing the dissociated fibroblasts were 
then shaken vigorously for 3-5min before filtering through a 100μm pored cell 
strainer, into serum-containing DMEM cell culture medium (10% (v/v) FCS, 1% 
(v/v) penicillin/ streptomycin, 1% (v/v) L-Glutamine), thereby quenching any 
enzyme activity. Cells were spun at 1000rpm for 10 min before seeding at a 
density of 25.000-30.000 cells/cm2 
 
2.4.3.1 Primary fibroblast cell passaging 
Once cells had reached 70% confluency, they were first washed with PBS to 
remove any remnant serum-containing media, plus any cell debris. The fibroblasts 
were then incubated for 2-5 min in 0.05% (v/v) trypsin/ 0.02% (v/v) versene, 
until they had all detached. At least an equal volume of serum-containing cell 
culture media was added to the culture flask, the cell mixture well resuspended 
then placed in a suitable falcon tube to centrifuge at 1000rpm, for 5min at room 
temperature. The supernatant was aspirated, the cell pellet resuspended in 10mL 
culture medium, and the cells counted using a haemocytometer. Finally, fibroblasts 
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were seeded into appropriate culture flasks for experiments, expanded at roughly 
20% of their original density, or cryopreserved. 
 
2.4.4 Cryopreservation of cultured cells 
When cells reached 70% confluency, and were destined for cryopreservation, they 
were washed and detached from the culture flasks as described in the cell 
passaging sections above. Once the cells had been counted and their total yield 
estimated, the cell pellet was resuspended in freezing medium [10% (v/v) diethyl 
sulphoxide (DMSO; Fisher, Leicestershire, UK), 90% (v/v) FCS], to a concentration 
of 2 or 4x106 cells/mL. DMSO was included in the freezing medium to prevent the 
formation of crystals during the freezing process that would otherwise lyse the 
cells. The cell suspension was transferred in 1mL aliquots to cryovials and frozen 
slowly at -80°C. After at least 2 days, the cell vials were transferred and stored long 
term in liquid nitrogen (-170°C). 
 
2.4.5 Cell growth rate estimation 
2.4.5.1 Alamar Blue assay 
Both isolated fibroblast and keratinocyte populations from passages 3 or 4 were 
seeded in triplicates in 6-well plates in their respective media, for growth rate 
evaluation by the Alamar Blue assay. After 16-24h, allowing cells to attach, Alamar 
Blue (AbD Serotec) was added to the cultured cells at a 1:10 ratio, and incubated at 
37°C, in the dark for 2-3 hours. Aliquots were then taken from all samples and 
fluorimetric analysis at an excitation emission spectra of 560/590 nm was carried 
out. Metabolism of Alamar Blue was measured as arbitrary units 
(A.U.).  Measurements were taken at days 1, 3, 5 and 7, with the day 0 values 
subtracted from the data, as normalization. Keloid cells were compared against 
their normal counterparts. 
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2.4.5.2 Population doubling  
An additional, more exact method of measuring cell growth rate was to estimate 
population doubling rates. For both fibroblast and keratinocyte cultures, 
cumulative cell population doubling levels were plotted against time. Calculations 
began at passage 2 or 3, and at each passage for four passages, a total number of 
viable cells were counted using a haemocytometer. The exact same number of cells 
were reseeded at every passage, and performed at exactly the same time interval, 
when cells reached 60-70% confluence. Keratinocytes were passaged every 5 days, 
whereas fibroblasts were passaged every 4 days. Population doubling level (PDL) 
of the cell population was calculated using the following formula: 
 
   log10(total cell count obtained) – log10(total cell count re-seeded) 
PDL  =              
log10(2) 
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3.1 Introduction 
3.1.1 Keloid scar tissue characterisation 
There are well-established morphological differences between keloids, 
hypertrophic scars, normal scars and normal skin. Their structures and how they 
link to function have been investigated for decades, yet there is still confusion in 
the field about the defining characteristics of keloid scarring. A recent 
comprehensive review by Jumper et al on the histopathology of keloid scarring 
brings to light the main common features and unresolved hypotheses that have 
been reported to date (Jumper et al., 2015).  
 
One useful technique used for investigating the scar tissue morphology is the 
Herovici polychrome stain. This technique was first developed in 1963 (Herovici, 
1963, Syed et al., 2011), which selectively stains the nuclei dark blue/ black, and 
the connective tissues both red/pink and blue. It was later confirmed that the blue 
fibres were made up of newly synthesised collagen fibres, and the red/pink fibres 
were made up of mature dense collagen fibres (Lillie et al., 1980, Levame and 
Meyer, 1987). In fact Levame et al suggested that the blue fibres correlated with 
collagen type III immunostaining, and the red/pink fibres correlated with collagen 
type I immunostaining (Levame and Meyer, 1987). This polychrome stain has 
previously been used to examine the ratio of collagen type I and III secretion in 
wound healing (Sebastian et al., 2011), mature burn scars (Rawlins et al., 2006), 
and keloids (Syed et al., 2011). In relation to the Herovici analyses presented in the 
current chapter, the red/pink and blue stains will be interpreted more broadly, 
referring to the collagen fibre thickness and maturity, rather than typesetting into 
collagens I or III.  
 
As described in Chapter 1, during the proliferative phase of wound healing (the 
development of granulation tissue) there is increased angiogenesis, allowing 
increased proliferation of fibroblasts (Darby and Hewitson, 2007). At this stage, 
fibroblasts are activated and begin to express large stress fibres, which are not 
normally seen in quiescent fibroblasts, as well as microfilament bundles (Darby 
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and Hewitson, 2007). The activated fibroblasts become much more contractile, 
then synthesise and deposit matrix molecules in the ECM, thereby playing a major 
role in granulation tissue maturation (Hinz, 2007, Hinz and Gabbiani, 2003). Once 
the activated fibroblasts are fully differentiated, they begin to express the 
cytoskeletal protein α-SMA (alpha-Smooth Muscle Actin), which is now a 
recognized marker for the myofibroblast phenotype (Darby et al., 1990, Sandbo 
and Dulin, 2011, Darby and Hewitson, 2007, Skalli et al., 1986, Darby et al., 2014). 
It has been well described that myofibroblasts appear for a short time in 
granulation tissue during wound healing (Darby et al., 1990, Darby and Hewitson, 
2007, Eddy et al., 1988). In fibrotic conditions however, myofibroblast expression 
is known to persist, leading to excessive matrix deposition and increased tissue 
contraction. For this reason, an increased myofibroblast expression has been 
linked to pathological fibrosis, including hypertrophic and keloid scarring (Skalli et 
al., 1989, Baur et al., 1975, Darby and Hewitson, 2007, Shih et al., 2010a).  
 
α-SMA, as the name suggests, is expressed in vascular smooth muscle cells, which 
are found within the walls of larger blood vessels such as the aorta, as well as small 
arteries, arterioles and veins (Gabbiani et al., 1981). Small blood vessels are often 
found in the deep dermal layers of skin, where they aid in transporting nutrients to 
the skin appendages (Darby and Hewitson, 2007). In an event of infection or 
injury, capillaries also enable the transportation of white blood cells to the site of 
inflammation. For extensive tissue vascularisation analyses, more robust 
endothelial markers such as CD31 (Kurokawa et al., 2010, Connolly et al., 2014) 
have previously been used in keloid and scar characterisation studies. However, as 
angiogenesis was not the main focus of the research in this chapter, it was deemed 
acceptable to comment on general differences between normal skin and keloid 
regions, using α-SMA alone. Added to this, α-SMA had the advantage of a dual 
functionality, being able to detect both blood vessel walls and myofibroblasts 
simultaneously. 
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3.1.2 Extracellular matrix regulation 
As fully described in Chapter 1, the deregulated balance in ECM production and 
degradation is key to keloid scarring. When a normal wound enters the later stages 
of repair, enzymes such as collagenases, gelatinases, and elastases ensure initial 
ECM structures are digested and replenished with more stable versions, until the 
injury has been reconstituted to its original state (O'Kane and Ferguson, 1997, Shih 
et al., 2010a). The major enzymes in this delicately balanced process include the 
matrix metalloproteinases (MMPs), plasminogen activator (PA)-plasmin, and a 
disintegrin and metalloproteases (ADAMs) (Shih et al., 2010a). PA converts 
plasminogen into plasmin, which consecutively breaks down fibrin (Toriseva and 
Kahari, 2009), and activates procollagenases to breakdown collagen (Tuan and 
Nichter, 1998). It is at this stage where young collagen type III is replaced by more 
mature, collagen type I to a ratio (type I/III) of approximately 6 in normal scars 
(Shih et al., 2010a). This is in contrast to keloid scars where the collagen type I/III 
ratio is close to 17 (Friedman et al., 1993, Shih et al., 2010a). It has not been 
concluded whether this effect is due to the lack of collagenase activity (particularly 
for type III), or an increased production of both collagen types (Niessen et al., 
1999, Abergel et al., 1985, Shih et al., 2010a). It is likely that both the lack of 
collagenase activity and increased collagen synthesis contribute to the problem.  
A number of proteases in the MMP family, including MMPs 1, 2, 3, 9, and 13, have 
been reported as overregulated in keloids at the protein level, but with conflicting 
results at the gene level. These MMPs are thought to contribute to scar tissue 
expansion beyond the injury site, as is characteristic of keloids (Leake et al., 2003, 
Oriente et al., 2000, Neely et al., 1999). One report in keloids showed MMP2 levels 
to be increased, though MMP9 levels to be decreased (Neely et al., 1999). 
Contradictory reports on MMP and TIMP expressions perhaps reflect the variable 
conditions and types of controls used across different studies. When testing serum 
from keloid patients and healthy individuals, there was no significant difference in 
expression of MMPs 1, 2 and 9, and TIMP1 and 2 (Ulrich et al., 2010). However, 
cultured fibroblasts from keloid patients and control healthy individuals showed 
an increased expression of all these proteins in the keloid cells (Ulrich et al., 2010, 
Fujiwara et al., 2005a). MMP13 was shown to be increased in keloid-derived 
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fibroblasts, which along with MMP1, was down-regulated upon treatment with 
decorin (Li et al., 2013). Other reports demonstrated MMP2 to be down-regulated 
in keloid-derived fibroblasts (Uchida et al., 2003). MMP14, also known as 
membrane tethered 1-MMP (MT1-MMP), has had little attention in the fibrotic 
scarring field, though it is considered as one of the important regulators of matrix 
re-modelling in the normal healing process (Imaizumi et al., 2009, Gillard et al., 
2004, Parks, 1999). Imaizumi et al (2009) indicated that in keloid fibroblasts, 
MMP2 activity is promoted in collagen bundles, with the cooperation of MMP14 
and TIMP2 (Seifert et al., 2008, Imaizumi et al., 2009). Despite all this, the 
imbalanced ECM production and degradation machinery is still poorly understood, 
and the mechanisms of action of seemingly crucial factors are unclear to date. 
 
3.1.3 Aims 
The primary aim of the work presented in this chapter was to characterise a range 
of normal skin and keloid specimens to be used in the following chapters. Overall 
tissue morphology of each normal skin and keloid will be explored, using routine 
H&E staining and herovici polychrome staining. Immunostaining for Ki67 and α-
SMA were used to investigate cell proliferation and fibrogenesis in keloid scars, 
compared to normal skin. Following this, protein expression patterns for MMPs 1, 
13, 2, and 14 were examined in the normal and keloid specimens by 
immunohistochemistry, to evaluate the potential imbalance in ECM production 
and degradation, characteristic of keloids.  
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3.2 Results  
3.2.1 Human keloid scar tissue collection  
Throughout the course of the research presented in this thesis, a total of 70 keloid 
scars were collected from both male and female patients, with a range of ages, 
ethnic origins, body locations, and types of surgical excision. Biopsies from each 
keloid were snap-frozen and stored at -80°C for nucleic acid or protein analysis, as 
well as fixed and processed into paraffin embedded blocks for 
immunohistochemical methods. Wherever possible, keratinocytes and fibroblasts 
were also extracted from the keloids and the resulting primary cultures stored in 
liquid nitrogen. A similar approach was taken with a total of 29 normal skin 
samples, which were collected for use as healthy controls. Only a small number of 
the collected keloid scars are presented in this thesis, as I aimed to focus on two 
common characteristics within the group of keloids: they are all inclusive of 
extralesional (adjacent normal) tissue; and the majority are from African-
Caribbean patients. Where possible, the same keloid and healthy control tissues 
were used for all the analyses presented in this and the following chapters, to 
minimize the effects of inter-patient variability as much as possible. 
 
3.2.2 Normal healthy skin characterisation 
A total of 9 healthy donor skin specimens were used for characterisation. Of these, 
8 were female and 1 male; 4 of the female samples were of Caucasian origin and 
the rest were of African-Caribbean origin patients (see Tables 2-1 and 2-2 in 
Chapter 2) for full patient details). It is deemed unethical to resect unaffected 
normal skin from keloid patients, as this will knowingly cause a new keloid to 
form. Therefore control tissue cannot be completely matched to each keloid 
patient, and must be retrieved from unrelated healthy individuals. As this disorder 
is highly correlated to the ethnicity of individuals (see section 1.4 in Chapter 1), it 
was of interest to use African-Caribbean control tissues, as the majority of keloids 
being analysed were from African-Caribbean patients. As the majority of published 
keloid research to date has used Caucasian control skin, regardless of the keloid 
patient ethnicity, it was also of interest to include a number of Caucasian control 
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samples in this thesis, so as to be able to compare the data with previously 
published research. Where possible, body location matches were made between 
keloid and control tissues, as it has been shown that fibroblasts can behave 
differently depending on which part of the body they originate from (Chipev and 
Simon, 2002). 
 
3.2.2.1 Normal skin tissue structure 
The overall structure and collagen make-up of the dermal compartment for each 
healthy skin specimen was evaluated through H&E and Herovici staining. In all 
patients, the epidermal thickness was uniform throughout the length of each 
sample, with no apparent differences between Caucasian and African-Caribbean 
individuals. Three representative patients are presented below, which show the 
variability seen within the group of control tissues used (n=9). The epidermis of 
facelift skin (Figures 3-1) had the least undulating appearance, with breast skin 
(Figures 3-3) showing more ridges, and abdominal skin (Figure 3-5) showing the 
most undulation. Almost all normal skin samples contained skin appendages such 
as hair follicles, sweat glands and sebaceous glands.  
 
Herovici staining allowed for visualization of young and mature types of collagen, 
coloured blue and pink, respectively. In all normal skin samples, the collagen fibres 
appear finer and more tightly packed in the papillary dermis, whereas they are 
slightly thicker in the reticular dermis. The thicker mature fibres in the deep 
dermal layers are characteristically loosely organised in no particular orientation. 
This holds true for all healthy normal skin specimens analysed (Figures 3-1, 3-3, 
and 3-5).  
 
3.2.2.2 Ki67 cell proliferation marker in normal skin 
All normal skin samples showed a similar level of Ki67 nuclear expression in the 
basal epidermal keratinocytes, with no expression in the suprabasal layers of the 
epidermis (Figures 3-2, 3-4, and 3-6). Patient 22 was the exception, showing 
almost no proliferative cells in the epidermis (Figure 3-6). Note that Ki67 
expression is restricted to the cell nuclei, and any diffuse brown chromogen 
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observed in the basal epidermal cell layer of certain patients is due to melanin 
pigmentation contained within melanocytes. Cell proliferation was observed at a 
higher rate in skin appendages such as hair follicles. Additionally, patients 4 and 21 
(Figures 3-2 and 3-4 respectively) showed a very small number of proliferative 
cells within the dermis. 
 
3.2.2.3 α-SMA expression in normal skin 
In the normal skin specimens analysed here, α-SMA expression was observed 
mainly in small blood vessels in all dermal layers (Figures 3-2, 3-4, and 3-6). This 
included larger vessels found in the lower reticular dermis near the subcutaneous 
fat layer, as well as very small capillaries surrounding hair follicle bulbs and sweat 
glands, and even in between the epidermal ridges in the papillary dermis. There 
was no evidence of myofibroblasts present in the dermis. 
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Figure 3-1 H&E and Herovici staining of normal skin from patient 4. 
Skin from a facelift of an over 40-year old Caucasian female patient. The top two 
panels show a H&E stain, whereas the lower two panels show a herovici (HVC) stain. 
There is a mixture of loosely organised young and mature collagen fibres in the whole 
dermis. [In pink = Mature Collagen fibres; In blue = Young Collagen fibres]. Images are 
representative of n=9 normal skin biopsies investigated. 
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Figure 3-2 Ki67 and α-SMA protein expression in normal skin patient 4 
DAB-Immunohistochemistry of patient 4 normal skin. Cell proliferation marker Ki67 
(top two panels) showed strong nuclear expression in cells within skin appendages 
such as hair follicles, and in the basal layer of the epidermis. α-SMA (α-Smooth Muscle 
Actin) expression was observed solely in the dermis, though was restricted to blood 
vessel walls. Images are representative of n=9 normal skin biopsies investigated. 
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Figure 3-3 H&E and Herovici stain for normal skin patient 21 
From the breast of an African-Caribbean female patient. The increased levels of 
melanin pigment in this patient can be seen as a diffuse brown colour in the basal 
epidermis. The top two panels show a H&E stain, whereas the two bottom panels 
show a herovici (HVC) stain. All collagen fibres in the dermis are loosely organised and 
randomly oriented. Mature collagen fibres are predominant here. [In pink = Mature 
Collagen fibres; In blue = Young Collagen fibres]. Images are representative of n=9 
normal skin biopsies investigated. 
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Figure 3-4 Ki67 and α-SMA protein expression in normal skin patient 21. 
DAB-Immunohistochemistry of patient 21 normal skin. Cell proliferation marker Ki67 
showed clear nuclear expression in a small number of basal keratinocytes, as well as a 
small number of dermal cells. α-SMA (α-Smooth Muscle Actin) expression showed 
mainly the presence of small blood vessels, although there was a small number of cells 
in the dermis indicating myofibroblasts. In both cases, the diffuse brown shading in the 
basal layer of the epidermis is the melanin pigment. Images are representative of n=9 
normal skin biopsies investigated.  
 
 101 
 
Figure 3-5 H&E and Herovici staining for normal skin patient 22 
From the abdomen of an African-Caribbean female patient. Slightly increased levels of 
melanin pigment can be seen here as a diffuse brown colour in the basal epidermis. 
The top two panels show a H&E stain, whereas the two bottom panels show a herovici 
(HVC) stain. All collagen fibres in the dermis are loosely organised and randomly 
oriented. Mature collagen fibres are predominant here. [In pink = Mature Collagen 
fibres; In blue = Young Collagen fibres]. Images are representative of n=9 normal skin 
biopsies investigated.  
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Figure 3-6 Ki67 and α-SMA protein expression in normal skin patient 22. 
DAB-Immunohistochemistry of patient 22 normal skin. Cell proliferation marker Ki67 
showed clear nuclear expression in very few basal keratinocytes. The diffuse brown 
shading in the basal layer of the epidermis is the melanin pigment. α-SMA (α-Smooth 
Muscle Actin) expression revealed no myofibroblasts. Images are representative of n=9 
normal skin biopsies investigated.  
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3.2.3 Normal, hypertrophic and keloid scars 
A total of 10 keloid scar specimens were used for characterisation, alongside one 
normal scar and one hypertrophic scar added for comparison. Of the keloids, 6 
were male, 3 were female and 1 was of unknown gender. There was one male and 
one female keloid from Caucasian individuals, one male of Asian origin, and the 
rest of the keloid scars were of African-Caribbean origin. The normal scar was 
from a female African-Caribbean patient, and the hypertrophic scar is of unknown 
gender and ethnicity, though it is likely to be Caucasian based on the lack of basal 
epidermal melanin observed in the H&E stain (Figure 3-9). These keloid scars 
were selected as they had been excised inclusive of extralesional material, enabling 
the analysis of the developing keloid into the surrounding normal tissue, as well as 
the central fibrotic scar. For this reason there is a range of body locations used, 
including abdomen, breast, neck, ear, and sternum. As mentioned above in section 
3.2.2, healthy control tissue was matched with the keloid tissue where possible, 
but only breast and abdomen normal tissue was available as matches.  
 
3.2.3.1 Normal and hypertrophic scar tissue structure  
The overall structure of the normal scar (Figure 3-7) appeared in part similar to 
normal skin, in that the epidermis was of similar thickness to normal skin 
epidermis, and was uniform across the tissue. The dermis however was much 
deeper than in normal skin, and any hair follicles or sebaceous glands present 
were restricted to the margins of the scar. Herovici staining of young and mature 
collagen fibres, showed that the normal scar tissue contained mostly mature 
collagen fibres. These were slightly thickened in areas, and slightly more densely 
organised than in normal skin, however they were still randomly oriented, as in 
normal skin (Figure 3-7). 
 
The hypertrophic scar epidermis was thickened and presented distinct ridges and 
protrusions in to the underlying dermis (Figure 3-9), as compared to both normal 
skin and normal scar tissue. The dermis was hugely thickened compared to both 
normal skin and normal scar tissue, and showed varying levels of cellular density 
within the ECM. Herovici staining revealed regions of thickened mature collagen 
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fibres and nodules in the papillary dermis, with a high density of young collagen 
fibres in the majority of the reticular dermis. These collagen fibres in the deep 
dermis were wavy, and highly organised in parallel to the overlying epidermis. In 
both normal and hypertrophic scar specimens, there were no skin appendages 
visible (Figure 3-9).  
 
3.2.3.2 Ki67 expression in normal and hypertrophic scar tissue 
Cell proliferation was minimal in the normal scar sample, with hardly any Ki67 
expression in the basal keratinocytes, no expression in the suprabasal epidermal 
layers, and no expression visible in the dermis (Figure 3-8). The hypertrophic scar 
specimen on the other hand showed an increased level of cell proliferation in the 
basal layer of the epidermis (Figure 3-10), as compared to either normal scar 
tissue or healthy control skin.  There was also some Ki67 expression in the upper 
dermal layers of the hypertrophic scar, which appeared to be increased, compared 
to normal skin. These observations are of course limited, due to the single sample 
analysed for both normal scar and hypertrophic scar tissues. For this reason,  
 
3.2.3.3 α-SMA expression in normal and hypertrophic scar tissue 
In the normal scar tissue, α-SMA expression revealed a very small number of 
dermal cells expressing α-SMA, showing evidence of a small population of 
myofibroblasts (Figure 3-8). The hypertrophic scar tissue (Figure 3-10) showed a 
highly increased level of α-SMA expression in the reticular dermal cells, suggesting 
increased myofibroblast activation. This pattern of myofibroblast expression 
correlated with the expression patterns of young collagen fibres identified in 
section 3.2.3.1 (Figure 3-9).  
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Figure 3-7 H&E and Herovici staining for a normal scar 
Normal scar tissue from the neck of a 31-year old African-Caribbean female patient. 
Skin pigmentation can be seen as a diffuse brown colour in the basal epidermis. 
Epidermal thickness appears normal, and the dermis is thickened. There is a 
predominance of mature collagen fibres in the whole dermis, presented as thickened, 
randomly organised fibres. [In pink = Mature Collagen fibres; In blue = Young  Collagen 
fibres]  
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Figure 3-8 Ki67 and α-SMA protein expression in a normal scar. 
DAB-Immunohistochemistry of normal scar tissue. Very little Ki67 expression was 
found in basal keratinocytes, with almost no expression in the dermis. The diffuse 
brown shading in the basal layer of the epidermis is the melanin pigment. α-SMA (α-
Smooth Muscle Actin) expression revealed a number of small blood vessels, as well as 
a low level of myofibroblasts.  
 107 
 
Figure 3-9 H&E and Herovici for a hypertrophic scar 
The ethnicity, gender and body region of this specimen is unknown, however the lack 
of melanin pigmentation in the basal keratinocytes suggests that the patient was 
Caucasian. The top two panels show a H&E stain, where it is clear the epidermis is 
thickened, with increased ridges into the collagenous dermis. There is an increased 
density of young collagen fibres, particularly in the reticular dermis. Both young and 
mature collagen fibres appear thickened and well-organised in parallel to the 
epidermis. [In pink = Mature Collagen fibres; In blue = Young Collagen fibres].   
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Figure 3-10 Ki67 and α-SMA protein expression in a hypertrophic scar. 
DAB-Immunohistochemistry of a hypertrophic scar specimen. Cell proliferation marker 
Ki67 showed strong nuclear expression in numerous basal keratinocytes along the 
whole epidermal layer, with little expression in the dermis. α-SMA (α-Smooth Muscle 
Actin) expression revealed a number of small blood vessels in the papillary dermis, and 
a high level of myofibroblasts in the reticular dermis. Myofibroblast expression 
appeared to mirror the pattern and orientation of the predominantly young collagen 
fibres observed in the previous Figure 3-9. 
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3.2.3.4 Keloid scar tissue structure 
When examining histological sections of each keloid sample, it became clear that 
there was great variability between patients. Just over half of the keloid scar 
specimens showed distinct differences in epidermal and dermal structures 
between the central, marginal and adjacent normal skin – demonstrating how the 
keloid develops as it expands outwards and upwards. Keloid patients 32, 36, 40, 
42, 51 and 70 (Figures 3-13, 3-19, 3-21, 3-23, 3-25, and 3-29) demonstrated the 
recognised keloid morphology. The central region of the keloid showed a 
thickened, fairly uniform epidermis with minimal undulations, and a deep, densely 
fibrous dermis. Herovici staining revealed randomly organised thick collagen 
nodules surrounded by finer young collagen fibres, together forming acellular, 
cigar-shaped structures. These large collagen bundles were found to run in parallel 
to the surface of the skin. The marginal, or edge, region of the keloid then followed, 
where the epidermis was still thickened but demonstrated particularly deep 
abnormal protrusions into the dermis. A mixture of young and mature collagen 
fibres appeared thickened but tightly packed and well organised, sometimes in 
parallel to the epidermis, sometimes in parallel to the nodular structures described 
in the keloid centre. Finally, the adjacent normal skin region showed a much 
thinner epidermis than the rest of the keloid, which was however more undulating 
than normal healthy skin. One defining feature of the adjacent normal skin tissue 
was that the dermis much resembled that of normal healthy skin, with loosely 
organised and randomly oriented mature collagen fibres.  
 
The intensity levels of the blue (young) and pink (mature) Herovici staining were 
measured and quantified, which revealed a statistically significant increase in 
mature collagen fibres between the keloid centre and edge regions (Figure 3-31). 
Within the keloid edge and adjacent normal regions, there was also a statistically 
significantly increased level of young collagen fibres, compared to mature fibres 
(Figure 3-31).  
 
Keloid patients 26, 34, and 35 (Figures 3-11, 3-15 and 3-17) showed similar 
distinctions between central and marginal scar regions, however there were no 
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clearly defined adjacent normal skin areas histologically identifiable. Conversely, 
the epidermal structure in keloid patient 55 (Figure 3-27) was so abnormal and 
full of irregular protrusions, that there was no distinct central region that 
appeared similar to other keloid specimens. Additionally, the dermis of keloid 
patient 55 did not show the characteristic collagen bundles seen in the central 
regions of other keloids. For this reason, this particular specimen was treated as 
having only edge and adjacent normal areas. Patient 55 also contained a high 
number of hair follicles, most of which were concentrated near the subcutaneous 
fat layer.  
 
3.2.3.5 Ki67 cell proliferation marker in keloid scar tissue 
There was a range of Ki67 expression patterns observed in the keloid scars 
presented in this chapter. The majority of the keloids appeared to demonstrate the 
highest level of cell proliferation in the edge region. Within this category, keloids 
from patients 26 and 34 (Figures 3-12 and 3-16), which had no defined adjacent 
normal skin, showed an increased basal keratinocyte proliferation in the central 
region compared to normal healthy control skin. Whereas the central region of 
keloid patient 35 (Figure 3-18), which also lacked adjacent normal tissue, 
displayed a similar level of Ki67 expression to healthy control skin. Patient 55 
(Figure 3-28), which lacks a defined central region, showed increased cell 
proliferation across the basal epidermis and the whole dermis of the main portion 
of the keloid, leading into a much less proliferative adjacent normal skin region.  
 
Also within the category of keloids displaying the highest cell proliferation rate at 
their margin, patient 36 (Figure 3-20) demonstrated a marked difference between 
the three regions: the centre basal keratinocytes and dermis had a higher number 
of Ki67-positive nuclei than healthy control skin, while the adjacent normal skin 
had almost no evidence of cell proliferation across the epidermis and dermis. 
Keloid scar 70 (Figure 3-30), showed similar Ki67 expression pattern to patient 
36, where the edge had the highest number of proliferating cells, followed by the 
centre, followed by the adjacent normal tissue. An interesting observation for 
patient 70 was that there was a small section within the central region, where the 
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epidermis resembled the more invasive morphology of the margin, and showed an 
increased number Ki67-positive cells (see high power image with dotted line 
border in Figure 3-30). 
 
In keloid patients 32, 40, 42 and 51 (Figures 3-14, 3-22, 3-24 and 3-26) there 
appears to be a fairly constant level of Ki67 expression across all scar regions. The 
only difference between the regions is that in the central and marginal areas there 
is a low level Ki67 expression in dermal cells, however in the adjacent normal 
dermis there is no expression of Ki67.  
 
In terms of quantifying these expression patterns, the number of Ki67-positive 
nuclei was counted and calculated as a percentage of the total number of nuclei 
present in the images of each tissue. Despite the impression of keloid scars and in 
particular the keloid edge regions showing increased cell proliferation levels, there 
was no significant difference between normal skin, keloid centre, keloid edge, or 
keloid adjacent normal skin (Figure 3-32).  There was a high level of variability 
between patients of the same group, however overall it appears that the 
qualitative assessment of keloid scar tissue being more proliferative than normal 
skin is due to the increased number of cells being present in the first place. 
 
It is important to note that Ki67 expression is restricted to the cell nuclei, and any 
diffuse brown shading observed in the basal epidermal cell layer of most keloid 
patients (especially notable in patient 40, Figure 3-22) is due to melanin pigment 
contained within melanocytes.  
 
3.2.3.6 α-SMA expression in keloid scar tissue 
As for Ki67 expression, there was also a range of α-SMA expression patterns 
observed in the keloid scars. Keloid patients 26 and 55 (Figures 3-12 and 3-28) 
revealed almost no myofibroblast expression across the whole tissues. In keloid 
patients 32, 40, 51 and 70 (Figures 3-14, 3-22, 3-26 and 3-30) there were 
numerous myofibroblasts visible in the dermal scar centres and edges. Adjacent 
normal tissue from these patients displayed no myofibroblasts. 
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Keloid patients 34, 36 and 42 (Figures 3-16, 3-20, and 3-24) displayed elevated 
myofibroblast expression in the central and marginal regions, particularly in the 
deep dermal layers. There were no myofibroblasts present in the adjacent normal 
tissue. Finally, keloid scar 35 (Figure 3-18) demonstrated a distinctly strong 
myofibroblast expression in the reticular dermis throughout the whole keloid.  
 
When comparing these observations against healthy control skin, it becomes clear 
that ECM synthesis-inducing myofibroblasts are increased in scarring tissue. See 
Table 3-1 for a summary of the keloid scar morphological and histological 
assessment presented so far. These results suggest that ECM remodeling is taking 
place in the fibrotic scars. In the next section of this chapter, protein expression 
patterns of certain MMPs were examined in the same keloids used above. 
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Figure 3-11 H&E and Herovici staining for keloid scar patient 26 
A recurrent earlobe keloid from an African-Caribbean female patient. In the H&E stain, it is clear the epidermis is thickened across the keloid, 
with the edge showing increased ridges into the dermis. The herovici (HVC) stain shows thick bundles of mature collagen fibres (in pink) across 
the whole dermis, with the fibres being more organised at the edge of the scar. There was no clear adjacent normal tissue distinguishable. 
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Figure 3-12 Ki67 and α-SMA protein expression in keloid scar patient 26. 
DAB-Immunohistochemistry of keloid patient 26. Strong expression of Ki67 was apparent across the whole keloid basal epidermis, with a slight 
increase in the edge, and very little expression in the dermis. α-SMA (α-Smooth Muscle Actin) expression revealed small blood vessels across 
the whole dermis, and little evidence of myofibroblast expression.  
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Figure 3-13 H&E and Herovici staining for keloid scar patient 32 
From the ear of a 20-year old Asian male patient. The H&E stain showed the epidermis is thickened in the centre of the keloid, with the edge 
showing increased ridges into the dermis. The herovici (HVC) stain shows nodules of mature collagen fibres (in pink) surrounded by young 
collagen fibres (in blue) in the central dermis; a mixture of the two types of collagen fibres organised in parallel in the edge dermis; and loosely 
organised mature collagen fibres in the adjacent normal tissue. [Adj. Normal = adjacent normal skin] 
 116 
 
Figure 3-14 Ki67 and α-SMA protein expression in keloid scar patient 32. 
DAB-Immunohistochemistry of keloid patient 32. Nuclear expression of Ki67 was observed across the whole keloid basal epidermis, with 
slightly increased dermal expression in the edge. α-SMA (α-Smooth Muscle Actin) expression revealed small blood vessels across the whole 
dermis, as well as myofibroblasts in the central and edge dermal regions. [Adj. Normal = adjacent normal skin] 
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Figure 3-15 H&E and Herovici staining for keloid scar patient 34 
From the post-auricular region of an African-Caribbean female patient. The increased melanin pigment is visible as a diffuse brown shading in 
the basal epidermis. The H&E stain showed the epidermis is thickened in the centre of the keloid, with the edge showing increased ridges into 
the dermis. The herovici (HVC) stain shows thickened, mature collagen fibres (in pink) surrounded by finer, young collagen fibres (in blue) in 
the central dermis; and an increased density of young collagen fibres at the edge dermis. 
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Figure 3-16 Ki67 and α-SMA protein expression in keloid scar patient 34. 
DAB-Immunohistochemistry of keloid patient 34. Ki67 expression was observed across the whole keloid basal epidermis, with a slight increase 
in the edge, and little expression in the dermis. α-SMA (α-Smooth Muscle Actin) expression revealed small blood vessels across the whole 
dermis, and areas of increased levels of myofibroblasts near the edges of the keloid. 
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Figure 3-17 H&E and Herovici staining for keloid scar patient 35 
From the left scapula of an African-Caribbean male patient. The slightly increased levels of melanin pigment is visible as a faint brown shading 
in the basal epidermis. The H&E stain showed a thickened epidermis in the keloid centre, with the edge showing increased ridges. The herovici 
(HVC) stain showed mature collagen nodules (in pink) surrounded by younger collagen fibres (in blue) in the central dermis; and a mixture of 
well- organised young and mature collagen fibres at the edge dermis.  
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Figure 3-18 Ki67 and α-SMA protein expression in keloid scar patient 35. 
DAB-Immunohistochemistry of keloid patient 35. Ki67 nuclear expression was apparent across the basal layer of the epidermis, with an 
increased expression at the edge, and little expression in the dermis. α-SMA (α-Smooth Muscle Actin) expression revealed small blood vessels 
across the papillary dermis, and an increased level of myofibroblasts in the reticular dermis. 
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Figure 3-19 H&E and Herovici staining for keloid scar patient 36 
A butterfly keloid from the breast of an African-Caribbean female patient. The increased melanin pigment is visible as a diffuse brown shading 
in the basal epidermis. The H&E stain showed a thickened epidermis in the keloid centre, with the edge showing invasive-looking ridges into 
the dermis. The herovici (HVC) stain shows mature collagen nodules (in pink) surrounded by younger collagen fibres (in blue) in the central 
dermis; a mixture of mature collagen nodules and young collagen fibres at the edge dermis; and loosely organised mature collagen fibres in 
the adjacent normal tissue. 
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Figure 3-20 Ki67 and α-SMA protein expression in keloid scar patient 36. 
DAB-Immunohistochemistry of keloid patient 36. This specimen was particularly large, therefore a small portion of each region is shown in the 
far left low magnification images. Ki67 expression was seen in the centre, with a high increase in the edge, and very little expression in the 
adjacent normal basal keratinocytes. α-SMA expression showed capillaries across the papillary dermis, and an increased level of 
myofibroblasts in the central and edge reticular dermis. 
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Figure 3-21 H&E and Herovici staining for keloid scar patient 40 
From the cheek of a 30-year old African-Caribbean male patient. The increased levels of melanin pigment is visible as a diffuse brown shading 
in the basal epidermis. The H&E stain showed the edge had increased ridges into the dermis. The herovici (HVC) stain showed mature collagen 
nodules (in pink) surrounded by young collagen fibres (in blue) in the central dermis; a mixture of well organised mature and young collagen 
fibres at the edge dermis; and loosely organised mature collagen fibres in the adjacent normal tissue. 
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Figure 3-22 Ki67 and α-SMA protein expression in keloid scar patient 40. 
DAB-Immunohistochemistry of keloid patient 40. Ki67 strong nuclear expression was observed in a number of basal keratinocytes, across the 
whole keloid epidermis. The diffuse brown shading in the basal layer of the epidermis is the melanin pigment. α-SMA expression revealed 
capillaries across the whole dermis, and a number of myofibroblasts in the reticular dermis of the keloid edge. 
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Figure 3-23 H&E and Herovici staining for keloid scar patient 42. 
A butterfly keloid from the abdomen of an over 40-year old Caucasian female patient. The H&E stain showed a slightly thickened epidermis in 
the keloid centre, with the edge showing increased ridges into the dermis. The Herovici (HVC) stain showed mainly young collagen fibres (in 
blue) surrounded by mature collagen fibres (in pink) in the central dermis; a mixture of mature collagen nodules and young collagen fibres at 
the edge dermis; and loosely organised mature collagen fibres in the adjacent normal tissue. 
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Figure 3-24 Ki67 and α-SMA protein expression in keloid scar patient 42 
DAB-Immunohistochemistry of keloid patient 42. Ki67 strong nuclear expression was observed in a number of basal keratinocytes, across the 
whole keloid epidermis, with a small number of proliferative cells seen in the central and edge dermis. α-SMA expression revealed capillaries 
across the whole dermis, and increased levels of myofibroblasts in the reticular dermis of the keloid centre and edge. 
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Figure 3-25 H&E and Herovici staining for keloid scar patient 51 
1. From the sternum of an African-Caribbean male patient. The increased levels of melanin pigment are visible as diffuse brown shading in 
the basal epidermis. The H&E stain showed a thickened slightly epidermis in the keloid centre, with the edge showing invasive-looking 
ridges into the dermis. The Herovici (HVC) stain shows mature collagen nodules (in pink) surrounded by young collagen fibres (in blue) 
in the central dermis; a mixture of young and mature collagen fibres at the edge dermis; and loosely organised mature collagen fibres 
in the adjacent normal tissue. 
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Figure 3-26 Ki67 and α-SMA protein expression in keloid scar patient 51. 
DAB-Immunohistochemistry of keloid patient 51. Ki67-positive cells were reduced in the central and adjacent normal basal epidermis. The 
diffuse brown shading in the basal layer of the epidermis is the melanin pigment. α-SMA expression showed increased number of capillaries 
and myofibroblasts in the central and edge regions of the dermis. 
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Figure 3-27 H&E and Herovici staining for keloid scar patient 55  
From the nape of the neck of an African-Caribbean male patient. The H&E stain showed increased ridges and protrusion into the dermis of the 
majority of this keloid. The Herovici (HVC) stain showed thickened collagen fibres (in pink) surrounded by finer collagen fibres (in blue) in the 
main portion of the keloid dermis; and a mixture of young and mature collagen fibres in the adjacent normal tissue.  
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Figure 3-28 Ki67 and α-SMA protein expression in keloid scar patient 55. 
DAB-Immunohistochemistry of keloid patient 55. This specimen did not show a typical “centre”, therefore only “edge” and “adjacent normal” 
regions were defined. Ki67-positive cells appeared reduced in the adjacent normal basal epidermis, and increased in the edge dermis. α-SMA 
expression showed revealed a number of capillaries in the dermis, though very few myofibroblasts.  
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Figure 3-29 H&E and Herovici staining for keloid scar patient 70 
From the post-auricular region of a 35-year old Caucasian male patient. The H&E stain showed a thickened epidermis in the centre, with the 
edge showing increased ridges into the dermis, and some areas of inflammation in the edge and adjacent normal tissue. The Herovici (HVC) 
stain showed mature collagen fibres (in pink) surrounded by young collagen fibres (in blue) in the centre; an increased density of well-
organised mature collagen fibres at the edge dermis; and loosely organised mature collagen fibres in the adjacent normal tissue. 
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Figure 3-30 Ki67 and α-SMA protein expression in keloid scar patient 70. 
DAB-Immunohistochemistry of keloid patient 70. Increased Ki67 expression was observed in edge basal keratinocytes. There was also a highly 
proliferative epidermal area within the central region of the keloid (see high-power image with dotted line border, far left). α-SMA expression 
was low overall, revealing capillaries across the whole dermis, and a small number of myofibroblasts in the keloid centre dermis. 
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Figure 3-31 Quantification of Herovici staining in Normal skin and Scar tissues 
The intensity levels of Blue and Pink/Red staining, representing young and mature 
collagen fibers respectively, were calculated in at least n=10 images per sample. Note that 
the NSc (normal scar) and HSc (hypertrophic scar) are from one individual tissue each, so 
they were not included in the statistical analysis. NS (normal skin) is based on n=9 tissues, 
and the Kel C, E and N (Keloid Centre, Edge and adjacent Normal regions) are based on 
n=12 tissues. Statistical analysis revealed no significant differences between normal skin 
and the keloid as a whole, though there was a statistically significant difference in mature 
collagen fibres (pink) between Keloid Centre and Edge. There was also an increased level 
of young collagen fibres compared to mature collagen fibres within the Keloid Edge and 
Adjacent Normal regions. * = p<0.05; Error bars represent the SD.  
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Figure 3-32 Quantification of Ki67 staining in Normal Skin and Scar tissues  
The percentage of Ki67-positive nuclei per total number of nuclei was calculated in at 
least n=10 images per sample. Note that the NSc (normal scar) and HSc (hypertrophic 
scar) are from one individual tissue each, so they were not included in the statistical 
analysis. NS (normal skin) is based on n=9 tissues, and the Kel C, E and N (Keloid Centre, 
Edge and adjacent Normal regions) are based on n=12 tissues. There was no statistically 
significant difference between Normal Skin and any of the Keloid regions, as tested by a 
Student’s T-test. Error bars represent the SD 
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Table 3-1 A summary of the histological features observed in each keloid region, based on the data from n=10 keloids. 
 
 
 Centre Edge Adjacent normal 
Overall 
morphology of 
tissue 
Epidermis thickened and flattened. 
Dermis very thick and highly 
collagenous. No skin appendages 
present. 
Epidermis slightly thickened, with 
highly irregular ridges. 
Dermis thickened, with some skin 
appendages visible. 
Both epidermis and dermis closely 
resembled healthy control skin 
morphology. Distance from scar 
margin to reach normal skin was 
variable between patients. 
Collagen 
organization 
Thickened mature collagen nodules, 
surrounded by finer collagen fibres, 
making up large acellular collagen 
bundles. 
A mixture of young and mature 
collagen fibres, highly organised in 
parallel bands. Usually in line with the 
thick collagen bundles of the centre. 
Mainly randomly oriented mature 
collagen fibres, as seen in healthy 
control skin. 
Cell 
proliferation 
(Ki67) 
No statistically significant differences in Ki67 expression across all keloid regions and normal skin, calculated in 
relation to the total number of cells present in each tissue.  
-SMA 
expression  
Variable between patients, though 
generally strong myofibroblast 
expression in reticular dermis, as 
compared to healthy control skin. 
Variable between patients, though 
mostly showing a similar pattern of 
expression as in the centre keloid 
region. 
Overall little to no expression, 
comparable to healthy control skin.  
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3.2.4 Matrix Metalloproteinases in normal and keloid tissue  
All 9 healthy control skin samples and 10 keloid specimens characterised above 
were further analysed for protein expression of MMPs 1, 2, 13 and 14, using DAB-
immunohistochemistry. In this section, images from 5 representative healthy 
control skin donors and 5 keloid scars are shown.  
 
3.2.4.1 MMP1 protein expression  
All normal healthy control patient tissues demonstrated a low expression of MMP1 
in the epidermis, with faint expression in the upper epidermal layers, and a 
stronger level of expression in the basal layer (Figure 3-33). There was also a 
small amount of MMP1 expression in the dermis, though most of this was 
restricted to skin appendages and small blood vessel walls, previously identified in 
section 3.2.2.3.  
 
A similar pattern of epidermal expression was seen in the selection of keloid scars 
(Figure 3-34), though there were some subtle differences between patients, and 
between keloid regions. Patient 35 showed almost no expression across the whole 
tissue, whereas patient 42 showed slightly increased MMP1 expression in the 
marginal epidermis, compared to the central epidermis. Both of these were overall 
under-regulated compared to normal skin. Keloids 34 and 40 revealed a 
comparable level of basal epidermal expression as for normal skin, though the 
central regions of the keloids 34 and 40 showed a reduced basal epidermal 
expression. For all keloids, there was a very small increase in MMP1 expression in 
the dermis, compared to healthy control tissue, with no apparent differences 
between keloid regions. Overall, there were minimal differences between keloid 
and normal tissues, with either no difference or a slight down-regulation observed 
in the keloids. 
3.2.4.2 MMP13 protein expression 
MMP13 expression was similarly distributed across the healthy control tissues, as 
for MMP1. In healthy skin donors 6, 9, and 18, epidermal expression was uniform 
across all layers. However, patients 6 and 9 also displayed areas of the epidermis 
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completely lacking MMP13 expression. Normal skin samples 4 and 21 showed a 
higher level of expression in the basal epidermis, though it was still overall a 
relatively weak signal (Figure 3-35). It was also noted that MMP13 showed 
nuclear expression in a number of epidermal cells, other than cytoplasmic 
expression.  
 
As for the keloid scars, expression of MMP13 in the epidermis ranged from very 
little expression in keloid patient 26, to inconsistent expression in keloids 34 and 
35, to near-uniform expression of the whole epidermis in keloid 42 (Figure 3-36). 
Here too, both nuclear and cytoplasmic expression of MMP13 was observed in the 
keloid epidermal compartment. Dermal expression of MMP13 in keloids was 
variable too, though overall slightly increased as compared to normal healthy skin. 
In keloid patient 42, it was notable that MMP13 expression in the dermis appeared 
to follow the patterns of the collagen fibre bundles identified with the Herovici 
stain in section 3.2.3.4. Overall, MMP13 protein expression in keloids was very 
slightly increased compared to normal skin, though no clear differences could be 
identified between scar regions. 
3.2.4.3 MMP2 protein expression 
MMP2 expression in both normal healthy skin and keloid scar tissue showed the 
strongest and most distinctive patterns out of the four MMPs examined here. In 
healthy normal skin, there was particularly strong MMP2 expression in the 
epidermis, though it was not uniform across all layers, or across the whole tissue 
sections. The basal epidermal layer retained the strongest signal, though all normal 
samples also showed regions of the epidermis where MMP2 expression was 
completely absent. In the dermis, MMP2 expression was more diffuse, and equally 
distributed across the whole tissue (Figure 3-37).  
 
The keloid scars showed increased MMP2 expression, as compared to normal 
healthy skin. In the epidermis, MMP2 expression patterns and intensities varied 
between patients: keloids 26, 34 and 40 showed slightly enhanced expression in 
the upper epidermal layers; keloid 35 revealed a weak and uniform level of 
expression across the whole epidermis; whereas keloid 42 demonstrated strong 
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expression only in the centre and edge regions of the scar (Figure 3-38). In the 
dermis of all the keloid scars, there was a trend of increased MMP2 expression 
observed in the marginal regions. For keloid patients 34, 35 and 42 in particular, it 
appeared that MMP2 expression was at its highest in the dermal matrix 
surrounding the thickened collagen bundles described in section 3.2.3.4 (Figures 
3-15, 3-17 and 3-23, respectively for patients 34, 35 and 42). These regions of 
increased MMP2 expression, and thickened collagen bundles also correlate with 
the increased myofibroblast expression observed in the same patients (section 
3.2.3.6, Figures 3-16, 3-18 and 3-24, respectively for patients 34, 35 and 42). For 
both healthy normal skin and keloid scars, MMP2 expression was also 
concentrated in hair follicle bulbs, their sebaceous glands, and in the lining of some 
small blood vessels.  
 
3.2.4.4 MMP14 protein expression 
MMP14 (MT1-MMP) protein expression demonstrated a very similar pattern to 
MMP2 expression described above. It was notably weaker than MMP2 overall, 
though followed the same trend of strong irregular distribution across the 
epidermis in both normal and keloid tissues. Normal skin patients 4 and 21 
showed almost no epidermal expression of MMP14, whereas normal donors 6 and 
9 demonstrated regions of strong or completely absent signal, and normal patient 
18 had a consistently uniform epidermal expression (Figure 3-39). In all healthy 
skin specimens, the dermal MMP14 expression was low and equally distributed in 
the ECM. As for the keloid scars, they followed a variety of MMP14 expression 
patterns. Keloid patients 26, 34 and 40 showed a weak but mostly uniform level of 
expression across all epidermal layers, though had increased dermal expression in 
the marginal regions. In keloid 35, MMP14 expression was only seen in the 
marginal region of the epidermis, though was increased in the reticular dermis of 
the whole tissue. Finally, keloid patient 42 displayed strong MMP14 expression in 
the central and marginal epidermis, with no signal in parts of the marginal and 
adjacent normal epidermis. Dermal expression in this specimen was strongest in 
the marginal regions, surrounding the thick collagenous bundles in the main 
portion of the keloid (Figure 3-40). 
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Figure 3-33 MMP1 protein expression in normal skin  
Representative DAB-immunohistochemistry images of MMP1 expression examined in 
n=9 healthy control patients revealed an overall weak level of expression in the 
epidermis, and almost no expression in the dermis. Appendages and blood vessel walls 
showed MMP1 expression. In NS6, NS9 and NS21, the intense cytoplasmic brown 
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colour in the basal epidermis is melanin, due to the patients being of African-
Caribbean origin. [NS = Normal Skin] 
 
Figure 3-34 MMP1 protein expression in keloid scars 
Representative DAB-immunohistochemistry images of MMP1 expression examined in 
n=12 keloid patients revealed an overall weak level of expression across the scar cross-
sections. In patients K26, K40 and K42, the epidermis showed areas of low expression. 
In most patients, the dermis showed very little expression, mainly concentrated in the 
edge region of the scar. In all patients apart from K42, the more intense cytoplasmic 
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brown colour in the basal epidermis is melanin, due to the patients being of African-
Caribbean origin. [K = Keloid Scar] 
 
Figure 3-35 MMP13 protein expression in normal skin  
Representative DAB-immunohistochemistry images of MMP13 expression examined in 
n=9 healthy control patients revealed a weak level of expression in both the epidermis, 
and dermis. Protein localization varied, appearing to be nuclear in some basal 
keratinocytes and hair follicle cells; cytoplasmic in the rest of the epidermis; and 
secreted in the ECM of the dermis. Appendages and blood vessel walls showed 
MMP13 expression. In NS6, NS9 and NS21, the intense cytoplasmic brown colour in 
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the basal epidermis is melanin, due to the patients being of African-Caribbean origin. 
[NS = Normal Skin] 
 
Figure 3-36 MMP13 protein expression in keloid scars  
Representative DAB-immunohistochemistry images of MMP13 expression examined in 
n=12 keloid patients revealed either no expression (K26) or a medium level of mainly 
cytoplasmic expression (K34, K35, K42) in the epidermis. In most patients, the dermis 
showed very little expression, mainly concentrated in the edge region of the scar. In all 
patients apart from K42, the more intense cytoplasmic brown colour in the basal 
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epidermis is melanin, due to the patients being of African-Caribbean origin. [K = Keloid 
Scar] 
 
Figure 3-37 MMP2 protein expression in normal skin  
Representative DAB-immunohistochemistry images of MMP2 expression examined in 
n=9 healthy control patients revealed an intermittently strong level of expression in 
the epidermis, and low levels in the dermis. Appendages, such as hair follicles and 
sweat glands, as well as blood vessel walls showed MMP2 expression. In NS6, NS9 and 
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NS21, the intense cytoplasmic brown colour in the basal epidermis is melanin, due to 
the patients being of African-Caribbean origin. [NS = Normal Skin] 
 
Figure 3-38 MMP2 protein expression in keloid scars  
Representative DAB-immunohistochemistry images of MMP2 expression examined in 
n=12 keloid patients showed strong expression in most of the epidermis, as compared 
to normal skin. In most patients, the dermis showed increased expression in the edge 
region of the scar, especially around thickened collagen bundles. In all patients apart 
from K42, the more intense cytoplasmic brown colour in the basal epidermis is 
melanin, due to the patients being of African-Caribbean origin. [K = Keloid Scar] 
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Figure 3-39 MMP14 protein expression in normal skin  
Representative DAB-immunohistochemistry images of MMP14 in n=9 healthy control 
patients revealed a similar pattern of expression to MMP2, though was overall weaker 
in the epidermis, and almost absent in the dermis. Appendages, such as hair follicles 
and sweat glands, as well as blood vessel walls showed MMP14 expression. In NS6, 
NS9 and NS21, the intense cytoplasmic brown colour in the basal epidermis is melanin, 
due to the patients being of African-Caribbean origin. [NS = Normal Skin] 
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Figure 3-40 MMP14 protein expression in keloid scars  
Representative DAB-immunohistochemistry images of MMP14 expression examined in 
n=12 keloid patients showed a slightly increased expression in the epidermis, as 
compared to normal skin. In most patients, the dermis showed a modest increase at 
the edges of the scars, especially around the thickened collagen bundles. In all patients 
apart from K42, the more intense cytoplasmic brown colour in the basal epidermis is 
melanin, due to the patients being of African-Caribbean origin. [K = Keloid Scar] 
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3.3 Discussion 
3.3.1 Tissue characterisation 
In the first half of this chapter, a detailed view of each individual keloid and healthy 
control skin specimen was characterised in terms of whole tissue morphology, 
using H&E staining, and collagen fibre formation, using a herovici chromogenic 
stain, whereby young and mature collagen fibres are visualized in blue or pink, 
respectively. DAB-Immunohistochemical analysis was used to examine cell 
proliferation by nuclear expression of Ki67, and fibrogenesis by α-SMA expression 
in dermal fibroblasts. I also included one normal scar and one hypertrophic scar 
for comparison against the keloid scars. 
 
The keloids were all extralesionally excised, inclusive of central, marginal and 
normal tissue adjacent to the scar, however it was not always possible to visualize 
all three regions under histological examination. In patients 26, 34, 35, the 
adjacent normal tissue was not distinguishable from the edge keloid tissue. Patient 
55 had a high level of inflammation, and the majority of the keloid was very 
irregular, meaning it was not possible to distinguish a central region, as seen in the 
rest of the keloid sample set. In the majority of the keloids it was possible to see 
the progression from the established scar tissue in the centre of the keloid, into the 
marginal expanding scar tissue at the edge of the keloid, and finally into the 
adjacent normal tissue.  
3.3.1.1 Tissue morphology and collagen fibre structures 
Several studies have aimed to define the morphological characteristics that 
differentiate keloid scars from hypertrophic scars, normal scars and normal skin. 
This characterisation is based on examining collagen and other ECM protein 
makeup of the tissues, (Ehrlich et al., 1994, Lee et al., 2004, Hellström et al., 2014, 
Chong et al., 2015), angiogenesis and hypoxia (Chong et al., 2015), proliferation 
and cellularity (Ehrlich et al., 1994, Chong et al., 2015), and immune cell infiltration 
(Chong et al., 2015). The histological hallmark of keloid scarring is an abundance of 
“keloidal collagen”; where interstitial collagen fibres are thickened, hyalinised, and 
have a distinct glassy appearance (Lee et al., 2004, Jumper et al., 2015). While 
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some studies have found keloidal collagen bundles are organised in line with the 
skin surface (Ehrlich et al., 1994), others have shown these collagen bundles to be 
haphazardly arranged in the dermis (Knapp et al., 1977, Da Costa et al., 2008).  The 
ratio of collagen type I to type III has also been reported to be increased in keloids 
(Uitto et al., 1985, Abergel et al., 1985, Peltonen et al., 1991), mostly due to 
collagen type I being increased in keloid tissue, while collagen type III levels 
remain similar to normal skin.  
 
In the data presented in this chapter, the central region of the keloid scar showed a 
flattened and thickened epidermis, as compared to normal skin. The dermis 
contained thickened and randomly organized mature collagen nodules, 
surrounded by finer, young collagen fibres. Together they formed large, acellular, 
cigar-shaped collagen bundles, running in parallel to the skin epithelium. The 
morphology of the keloid edge was highly variable between keloids, in both 
epidermal and dermal compartments. On the whole, the epidermis of the keloid 
edge was more invasive-looking, within which the epidermal cell layers were less 
defined due to the increased undulating appearance. The dermis generally 
revealed a higher proportion of young collagen fibres, often interlaced with mature 
collagen fibres. The collagen fibres were highly organised into parallel wavy bands, 
which were usually seen in line with the central keloid collagen bundles, and not 
necessarily in line with the skin surface. This was in contrast to the hypertrophic 
scar tissue analysed, where the wavy collagen fibres observed in the reticular 
dermis were organised in parallel to the epidermis. 
 
Many of these findings are in line with findings in a number of earlier studies 
(Blackburn and Cosman, 1966, Kischer and Brody, 1981, Ehrlich et al., 1994). 
Ehrlich et al (Ehrlich et al., 1994) showed that bundles of collagen fibrils in mature 
keloid scars were indeed randomly oriented, however the closely packed parallel 
collagen fibres were only seen in hypertrophic scars. This was in contrast to my 
findings, where the collagen parallel band pattern was mostly observed at the 
keloid edge. It is likely that the keloid specimens used in Ehrlich’s study were not 
inclusive of the marginal scar regions, and so they only observed the collagen fibre 
patterns in the mature central keloid scars. 
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The concept that there are structural and functional differences between the 
central, edge and adjacent normal sites of the keloid has not been thoroughly 
studied. One clinical study examined the level of disease recurrence and prognosis, 
after surgical excision of the whole keloid inclusive or not of the extralesional 
margin (Tan et al., 2010). The study authors found that keloid scar recurrence was 
increased in patients where the leading edge of the keloid scars had not been fully 
removed (Tan et al., 2010). In other studies, the different lesional sites of the 
keloid have revealed differences in gene expression regulation (Seifert et al., 2008, 
Shih et al., 2010b), more of which will be discussed in Chapter 4. In terms of 
collagen structure and morphology, Syed et al found that the thickened collagen 
bundles were found to be larger and appear more frequent at the edge of the 
keloid, compared to the central and adjacent normal tissue (Syed et al., 2011). The 
same study also reported that the ratio of mature-to-young collagen was at its 
highest at the keloid margin compared to the rest of the keloid, shown in both 
tissue and cultured fibroblasts (Syed et al., 2011).  This was supported by my 
analysis of the Herovici staining, where the Keloid Edge region showed the largest 
difference between young and mature collagen fibres, compared to all other 
regions (Figure 3-31). 
 
A distinction of the normal tissue directly adjacent to the keloid has previously 
been described in terms of differences in gene expression patterns (Seifert et al., 
2008, Shih et al., 2010b, Syed et al., 2011), though most studies on keloid scarring 
only describe the central and marginal regions of the scars. My research shows 
that the tissue morphology and collagen structure in the adjacent normal tissue of 
the keloid was very similar to that of healthy control skin, especially in the dermis. 
The epidermis was sometimes slightly thicker, more proliferative, and with more 
protrusions than observed in healthy control skin samples. Nonetheless, there was 
some variability in the size of the keloid margin; i.e. the adjacent normal tissue 
truly resembling healthy control skin was at a distance of 2-10mm from the 
leading edge of the keloid. This could be a contributing factor in explaining why 
certain extralesionally-excised keloids appeared to lack healthy-looking tissue 
beyond the keloid edges, under histological examination. As it is not universal 
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practice to excise a larger than 2-4mm margin of normal skin around the keloid 
margin, it is possible that the majority of extralesionally-excised keloids discussed 
in the literature, do not in fact contain truly adjacent normal tissue.  
 
A number of keloid specimens demonstrated areas of inflammation, identified by a 
high concentration of polymorphonuclear cells (characteristic of white blood cells) 
seen in the dermis. Patients 26, 32, 51 and 70 (Figures 3-11, 3-13, 3-25, and 3-
29) showed small patches of inflammatory invasion around the edges of the 
keloid, whereas patient 55 (Figure 3-27) had a high level of inflammation in the 
main portion of the keloid away from the adjacent normal skin. 
3.3.1.2 Cell proliferation 
I examined the pattern of cell proliferation in keloid tissues, using Ki67 as a 
marker of cells in the proliferative state (Scholzen and Gerdes, 2000). Across the 
whole keloid, it appeared as if the proportion of cells in the proliferative state was 
increased in comparison to healthy control skin, with the basal layer of the 
epidermis showing the highest level of Ki67 expression. However, quantifying the 
number of proliferative cells as a percentage of the total cells present in the tissue, 
demonstrated that there was no statistically significant difference between any of 
the sample groups. This held true whether comparing normal skin to keloid scar as 
a whole, or comparing the individual keloid regions.  
 
During normal wound healing, the proliferation phase is marked by the formation 
of granulation tissue, re-epithelialisation, angiogenesis, and leads on to tissue 
remodeling by increasing ECM deposition (Baum and Arpey, 2005, Jumper et al., 
2015). It is thought that an extended proliferation phase during wound healing 
strongly influences keloid scar formation (Jumper et al., 2015, Young et al., 2013). 
The keloid epidermis is often thickened with flattened rete ridges (Lee et al., 2004, 
Köse and Waseem, 2008), and the basal keratinocytes express increased levels of 
keratin 16 – a hyperproliferation marker (Bloor et al., 2003, Ong et al., 2010, 
Jumper et al., 2015). It has long been known that local autocrine and paracrine 
signaling occurs between the epidermal and dermal cells, influencing 
inflammatory responses (Pasparakis et al., 2014) and other wound healing 
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processes during scar formation (Garner, 1998, Machesney et al., 1998, Jumper et 
al., 2015). Keratinocytes have been shown to help regulate fibroblast proliferation, 
apoptosis, and collagen production, during normal wound healing (Jumper et al., 
2015, Wang et al., 2015, Köse and Waseem, 2008).  
 
Few studies have been reported on the keratinocyte-fibroblast interaction in 
keloids, though it has been shown that keloid keratinocytes increase proliferation 
and reduce apoptosis of the associated fibroblasts (Funayama et al., 2003, Phan et 
al., 2003). Also, co-culturing keloid keratinocytes with normal fibroblasts leads to 
increased production of collagen type I by the fibroblasts (Lim et al., 2002b, 
Mukhopadhyay et al., 2005). Based on this, it is assumed that a prolonged period of 
increased keratinocyte proliferation would stimulate the associated fibroblasts to 
continue producing more ECM proteins, eventually leading to the fibrotic state of a 
keloid scar.  
3.3.1.3 -SMA expression 
3.3.1.3.1 Myofibroblasts 
I used immunohistochemical detection of α-SMA protein expression, primarily as a 
marker for fibroblast activation (Darby et al., 1990) in the keloid scars under 
examination. Myofibroblasts are differentiated fibroblasts which contain 
cytoplasmic bundles of microfilaments, nuclear indentations, and cell-cell and cell-
stroma connections (Ehrlich et al., 1994). Myofibroblasts are thought to develop 
gradually during wound contraction, from granulation tissue fibroblasts, and 
temporarily express α-SMA while they help to remodel the wound bed (Eddy et al., 
1988, Darby et al., 1990, Welch et al., 1990, Tsukada et al., 1987). In fibrotic 
conditions, including hypertrophic scars (Baur et al., 1975) and keloids (Ehrlich et 
al., 1994), myofibroblasts have been shown to persist, continually synthesizing 
ECM, which leads to the characteristic collagenous tissue of fibrosis (Gabbiani and 
Majno, 1972, Skalli et al., 1989).   
 
In this chapter, normal skin and the normal scar showed no myofibroblast 
expression, whereas the hypertrophic scar and the majority (8 out of 10) of the 
keloid scars displayed increased levels of myofibroblasts in the reticular dermal 
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layers. Previous work on the role of myofibroblasts and how best to detect them in 
hypertrophic scarring and keloids has been conflicting (Jumper et al., 2015, 
Matsuoka et al., 1988, Sarrazy et al., 2011). It has been suggested that α-SMA 
staining could help differentiate between hypertrophic scars and keloids, as only 
hypertrophic scars demonstrated myofibroblast expression (Ehrlich et al., 1994). 
It has since been confirmed that keloids do in fact express α-SMA, though it cannot 
reliably be used as a predictive marker of distinction between scar types, as there 
is substantial expression level variability between hypertrophic and keloid 
patients (Jumper et al., 2015, Lee et al., 2012, Lee et al., 2004). The conflicting 
results between studies may be linked to the variability in how keloid scars have 
been excised (as discussed above in section 3.1.1.1), i.e. whether the samples 
analysed are inclusive of the marginal and extralesional keloid sites, as is the case 
in my sample set. Another observation from my findings was that particularly 
concentrated areas of myofibroblast expression appeared to correlate well with 
the acellular collagen bundles identified earlier on (section 3.1.1.1). This is in 
agreement with studies where α-SMA staining was found positive within collagen 
nodules of keloid tissue (Santucci et al., 2001, Hunasgi et al., 2013, Jumper et al., 
2015). In fact, it was postulated that α-SMA expression may decrease overtime in 
hypertrophic scars, allowing for distinction between young and old lesions; 
whereas α-SMA expression in keloids remains constant regardless of lesion age. 
During normal wound healing, myofibroblasts eventually apoptose once wound 
contraction and re-epithelialisation has been completed. The failure of 
myofibroblasts to apoptose in keloid scars could explain the ongoing growth and 
proliferation seen in these fibrotic lesions (Darby et al., 2014, Santucci et al., 2001, 
Sarrazy et al., 2011, Hinz, 2007, Jumper et al., 2015). 
3.3.1.3.2 Tissue vascularisation 
As α-SMA is a major component of vascular smooth muscle cells (Gabbiani et al., 
1981), blood vessels were also easily visible in the tissues examined in this 
chapter. There was an apparent increased number of blood vessels in the whole 
keloid and hypertrophic scar dermis compared to normal skin, with particularly 
high density of capillaries observed at the keloid scar edge, and in between the 
epidermal protrusions across all keloid regions. This observation is supported by 
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an early study, where through scanning electron microscopy, they observed a 
higher number of blood vessels in the hypertrophic and keloid scars, compared to 
normal scar tissue (Lametschwandtner and Staindl, 1990, Ehrlich et al., 1994). 
Later, it was found that keloid scars actually demonstrate a decreased level of 
angiogenesis, compared to hypertrophic and normotrophic scars, as tested by 
measuring factor VIII-related antigen by IHC staining (Beer et al., 1998). Since then 
there have been several studies showing increased vascularization in keloid scars, 
compared to normal skin (Gira et al., 2004, Trompezinski et al., 2000, Mogili et al., 
2012, Fujiwara et al., 2005b). Vascular endothelial growth factor (VEGF) gene 
expression was found to be increased in keloid epidermis (Gira et al., 2004); TGF-
β1 action appeared to promote VEGF secretion in keloid fibroblasts in vitro 
(Trompezinski et al., 2000, Fujiwara et al., 2005b) and in vivo (Fujiwara et al., 
2005b); and in keloid patient sera and tissues, VEGF was found to be increased, 
while endostatin (anti-angiogenic factor) was decreased compared to healthy 
controls (Mogili et al., 2012). 
 
Using α-SMA as a sole marker of angiogenesis or tissue vascularization is clearly 
very limited, with several growth factors being responsible for this process (Syed 
and Bayat, 2012, Zhang et al., 2015). Imaging techniques for vessel detection 
would also provide a much more comprehensive examination of vascularization 
within tissues (Cole and Herron, 2010). Given the inherent variability between 
keloid patients, a much more thorough, multi-faceted examination of angiogenesis 
and vascularization would be interesting to complete in a wide array of keloid 
lesions, as this may help to further elucidate some of the variable histopathology of 
this disorder. 
 
It is clear that the definition of the separate keloid regions is subject to bias, as 
there are no definitive boundaries between each region. In most cases, the scar 
tissue morphology changes gradually from region to region, with each individual 
keloid demonstrating unique differences in morphology and fibrogenic 
characteristics. It would be interesting to further classify keloid specimens 
according to gender, patient age, scar age, body location of scar, and treatment 
history, in order to be able to correlate the observed characteristics to specific 
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changes in tissue morphology, and thereby establish a more clear cut method of 
defining the different keloid sites. This, however, would require a much larger 
number of samples, to enable the application of more sophisticated and rigorous 
statistical analysis for sound conclusions to be made, which was beyond the 
boundaries of the research presented in this thesis. 
 
It would have been interesting to also look at keratin expression and apoptosis 
markers for a more comprehensive characterisation, however as keloid tissue 
morphology and states of proliferation and apoptosis have been widely published, 
I focused on confirming that these keloids were indeed fibrogenic and displayed 
the basic characteristics previously observed. The data presented in this chapter 
provide additional tissue morphology information derived from the marginal and 
extralesional sites of the keloids, which is rather limited in current literature. 
Accordingly, I aim to present a more complete impression of the keloid 
development. 
3.3.2 MMP expression in keloids 
Matrix metalloproteinases are a subfamily of extracellular zinc- and calcium-
dependent endopeptidases, which are part of the metzincin superfamily of 
proteins (Bode et al., 1993, Huxley-Jones et al., 2007). Moreover, MMPs are 
historically recognized for their role in catabolizing specific ECM molecules. More 
recently however, it has become clear that the primary role of the MMPs is to 
process bioactive molecules such as growth factors, cytokines and chemokines, 
thereby regulating the activity of these proteins and the downstream effects on cell 
behaviour (Gill and Parks, 2008, Egeblad and Werb, 2002, Mott and Werb, 2004). 
Such cell processes include leucocyte activation, chemokine processing, and 
antimicrobial defense (Parks et al., 2004, Manicone and McGuire, 2008, Gill and 
Parks, 2008). During wound healing (described in detail earlier in Chapter 1), 
MMPs participate in the regulating mechanisms of all the tissue repair phases: 
inflammatory cells express MMPs, which then regulate trans-epithelial migration 
of leukocytes and chemokine activity (Parks et al., 2004); MMPs cleave 
components of cell-cell junctions and cell-ECM contacts at the wound edges in 
order to achieve re-epithelialization (Singer and Clark, 1999); and finally tissue 
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remodeling is aided by MMP activity, both via direct proteolytic degradation of 
ECM proteins and through their effects on cell migration (Gill and Parks, 2008). 
 
In fibrosis of the liver, lung and kidney, MMPs have shown to be both inhibitory 
and stimulatory, depending on the tissue type, cell types involved, and other MMPs 
present (Giannandrea and Parks, 2014). Some research groups have supported 
using circulating levels of certain MMPs, including MMPs 1, 2, 7, 8, 9, and 13, or 
their degradation products (collagen fragments) as potential biomarkers of active 
fibrosis taking place (Veidal et al., 2011, Leeming et al., 2011, Rosas et al., 2008). 
Nonetheless, identified roles for specific MMPs are usually not the same across 
different organ systems (Giannandrea and Parks, 2014). MMP research within 
keloid scarring has been varied, but conflicting, as discussed earlier on (section 
3.1.2). 
 
In this chapter, protein expression patterns of MMPs 1, 2, 13 and 14 were 
examined in all of the characterised normal (n=9) and keloid (n=10) specimens. 
Images from 5 representative normal skin samples and 5 representative keloid 
scars were presented in the data, showing the varied patterns of MMP expression 
observed across the full sample set.  
3.3.2.1 Collagenases -1 and -3 (MMP1 and MMP13) 
MMP1 (collagenase-1) and MMP13 (collagenase-3) are capable of cleaving fibrillar 
collagen types I, II, III, V and IX (Reynolds, 1996, Ulrich et al., 2010, Ala-aho and 
Kähäri, 2005), though they have been shown to act on a wide range of ECM 
substrates including fibronectin, aggrecan, laminin, vitronectin, and perlecan (Ala-
aho and Kähäri, 2005). As with most MMP family members, MMPs 1 and 13 also 
have a major role in regulating chemokine activity, affecting cell migration and 
proliferation in inflammatory and wound repair responses (Parks et al., 2004, 
McCawley and Matrisian, 2001).  
 
In the keloid samples analysed in this chapter, both MMPs 1 and 13 showed a very 
low level of protein expression overall, in both the epidermis and dermis, with 
very few differences between normal skin and keloid scars. MMP1 protein 
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expression in keloid scars was either the same as in normal skin, or slightly lower 
than in normal skin. MMP13 protein expression appeared to be very slightly 
increased in keloids compared to normal skin. These findings are in line with 
previous studies, though there are also areas of conflict. Looking at primary 
cultured fibroblasts, MMP1 gene and protein expression was significantly 
decreased, while MMP13 was significantly increased in keloid-derived fibroblasts 
compared to normal fibroblasts (Uchida et al., 2003). By contrast, MMP1 protein 
expression levels were shown to be increased by 6-fold in keloid-derived 
fibroblasts compared to normal fibroblasts, in another study (Fujiwara et al., 
2005a). This discrepancy could be due to in vitro studies on MMPs being 
notoriously poor at predicting their physiologic functions (Giannandrea and Parks, 
2014, Parks et al., 2004, Gill and Parks, 2008). In keloid patients who underwent 
pulsed-dye laser (PDL) treatment, some scar tissue regression was observed, and 
MMP13 protein expression was significantly increased, while there was no change 
in MMP1 protein expression, as tested by IHC and Western Blot (Kuo et al., 2005). 
This suggests that MMP13 could be acting as an anti-fibrotic enzyme through PDL 
treatment, though it was not clear from the study whether MMPs 1 and 13 were 
altered in keloid tissues compared the normal tissues, regardless of the effect of 
the PDL treatment.  
 
In other forms of fibrosis, Iimuro et al used a thioacetamide (TAA)-induced rat 
model of acute hepatocellular injury to show that overexpressing MMP1 in fibrosis 
increased scar tissue degradation (Iimuro et al., 2003). This proposed potential 
therapeutic strategy was further tested in myocardial (Foronjy et al., 2008) and 
muscle (Kaar et al., 2008) fibrosis mouse models, where a degradation of the scar 
tissue was also observed. In a chronic liver fibrosis mouse model, where mice are 
treated with carbon tetrachloride (CCl4) over a period of at least 10 weeks, MMP13 
also demonstrated anti-fibrotic effects. Fibrosis was seen to persist in MMP13-
deficient CCl4-treated mice (Fallowfield et al., 2007); and overexpression of 
MMP13 in CCl4-treated rats appeared to promote hepatocyte proliferation and 
tissue remodeling, via the activation of HGF (hepatocyte growth factor), MMP2 and 
MMP9 (Endo et al., 2011). However, it is unlikely that the anti-fibrotic effect of 
MMP13 is due to MMP2 and MMP9 acting directly on interstitial collagen, as their 
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catalytic domain structures do not interact easily with the large fibrillar triple 
chains of interstitial collagens (Giannandrea and Parks, 2014, Parks et al., 2004). 
Conversely, MMP13 also demonstrated pro-fibrotic effects, in a bile-duct ligation 
(BDL) model of liver injury, where a loss of MMP13 led to a reduction in cytokine 
production, myofibroblast activation, collagen expression, and of the fibrotic tissue 
in general (Uchinami et al., 2006). 
 
My findings support elements of the literature discussed above, which show MMP1 
to be unaltered or decreased in keloids and other fibroses, and MMP13 to be 
increased, compared to healthy control tissue. Kuo et al suggested that increased 
MMP13 production may be involved in the remodeling of keloid scar tissue, by 
cleaving collagen type III and allowing new collagen type I to be synthesized (Kuo 
et al., 2004, Kuo et al., 2005). The high concentration of collagen type I present in 
the keloid dermis, alongside the increased level of MMP13 and minimal difference 
in MMP1 expression in the keloid dermis noted in this chapter, would support this 
hypothesis.  
3.3.2.2 Gelatinase A (MMP2) 
MMP2 is capable of cleaving collagen types IV, V, VII, X, XI and XIV, gelatin, elastin, 
proteoglycan and fibronectin, and is expressed by a range of cell types including 
keratinocytes, fibroblasts, and endothelial cells (Hernández-Pérez and 
Mahalingam, 2012, Kerkelä and Saarialho-Kere, 2003, Sawicki et al., 2005). MMP2 
is also widely studied in the context of inflammation and modulating chemokine 
activity (Parks et al., 2004, McQuibban et al., 2000). 
 
In my findings, MMP2 showed a marked increase in protein expression in the 
keloid scars, particularly in the dermis. This supports several studies where MMP2 
has been shown to be overexpressed in keloids (Ulrich et al., 2010, Bran et al., 
2010, Fujiwara et al., 2005a, Tanriverdi-Akhisaroglu et al., 2009, Imaizumi et al., 
2009). MMPs 1, 2 and 9 circulating protein expression in hypertrophic scar and 
keloid patient sera showed no significant differences to healthy control patients. 
However, when the same patients’ scar tissues were analysed for gene expression 
levels, only MMP2 was significantly increased in keloid and hypertrophic scars 
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compared to normal scar tissue (Ulrich et al., 2010). Interestingly, TIMP1 and 
TIMP2 also showed significantly increased gene expression in the aberrant scars, 
compared to normal scar tissue (Ulrich et al., 2010). In cultured cells, MMP2 gene 
expression (Fujiwara et al., 2005a), and protein secretion (Bran et al., 2010) was 
shown to be increased in keloid-derived fibroblasts, compared to normal 
fibroblasts. In patient material, normal skin showed the highest level of pro-MMP2 
compared to hypertrophic and keloid scars as tested by ELISA, though fibroblasts 
derived from the same keloids revealed the highest levels of active MMP2 
compared to normal fibroblasts, as tested by gelatin zymography (Tanriverdi-
Akhisaroglu et al., 2009).  
 
In terms of keloid regional differences, there appeared to be increased levels of 
MMP2 expression at the keloid edge, particularly surrounding the enlarged 
collagen bundles identified in the characterisation steps. Imaizumi et al reported a 
similar finding, when comparing keloid and mature scar tissue. They found that 
MMP2, TIMP2 and TIMP3 were all significantly increased in keloids compared to 
mature scar tissue (Imaizumi et al., 2009). However in my findings, I also observed 
a high MMP2 expression in the keloid epidermis, which appeared not to be seen 
(and not addressed) by Imaizumi et al. Another interesting finding in the same 
study, was the co-expression of MMP2, MMP14 and TIMP2 in keloid fibroblasts, 
supporting the hypothesis that these three enzymes regulate each other’s activity 
(Imaizumi et al., 2009). More specifically, it is thought that MMP14 binds to the N-
terminal of TIMP2, which then allows for the catalytic domain of TIMP2 to bind to 
the HPX (hemopexin) domain of pro-MMP2. Another MMP14 molecule then binds 
to pro-MMP2 leading to a two-step activation step of MMP2 (Hadler-Olsen et al., 
2011, Visse and Nagase, 2003). Taken together, the MMP2 overexpression and 
increased activity may aid the keloid expansion, by breaking down surrounding 
ECM, and allowing the resident myofibroblasts to migrate and deposit new 
collagen fibres (Neely et al., 1999).  
3.3.2.3 MT1-MMP (Membrane tethered 1-MMP; MMP14) 
MMP14 is a membrane-tethered family member, which is best known as an 
activator of pro-MMP2, though can also facilitate the proteolysis of fibrillar 
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collagens, syndecan-1 and laminin, as well as cleave monocyte chemotactic 
proteins (Parks et al., 2004, Goldsmith et al., 2013). In terms of fibrosis, it is 
thought to enhance pro-fibrotic signaling pathways (Goldsmith et al., 2013). 
 
In the data above, MMP14 showed a very similar pattern of expression as MMP2, 
though was overall weaker than MMP2 in both normal skin and keloid scars. 
Certain keloids did show a marked increase in dermal expression compared to 
normal skin, especially in the marginal dermal regions, surrounding the dense 
collagen bundles, as for MMP2. This is most likely due to MMP14 being recognized 
as an activator of pro-MMP2 (Visse and Nagase, 2003, Itoh and Seiki, 2006, 
Imaizumi et al., 2009, Hadler-Olsen et al., 2011). MMP14 has not been widely 
studied in keloids or hypertrophic scarring, though its role in keloid development 
could be interesting, as it has been suggested that it has a key role in epithelial cell 
proliferation, post-injury (Atkinson et al., 2007). In this study, MMP14 knockouts 
of an airway epithelial-specific injury mouse model showed impaired wound 
healing compared to wildtype. This was thought to be linked to keratinocyte 
growth factor (KGF) receptor, which was seen to be overexpressed in the wildtype 
mice, but not the MMP14 knockouts (Atkinson et al., 2007).  
 
In myocardial fibrosis, it has been reported that MMP14 is likely to play an 
important role in the activation of the pro-fibrotic molecule TGFβ (Goldsmith et al., 
2013, Tatti et al., 2008). In animal models of pressure overload (PO) – a precursor 
to cardiac hypertrophy – early and sustained induction of MMP14 has been 
observed (Zile et al., 2012). In a myocardial infarction (MI) mouse model, MMP14 
activity was found to have different effects within the MI region, and in the 
surrounding tissue. MMP14 appeared over-expressed in the MI region, in 
conjunction with MMP2 increased activity, whereas the increased MMP14 levels in 
the surrounding tissue was correlated with an increase in TGF-β signaling and 
collagen synthesis (Spinale et al., 2010).  This pattern ties in with some of my 
observations, where MMP14 and MMP2 over-expression in the keloid tissues were 
identified in the similar regions to each other, and showed an increased 
concentration at the scar edges, where the thickened collagen bundles were 
located. 
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In most studies where MMP levels have been linked to keloid scarring, primary cell 
cultures have been used, of which mostly the fibroblasts have been monitored. 
Where histological analyses of MMPs have been made, the main focus has been on 
the dermis. This is undoubtedly important, however, with growing evidence that 
epithelial-mesenchymal interactions lead to alterations in cell behaviour of either 
compartments (Ghaffari et al., 2009b, Mukhopadhyay et al., 2005, Funayama et al., 
2003, Lim et al., 2002b, Hahn et al., 2013), it is likely that the aberrant mechanisms 
taking place here are present in both epidermis and dermis. 
 
Evaluating the protein expression of MMPs 1, 2, 13 and 14 in keloid and normal 
tissues show a first impression of the kind of MMP activity that might be taking 
place in the keloid scars. The high concentration of collagen I present in the keloid 
dermis, shows there is an imbalance of tissue remodeling processes. The small, 
almost non-existent differences in protein expressions of MMPs 1 and 13 support 
the fibrotic condition of the keloids. Whereas the clear overexpression of MMP2 
and its activator, MMP14, in keloids suggests that fibrotic expansion is taking 
place. Seeing as MMPs are known to be regulated by their microenvironment, 
depending on which cell types, chemokines, cytokines and ECM molecules are 
present, it becomes clear that studying their expression and function in isolated 
cell cultures will most likely not be representative of their actual action in vivo 
(Giannandrea and Parks, 2014, Parks et al., 2004, Gill and Parks, 2008). As their 
action depends on which effectors and inhibitors are in their microenvironment, it 
becomes important to examine the composition of this microenvironment. In the 
following chapter, a more focused approach has been applied to explore which 
genes are expressed differently in keloid scars compared to normal skin, in the 
context of the ECM and related adhesion molecules. 
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4.1 Introduction 
4.1.1 Gene expression analyses in keloids 
To date, there have been a number of studies investigating the genetic aspects of 
keloid scarring (Shih and Bayat, 2010b), including inheritance patterns (Clark et 
al., 2009, Marneros et al., 2001, Omo-Dare, 1975), genome-wide association 
studies (GWAS) (Nakashima et al., 2010b, Marneros et al., 2004a, Velez Edwards et 
al., 2014), and whole genome microarrays (Tosa et al., 2005, Smith et al., 2008, Na 
et al., 2004, Chen et al., 2003, Hahn et al., 2013).  
 
Across a number of studies, a variety of sample types have been tested, different 
technology platforms used, and the stringency of the analyses performed has been 
inconsistent, in terms of the threshold set for statistical significance (Shih and 
Bayat, 2010b, Huang et al., 2013a). Using keloid scar tissue, Chen et al. compared 
against internal control samples (Chen et al., 2003), whereas Naitoh et al. used a 
combination of internal and external control skin (Naitoh et al., 2005). Some 
examined keloid-derived fibroblasts (Smith et al., 2008, Seifert et al., 2008), whilst 
Hahn et al. are the only ones to date to report on microarray analysis of keloid-
derived keratinocytes (Hahn et al., 2013). The ethnicity of the patients is not 
always mentioned, though Chen et al. examined Chinese patients (Chen et al., 
2003), Nakashima et al. focused on the Japanese population (Nakashima et al., 
2010b), Velez Edwards et al. recruited mainly African-American keloid patients 
(Velez Edwards et al., 2014), and Hahn et al. examined a Caucasian and African-
American patients (Hahn et al., 2013). 
 
Two groups have aimed to collate the current published gene expression profile 
datasets, and identify which genes showed to be significantly altered in keloids 
compared to normal skin, across at least two separate microarray studies (Shih 
and Bayat, 2010b, Huang et al., 2013a). Shih et al. found a total of 25 genes 
reported to be up- or down-regulated in more than one microarray study, loosely 
categorized into three functional groups: ECM (extracellular matrix), inflammation, 
and apoptosis (Shih and Bayat, 2010b). Three years later, Huang et al. identified a 
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total of 64 genes to be altered in keloids, 48 of which appeared to also be altered in 
hypertrophic scarring (Huang et al., 2013a). This relatively small proportion of 
overlap between microarray studies where over 1100 genes have been identified 
as altered collectively over the last decade, was most likely affected by the lack of 
consistency between microarray studies, as mentioned above. Overall, genes 
related to ECM and tissue structure were over-expressed in keloid tissue and 
fibroblasts, such as collagens, fibronectin, aggrecan, and versican. MMP (matrix 
metalloproteinase) gene expression was inconsistent, with MMPs 2 and 14 found 
to be over-expressed, while MMPs 1 and 3 were under-expressed in keloids. Genes 
linked to the TGF-β pathway were overexpressed in keloids, as were cell survival 
and cell proliferation related genes. Across both keloid and hypertrophic samples, 
genes related to skeletal development were significantly altered in keloids 
compared to normal skin (Huang et al., 2013a). See Table 4-1 for a summary of 
some of these altered genes. 
 
Very few gene expression studies have been reported comparing the different 
keloid sites. One group examined the differences in gene expression profiles 
between the deep dermis of the centre, superficial dermis of the centre, and the 
edge (Seifert et al., 2008). Overall there were some small differences in levels of 
gene expression between the regions, however they all followed similar trends, i.e. 
all three regions were either overexpressed or underexpressed compared to 
external control skin, with no genes showing an overexpression in one region and 
an underexpression in another region. Interestingly, the superficial central scar 
showed a slight increase in apoptosis-related gene expression, compared to the 
rest of the keloid. This supports the notion that the keloid is not a static fibrotic 
tissue, and is continually undergoing gradual remodelling, with an expanding edge 
and apoptotic centre (Seifert et al., 2008).  
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Table 4-1A Summary of genes found to be altered in at least two microarray studies 
(continued on next page) 
All genes were up-regulated in keloid compared to normal skin, except where 
indicated with an asterisk (*), signifying a down-regulation in keloids. Based on two 
reports (Shih and Bayat, 2010b, Huang et al., 2013a). 
Gene code Gene full name Involved in… References 
A2M Alpha-2-
macroglobulin 
Inflammation, 
protease inhibitor 
(Chen et al., 2003, Hu et al., 
2006) 
ACAN Aggrecan ECM, 
inflammation 
(Naitoh et al., 2005, Seifert 
et al., 2008) 
ADIPOQ Adiponectin, C1Q and 
collagen domain 
binding 
Fat metabolism, 
ECM remodelling 
(Huang et al., 2013a) 
ANXA1 Annexin-A1 Inflammation, 
apoptosis 
(Hu et al., 2006, Seifert et 
al., 2008) 
BMP6 Bone morphogenetic 
protein 6 
Apoptosis (Huang et al., 2013a)  
NREP 
(C5ORF13) 
Neuronal 
regeneration related 
protein 
ECM remodelling (Smith et al., 2008, Hu et 
al., 2006, Naitoh et al., 
2005) 
COL1A1 Collagen I alpha1 ECM (Naitoh et al., 2005, Seifert 
et al., 2008) 
COL1A2 Collagen I alpha2 ECM (Chen et al., 2003, Hu et al., 
2006) 
COL4A2 Collagen IV alpha2 ECM (Hu et al., 2006, Seifert et 
al., 2008) 
COL5A2 Collagen V alpha2 ECM (Chen et al., 2003, Hu et al., 
2006) 
COL6A1 Collagen VI alpha1 ECM (Hu et al., 2006) 
COL15A1 Collagen XV alpha1 ECM (Naitoh et al., 2005, Seifert 
et al., 2008) 
DCN Decorin  ECM (Hu et al., 2006, Chen et al., 
2003) 
EGFR * Epidermal growth 
factor receptor 
Inflammation, 
apoptosis 
(Seifert et al., 2008) 
FAP Fibroblast activation 
protein alpha 
Proliferation, 
inflammation 
(Naitoh et al., 2005, Seifert 
et al., 2008) 
FN1 Fibronectin 1 ECM, 
inflammation, 
apoptosis 
(Chen et al., 2003, Naitoh 
et al., 2005, Seifert et al., 
2008) 
HIF-1A Hypoxia-inducible 
factor alpha subunit 1 
Apoptosis (Seifert et al., 2008) 
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Table 4-1B (Continued from Table 4-1A) 
Gene code Gene full name Involved in… References 
IGFBP7 Insulin-like growth 
factor binding protein 
7 
Inflammation (Seifert et al., 2008, Smith 
et al., 2008) 
JAG-1 Jagged-1 Angiogenesis, 
ECM remodelling 
(Smith et al., 2008, Hu et al., 
2006) 
JUP * Junction plakoglobin Cell junction 
organisation 
(Hu et al., 2006, Smith et al., 
2008, Hahn et al., 2013) 
MMP1 * Matrix 
Metalloproteinase 1 
(collagenase 1) 
ECM remodelling (Smith et al., 2008) 
MMP2 Matrix 
Metalloproteinase 2 
(gelatinase A) 
ECM remodelling  (Huang et al., 2013a) 
MMP3 * Matrix 
Metalloproteinase 3 
(stromelysin 1) 
ECM remodelling (Smith et al., 2008, Seifert et 
al., 2008, Hahn et al., 2013) 
MMP14 Matrix 
Metalloproteinase 
14 (MT1-MMP) 
ECM remodelling (Huang et al., 2013a) 
NRP1 * Neuropilin 1 Cell migration, 
apoptosis 
(Smith et al., 2008, Chen et 
al., 2003) 
OGN Osteoglycin ECM, ossification (Naitoh et al., 2005, Smith et 
al., 2008) 
POSTN Periostin, osteoblast 
specific factor 
ECM remodelling (Naitoh et al., 2005, Hu et al., 
2006, Hahn et al., 2013) 
SERPINF1 * Serpin peptidase 
inhibitor, clade F 
Apoptosis (Seifert et al., 2008, Smith et 
al., 2008) 
TGF-β1 Transforming 
growth factor beta 1 
ECM, 
proliferation 
(Seifert et al., 2008, Chen et 
al., 2003) 
TGF-βRIII * Transforming 
growth factor beta 
receptor III 
ECM, 
inflammation 
(Hu et al., 2006, Seifert et al., 
2008) 
THBS2 * Thrombospondin 2 Angiogenesis, 
ECM interactions 
(Seifert et al., 2008) 
THBS4 Thrombospondin 4 ECM interactions 
& remodelling 
(Naitoh et al., 2005) 
TNC * Tenascin C ECM remodelling (Huang et al., 2013a, Hahn et 
al., 2013) 
VCAN Versican ECM, 
inflammation 
(Naitoh et al., 2005, Chen et 
al., 2003, Seifert et al., 2008) 
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It is possible that the gene expression studies described above, are based on keloid 
scars which have been excised with varying margins of adjacent normal skin. As 
discussed in Chapter 3, defining the different keloid regions is subject to bias, and 
highly variable between patients. For this reason, most attempts at analyzing the 
different keloid regions separately are not easily reproducible across research 
groups. In the case of the expression data on isolated fibroblasts, the expression 
patterns observed may not be representative of the processes taking place in vivo. 
The impact of the resident keratinocytes, possible immune cell infiltration, 
underlying adipocytes, as well as circulating growth factors and cytokines from the 
increased blood supply to the scar tissue are not accounted for in a fibroblast-only 
analysis. This complication is partly explored in Hahn et al.’s study, where they 
performed microarray analysis on isolated keloid fibroblasts and keratinocytes, 
then followed up with RT-PCR analysis on whole keloid tissue (Hahn et al., 2013). 
A total of 25 genes were significantly altered in keloid fibroblasts, 31 genes were 
significantly different in keloid keratinocytes, though only 9 of these genes 
continued to be altered in whole tissue. Interestingly, when they compared lesional 
to non-lesional cells taken from the same patient, there was little difference in gene 
expression levels despite there being a significant difference between keloid and 
external control cells (Hahn et al., 2013).  
 
Consequently, the gene expression data described below are based on analyzing a 
cross-section of whole keloid scars – containing central, edge and adjacent normal 
tissue, with both dermal and epidermal compartments. This way, a snapshot of the 
complete fibrotic lesion is taken into consideration, inclusive of all cell types, and 
all tissue compartments. 
 
4.1.2 Aim 
The primary aim of the work presented in this chapter was to identify which genes 
are differentially expressed in keloid scar tissue, compared to normal skin, in the 
context of the ECM. In particular, Real-Time qPCR arrays were selected as a 
relatively focused approach to examine 84 genes thought to be key in ECM 
structure and regulation. Additionally, a further 84 genes were examined under 
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the same technology platform, which are associated with 10 of the most well 
studied signalling pathways. Finally, a selection of the most significantly altered 
genes were validated by individually designed Real Time qPCR assays, using the 
relative standard curve method. Put together, this will give an insight into the 
processes potentially taking place in this subset of keloid scars.  
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4.2 Results 
4.2.1 Gene expression levels of extracellular matrix & adhesion 
molecules, in keloid scars  
The Human ECM and Adhesion Molecules RT2 Profiler qPCR array (see section 
2.3.2, Chapter 2) was used to evaluate the expression profiles of 84 genes related 
to cell-cell and cell-matrix interactions, as well as key structural ECM proteins. 
Complete cross-sections of five extralesionally-excised keloids (encompassing 
central, marginal and adjacent normal skin regions) and five healthy control skin 
specimens were used in the analyses (see Tables 2-1 and 2-2 for patient details, 
Chapter 2). The specimens were inclusive of the epidermal and dermal 
compartments of the tissues, so as to obtain an overall impression of the whole 
tissues.  
 
4.2.1.1 Differences within normal skin specimens 
Seeing as this disorder shows a very high level of inter-patient variability, and a 
high correlation of severity level to patient ethnicity, I aimed to include healthy 
controls of African-Caribbean origin to be in keeping with the keloid scars used 
here. At the time of completing the ECM qPCR array analyses, I had only two 
African-Caribbean normal skin samples available, which were combined with 
three Caucasian normal skin samples to increase the healthy control sample group 
number.  
 
Analysis started with examining the differences in gene expression within the 
control group, between Caucasian and African-Caribbean normal skin to ensure 
there were no significant differences within the control group. The majority of the 
genes on the Human ECM and Adhesion Molecules RT2 Profiler qPCR arrays 
showed no significant differences between Caucasian and African-Caribbean 
normal skin. There was a total of 7 genes with decreased expression in normal 
African-Caribbean skin compared to normal Caucasian skin: COL11A1 (collagen XI; 
42.73-fold down-regulated), CTNND1 (delta 1 catenin; 10.35-fold down-
regulated), HAS1 (hyaluronan synthase 1; 3.74-fold down-regulated), ITGA4 
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(integrin alpha 4; 3.18-fold down-regulated), MMP1 (2.38-fold down-regulated), 
MMP7 (11.28-fold down-regulated), MMP10 (4.11-fold down-regulated), MMP11 
(3.03-fold down-regulated), and MMP12 (8.07-fold down-regulated) (Figure 4-1) 
One gene showed an increased expression in normal African-Caribbean skin 
compared to normal Caucasian skin: MMP3 (3.15-fold up-regulation). Notably, the 
fact that I had only two African-Carribean samples of normal skin meant it was not 
possible to test the statistical significance against the three Caucasian samples. 
Nonetheless, the most obvious changes were taken into consideration when 
examining the fold-differences in gene expression in the keloids vs normal skin 
samples, which is described in the following section. 
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Figure 4-1 Scatterplot showing fold-changes in expression of ECM genes between 
African-Caribbean and Caucasian normal skin samples, using an ECM qPCR array.  
All values outside of the two pink lines show a more than 2-fold difference in gene 
expression in African-Caribbean normal skin (n=2), compared to Caucasian normal skin 
(n=3). In total there were 7 genes that showed a down-regulation in African-Caribbean 
skin compared to Caucasian normal skin: COL11A1 (-42.73), CTNND1 (-10.35), HAS1 (-
3.74), ITGA4 (-3.18), MMP1 (-2.38), MMP7 (-11.28), MMP10 (-4.11), MMP11 (-3.03), 
and MMP12 (-8.07). By contrast, MMP3 showed an up-regulation of 3.15-fold. 
Statistical analysis of data was not carried out due to the very small number of African-
Caribbean samples. X axis (Control)= Caucasian normal skin; Y axis (Test)= Afro-
Caribbean normal skin. 
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4.2.1.2 Differences between keloid and normal skin 
Out of the original 84 ECM-related genes examined, a total of 34 genes 
demonstrated a minimum of 2-fold up-regulation in keloid tissue compared to 
normal skin, with 18 showing statistical significance (at least p<0.05), as tested by 
an unpaired Student’s T-test. A further 8 genes showed a minimum of 2-fold down-
regulation in keloids, 3 of which did so in a statistically significant way (at least 
p<0.05) (Figure 4-2) A summary of all the statistically significantly altered genes, 
with a 2-fold change or more, is presented in Table 4-2. See Appendix C for the 
full list of results for all 84 genes tested. 
 
It is worth noting that almost all the genes that were altered between the African-
Caribbean and Caucasian control samples (Figure 4-2) did not demonstrate any 
significant change in expression when comparing the keloid and normal tissues. 
The exceptions were MMP1 and MMP3.  MMP1 had a 2.38-fold lower expression in 
normal African-Caribbean skin compared to normal Caucasian skin, however when 
comparing keloid to normal skin samples, MMP1 showed a great up-regulation of 
51.78-fold. On the other hand, MMP3 had a 3.15-fold higher expression in normal 
African-Caribbean skin compared to normal Caucasian skin, and an even higher 
up-regulation of 9.22-fold in keloid samples compared to all normal skin samples. 
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Figure 4-2 Volcano plot of Extracellular Matrix & Adhesion Molecule RT2 Profiler 
qPCR array. 
A total of 21 genes were shown to be more than 2-fold significantly altered in keloid 
scars compared to normal skin (n=5). The pink shaded areas show the levels of fold-
changes: up-regulation to the right (positive values on X axis), and down-regulation to 
the left (negative values on X axis). The blue shaded areas show increasing levels of 
statistical significance. Statistical analysis was carried out using the Student's T-test, 
with * = p<0.05; ** = p<0.01; and *** = p<0.001. See Table 4.2 for specific values of 
gene expression fold-changes and their associated p values. 
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Table 4-2 Genes from the ECM qPCR array that were significantly different between 
keloid and control skin. (n=5) 
Gene symbol 
Fold change in 
expression 
P value 
(Student’s T-test) 
MMP1 51.78 0.0026 
SPP1 29.59 0.0320 
COL1A1 24.84 0.0134 
MMP13 24.34 0.0005 
COL5A1 18.26 0.0137 
COL12A1 11.44 0.0416 
FN1 9.28 0.0183 
SPARC 9.24 0.0334 
MMP3 9.22 0.0293 
TNC 5.85 0.0080 
COL16A1 5.50 0.0199 
MMP16 5.18 0.0496 
LAMA1 4.81 0.0084 
COL6A1 4.73 0.0269 
THBS2 4.58 0.0168 
COL6A2 4.52 0.0368 
COL14A1 4.33 0.0329 
MMP14 3.85 0.0469 
LAMB3 -2.04 0.0419 
LAMA3 -2.80 0.0103 
CLEC3B -5.20 0.0071 
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Examining more closely the significantly altered genes in this sample group, it 
becomes evident that several functions within the ECM environment are affected. 
Other than the well-established fibrogenic marker Collagen I (COL1A1), there is 
over-expression of several structural protein genes including Collagens V, VI, XII, 
XIV, and XVI; and Fibronectin (FN). In parallel, a number of members from the 
matrix metalloproteinase (MMP) family were highly up-regulated in keloid skin 
compared to normal skin, including MMPs 1 and 13.  
 
4.2.2 Gene expression levels from 10 signal transduction pathways, in 
keloid scars  
The Human Signal Transduction PathwayFinder (STP) RT2 Profiler qPCR array 
(see section 2.2.2, Chapter 2) was used to evaluate the expression profiles of 84 
target genes responsive to activation or inhibition of 10 of the most commonly 
studied signalling pathways. Gene expression results from the same pathway can 
vary widely, depending on the tissue and experimental conditions. This array 
aimed to avoid this confusion by focusing on pathway target genes, thereby giving 
a more complete impression of alterations in developmental, immunological, 
metabolic and stress-activated processes.  
As for the previous ECM qPCR array, complete cross-sections of five 
extralesionally-excised keloids (encompassing central, marginal and adjacent 
normal skin regions) and five healthy control skin specimens were used in the 
analyses (see Tables 2-1 and 2-2 for patient details, Chapter 2). The specimens 
were inclusive of the epidermal and dermal compartments of the tissues, in order 
to get an overview of changes in gene expression across the whole tissues.  
 
4.2.2.1 Differences within normal skin specimens 
As for the previous ECM qPCR array, the five normal skin control samples were of 
varying ethnic origin, therefore the differences in gene expression between 
African-Caribbean and Caucasian skin within the control group were examined. In 
contrast to the ECM qPCR array (section 4.2.1.1), the STP qPCR array 
investigations included three African-Caribbean and two Caucasian normal skin 
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samples (rather than two African-Caribbean and three Caucasian samples). The 
difference in sample make-up was due to the timing of the investigations – at the 
time of the ECM qPCR arrays, I had no expectation that there would be more than 
two African-Caribbean samples available. However, at the time of the STP qPCR 
array investigations, an additional African-Caribbean control skin was made 
available.  
 
The majority of the genes examined showed no significant differences between the 
two ethnicities, within the normal control group. However, three genes did show 
increased fold changes in normal African-Caribbean skin: ADM (adrenomedullin; 
2.77-fold up-regulated), EMP1 (epithelial membrane protein 1; 4.44-fold up-
regulated), and WNT6 (wingless-type MMTV integration site family member 6; 
2.6-fold up-regulated). Additionally, seven genes presented decreased expression 
in normal African-Caribbean skin compared to normal Caucasian skin: EPO 
(erythropoietin; 4.39-fold down-regulation), FABP1 (fatty acid binding protein 1; 
7.59-fold down-regulation), FOSL1 (FOS-like antigen 1; 2.43-fold down-
regulation), LRG1 (leucine-rich alpha-2-glycoprotein-1; 3.95-fold down-
regulation), MMP7 (matrix metalloproteinase 7; 4.74-fold down-regulation), TNF 
(tumour necrosis factor; 3.94-fold down-regulation), and WNT3A (wingless-type 
MMTV integration site family member 3A; 2.77-fold down-regulation) (Figure 4-
3). It is worth noting that MMP7 also appeared down-regulated in normal African-
Caribbean skin in the ECM qPCR array (Figure 4-1) providing an extra level of 
confidence in the data. The small number of Caucasian samples used meant 
statistical significance was not tested. Nonetheless, these gene alterations were 
taken into consideration when investigating the fold-differences in gene 
expression in the keloids, as compared to the whole normal control group of 
samples.  
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Figure 4-3 Scatterplot showing fold-changes in expression of Signal Transduction 
Pathway genes between African-Caribbean and Caucasian normal skin, using the STP 
qPCR array. 
All values outside of the two pink lines show a more than 2-fold difference in gene 
expression in African-Caribbean normal skin (n=3), compared to Caucasian normal skin 
(n=2). In total, 3 genes demonstrated an up-regulation in normal African-Caribbean 
skin compared to normal Caucasian skin: ADM (+2.77), EMP1 (+4.44), and WNT6 
(+2.6). By contrast, a total of 7 genes revealed a down-regulation in African-Caribbean 
skin: EPO (-4.39), FABP1 (-7.59), FOSL1 (-2.43), LRG1 (-3.95), MMP7 (-4.74), TNF (-3.94), 
and WNT3A (-2.77). Statistical analysis was not performed due to the small group 
numbers. 
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4.2.2.2 Differences between keloid and normal specimens 
Out of the original 84 STP-related genes examined, a total of 10 genes 
demonstrated a minimum of 2-fold up-regulation in keloid tissue compared to 
normal skin, with 4 showing statistical significance (at least p<0.05), as tested by a 
Student’s T-test. A further 16 genes showed a minimum of 2-fold down-regulation 
in keloids, with 6 being significant (at least p<0.05) (Figure 4-4). A summary of all 
the significantly altered genes, with a 2-fold change or more, can be seen in Table 
4-3. See Appendix D for the full list of results for all 84 genes. 
 
In this qPCR array, none of the genes previously shown to be altered between 
African-Caribbean and Caucasian normal skin samples (Figure 4-3) revealed any 
difference between keloid and normal skin sample groups.  
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Figure 4-4 Volcano plot of Signal Transduction Pathway Finder Real-Time qPCR array. 
A total of 10 genes were shown to be more than 2-fold significantly deregulated in 
keloid scars vs. normal skin (n=5). The pink shaded areas show the levels of fold-
deregulation: up-regulation to the right (positive values on X axis), and down-
regulation to the left (negative values on X axis). The blue shaded areas show 
increasing levels of statistical significance. Statistical analysis was carried out using 
Student's T-test with  * = p<0.05; ** = p<0.01; and *** = p<0.001. See Table 4-3 for 
specific values of gene expression fold-changes and their associated p values. 
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Table 4-3 Genes from the STP qPCR array that were significantly different between 
keloid scars and control skin. (n=5) 
Gene symbol 
Fold change in 
expression 
P value 
(Student’s T-test) 
WISP1 10.10 0.0439 
ID1 2.84 0.0328 
HEY1 2.62 0.0327 
VEGFA 2.06 0.0191 
EGFR -2.23 0.0098 
BCL2 -3.12 0.0027 
GATA3 -3.15 0.0237 
BMP4 -3.67 0.0104 
SORBS1 -3.97 0.0162 
BMP2 -5.04 0.0191 
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4.2.2.3 Summary of statistically significantly altered genes analysed 
The results of the data presented in Table 4-2 and 4-3 are summarised in Figure 
4-5. A relatively high level of inter-patient variability was observed within the 
selection of keloids. This, along with the relatively low number of samples 
examined, could explain why the standard deviation values were very high. It 
becomes clear that keloid tissue has a gene overexpression of structural ECM 
proteins such as collagens, fibronectin and osteogenic-related proteins SPARC and 
SPP1, as well as ECM-degrading MMPs. It is also clear that apoptosis-related genes 
such as BCL2, BMP2 and BMP4 are underexpressed in keloids, while proliferation-
linked genes such as WISP1 are overexpressed in keloid tissue.  
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Figure 4-5 Summary of genes identified from both ECM and STP qPCR arrays, that showed significant up- or down-regulation in keloid scars 
compared to normal skin.  
This graph is derived from the data presented in Tables 4-2 and 4-3, all of which were statistically significant (at least p<0.05). Error bars show 
the SD of the mean of n=5 keloid patients, each compared to the mean of all n=5 healthy controls.* = p<0.05; ** = p<0.01; and *** = p<0.001. 
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4.2.3 Validation of qPCR array findings  
Taking into account the high inter-patient variability in the qPCR array findings, as 
well as the fact that the qPCR array investigations were performed once per 
patient, a selection of the top 31 most altered genes were validated by Real Time 
qPCR, using the Relative Standard Curve method. 
4.2.3.1 Development of Real Time qPCR assays by Relative Standard Curve 
method  
In order to validate the qPCR array findings outlined in sections 4.2.1 and 4.2.2, 
primer sets were manually designed (see Table 2-8, Chapter 2) and the qPCR 
assays were optimized for the Relative Standard Curve method. As opposed to the 
ΔΔCt method, where the assumption is that all assays are 100% efficient and the 
reaction product doubles with each round of polymerisation (2ΔΔCt), a 4- to 6-point 
standard curve is made from a pooled RNA sample, known to express most genes 
(see section 2.2.3.1, Chapter 2), and used to calculate the specific reaction 
efficiency rate for each individual Real Time qPCR assay. This way, even though the 
final data is still relatively quantified, there is a lower chance of false positives 
occurring (Larionov et al., 2005). The 18 genes of interest (GOI), plus the two 
reference genes selected for validation are listed in Table 2-8, Chapter 2. Due to 
the large number of samples and genes being tested, two reference genes were 
included, providing a higher level of confidence during data normalization (ΔCt). 
HPRT1 (hypoxanthine phosphoribosyltransferase 1) and B2M (beta-2-
microglobulin) were selected based on the results from both qPCR arrays, where 
these two genes were the most stably expressed out of the original five reference 
gene used in the qPCR arrays (see Appendices C and D). The ΔΔCt values were 
calculated by normalizing each keloid or normal skin value against the mean from 
all five normal skin ΔCt values.  
 
To optimise the qPCR assays, they were first run using the serially diluted control 
samples at a combined annealing/ extension temperature of 62°C. For the assays 
which showed non-specificity at 62°C, a range of temperatures from 58 - 64°C was 
tested, and the PCR products run on a 2% (w/v) agarose gel to establish which 
conditions resulted in the highest specificity (Figure 4-6A to C). 
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Figure 4-6A Standard curves and melting curves for each of the manually designed 
Real Time qPCR assays, used for validation of PCR array data. 
A total of 2 reference genes and 18 GOIs (listed alphabetically, from left to right) were 
optimized for Real Time qPCR, by the Relative Standard Curve method. A 3 or 4-point 
standard curve was formed from a pooled RNA standard, and the optimal annealing/ 
extending temperature selected, as outlined in section 4.2.3.1. The variation in slopes of 
each assay demonstrates that they do not have a uniform level of efficiency, making this 
method more accurate than the ΔΔCt method. Most genes showed linearity along all 
four standards, however BMP2 was linear only across the first three standards, possibly 
due to it being expressed at a lower level in the pooled RNA standard sample, compared 
to the rest of the genes. Melting curves for each assay were carried out during 
optimization steps, using the 3 or 4-point standards. The majority of these showed a 
single clean peak, suggesting a high level of assay accuracy. (Figure continued on next 
page) 
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Figure 4-6B Continued from Figure 4-6A 
Showing a continuation of Figure 4-6. The standard curve for MMP13 was linear only 
across the first three standards, possibly due it being expressed at a lower level in the 
pooled RNA standard sample, compared to the rest of the genes. Most genes here 
showed a clean single peak for their melting curve. (Figure continued on next page) 
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Figure 4-6C Continued from Figure 4-6B 
Showing a continuation of Figure 4-6. Here, SORBS1 and WISP1 were linear only across 
the first three standards, possibly due to those genes being expressed at a lower level in 
the pooled RNA standard sample, compared to the rest of the genes. Most genes 
showed a clean single peak, apart from VEGFA, which consistently showed a double 
peak, possibly representing splice variants of the same gene. SORBS1, SPARC and WISP1 
showed additional smaller peaks for the most diluted standards.  
 186 
Most genes showed a clean single peak in their melting curves. For SORBS1, SPARC 
and WISP1, the additional smaller peaks at the lower temperatures represent the 
most diluted standards, where the Ct values were higher than 35. In all of these 
cases, the test sample Ct values appeared within the Ct values of two highest 
standards, and so therefore did not significantly impact on the specificity of the 
final results. For VEGFA, there was a consistent double peak in their melting 
curves, for which one reason could be the presence of transcript variants. Based on 
information collated on the human gene database GeneCards, VEGFA does consist 
of a number of variants (GeneCards, 2016). However, as I did not follow through 
with extensive analyses of VEGFA in my research, I did not explore this further.  
 
4.2.3.2 Validating expression of identified altered genes by Real Time qPCR 
(Relative Standard Curve method) 
Out of the 31 significantly different genes originally identified in the qPCR arrays, 
16 of these were validated on the same range of keloid and normal tissues, using 
the optimized assays from section 4.2.3.1. Added to this selection was SFN 
(stratifin/ 14-3-3σ), which has been shown to interact with SPARC to control 
COL1A1 synthesis and expression in normal fibroblasts. It has been proposed that 
a lack of SFN and an overexpression of SPARC cause greater expression of COL1A1 
via TGF-β activation, potentially explaining the development of hypertrophic scars 
(Chavez-Muñoz et al., 2012). Although MMP2 was less than 2-fold up-regulated in 
the qPCR array data, and was not significantly different to normal tissue, it was 
included in the validation as its protein expression levels were increased in keloids 
(see section 3.2.4, Chapter 3).  
 
The fold changes in expression of the 18 selected genes are shown in Figure 4-7 
and Table 4-4 Most of the genes revealed very little variance between samples, 
however genes such as SPARC, SPP1, WISP1 and HEY1 showed high inter-patient 
variability. When the Student’s T-test was applied to see if the keloid results were 
statistically significantly different from the normal tissue controls, only 4 genes 
were deemed significantly different (p<0.05): BCL2, BMP2, SORBS1, and EGFR. By 
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contrast, all of the selected genes (except for MMP2 and SFN) had shown to be 
significantly different in the original qPCR arrays, using the same statistical test.  
 
In Figure 4-8, the original qPCR array data is compared side by side with the 
validated qPCR data. Even though the same levels of change in gene expression are 
not directly reproduced in the validation, the fold-changes for most genes are 
similarly altered, i.e. both array and validation results showing an up- or down-
regulation.  The exception is HEY1, where the array data showed an up-regulation 
in keloids, whereas the validation results displayed a down-regulation. 
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Figure 4-7 Validation of gene expression patterns identified by qPCR arrays 
Expression levels of sixteen of the most altered genes from the qPCR arrays (ΔΔCt 
method), were validated using the qPCR Relative Standard Curve method. MMP2 
(matrix metalloproteinase 2) was included in the analyses, due to the increased 
protein expression observed in Chapter 3; SFN (stratifin) was included due to its well-
published interaction with SPARC (osteonectin) affecting collagen synthesis. Gene 
expression changes were subtle, with only 4 genes showing statistical significance, as 
tested using the Student’s T-test (p<0.05). n=5 keloids, compared against n=3 normal 
skin samples. Error bars represent the SD of the mean.  
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Table 4-4 Gene expression fold-changes from the validation qPCR assays  
Data is from Figure 4-7. In blue are the statistically significantly altered genes (p<0.05), 
in keloids compared to normal skin. (n=5 keloids; n=3 normal controls) 
Gene 
symbol 
Mean  
fold-changes 
St. Deviation of 
mean fold-
changes 
P value 
(Student’s T-
test) 
SPP1 5.008 8.350 0.1845 
SPARC 3.300 2.973 0.1207 
COL1 3.069 1.260 0.0513 
MMP2 2.119 0.715 0.0598 
MMP13 1.917 2.412 0.2460 
WISP1 1.872 3.647 0.3793 
TNC 1.643 0.493 0.1085 
MMP1 1.517 0.520 0.1236 
MMP14 1.259 1.490 0.4132 
MMP3 1.248 1.531 0.3898 
VEGFA 1.083 1.026 0.3373 
GATA3 -1.184 0.054 0.0538 
BCL2 -1.226 0.095 0.0019 
EGFR -1.352 0.188 0.0256 
SORBS1 -1.408 0.382 0.0384 
BMP2 -1.452 0.090 0.0101 
SFN -1.534 0.725 0.0926 
HEY1 -7.734 1.002 0.2055 
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Figure 4-8 Comparison between validation and Real Time qPCR array data 
The validated qPCRs showed more subtle changes in gene expression levels, as 
compared to the original qPCR array data. In almost all of the genes tested, the 
alterations were consistently in the same orientation, with the exception of HEY1, 
which showed opposite trends between the PCR array and validation data. Error bars 
represent the SD of the mean, with n=5 samples. Solid blue bars (arrays) represent 
data also presented in Figures 4-2, 4-4 and 4-5; hatched blue bars (validations) 
represent data also presented in Figure 4-7. 
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4.3 Discussion 
In this chapter, I have identified a range of differentially expressed genes in the 
African-Caribbean keloids used in this study, when compared to a mixture of 
African-Caribbean and Caucasian normal skin samples. More specifically, the genes 
for structural proteins Collagens I, V, VI, XII, XIV, and XVI; fibronectin; and laminin 
chain alpha1, were all over-expressed in keloid scars. Similarly, the genes for 
secreted MMPs 1, 3, 13, as well as membrane-tethered MMPs 14 and 16 were over-
expressed in keloids. By contrast, laminin chains alpha3 and beta3 were both 
under-expressed, as was tetranectin (CLEC3B). Interestingly, two genes linked to 
matrix mineralisation and ossification (Hall, 2014), SPARC (osteonectin) and SPP1 
(osteopontin), were both shown to be over-expressed in keloid scar tissue. 
Another ECM-related gene, TNC (tenascin C), was also over-expressed in keloids, 
which further suggests the on-going wound healing signals are present in keloid 
scars (Chiquet-Ehrismann and Chiquet, 2003). 
 
In terms of signal transduction pathway target genes, there was a down-regulation 
of genes linked to apoptosis, including BCL2 (Wei et al., 2008), BMP2 and BMP4 
(Carreira et al., 2014). Genes related to cell survival and development, such as 
WISP1 (Su et al., 2002, Xu et al., 2000), HEY1 (Nakagawa et al., 2000), and ID1, 
were up-regulated in keloids, even though cell proliferation and survival-linked 
gene EGFR was shown to be under-expressed. SORBS1 was also under-regulated, 
suggesting an effect on signalling through the PPAR (peroxisome proliferator-
activated receptor) (Chen et al., 2012) and IR (insulin receptor) (Yang et al., 2003) 
pathways There was also increased gene expression levels of VEGFA, suggesting a 
positive impact on angiogenesis (Murphy and Fitzgerald, 2001) in the keloids. 
 
In the following sections, I discuss the differences between the two types of 
relative quantitation used for the qPCR analyses of this chapter, as well as the 
choice of statistical tests used. Then a review of the current literature on some of 
the most significantly altered targets identified above, and their associated factors, 
is presented.   
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4.3.1 Assessment of methodology used 
4.3.1.1 Differences in PCR methods 
Apart from the high inter-patient variability, the difference in qPCR methodologies 
used for the qPCR arrays and validation qPCR assays very likely had an impact on 
the final calculations. In all the qPCR data presented here, a form of relative quanti-
tation was used, with the ΔΔCt method being used in the qPCR arrays, and the 
relative standard curve method used for the validation qPCR assays.  
 
The ΔΔCt method is the most widely used in gene expression studies, as it is the 
least labour intensive, and most cost effective, since there is no space required for 
standard curve preparations on the qPCR plates, and the data analysis is simpler 
(Livak and Schmittgen, 2001). Considering the tendency for misinterpretation of 
qPCR data, for most researchers the ΔΔCt method gives enough information for 
their requirements. The main disadvantage of the ΔΔCt method is that it assumes 
the qPCR assays show equal efficiency in the samples being tested, i.e. that the 
amplification efficiencies of the target and reference assays are approximately 
equal, using the formula [2-ΔΔCt].  Equal assay efficiency is generally more easily 
achieved in the case of analyzing more uniform samples such as cell lines, ensuring 
high RNA integrity, inhibitor-free cDNA synthesis, and when the differences 
between test and control samples are at least 5-fold (Larionov et al., 2005, Livak 
and Schmittgen, 2001). When this method is used on clinical samples, which 
inherently tend to have more issues with nucleic acid integrity, it is more likely 
that smoothing of the data will produce a higher rate of false positives (Rutledge 
and Côté, 2003, Larionov et al., 2005). 
 
In the case of performing relative quantitative qPCR analysis on clinical samples, 
the inherent heterogeneity in the samples as well as the higher concentration of 
inhibitors and nucleases present, mean the final RNA integrity and cDNA quality is 
less consistent than for cell lines. Also, genetic variability is much higher between 
patient samples, meaning additional reference genes are required for the 
normalization steps in qPCR data analysis. Put together, it becomes less likely that 
the qPCR assay efficiency rates will be consistent between reference and target 
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genes in these sample sets, and the ΔΔCt method assumptions are therefore not 
appropriate (Larionov et al., 2005). The use of a standard curve enables a more 
representative calculation of the assay efficiency rates, which can then be taken 
into consideration during data analysis (Larionov et al., 2005, Rutledge and Côté, 
2003). The data is still processed in a relative manner, determining the difference 
in gene expression of the test samples against that of the control samples. This 
way, whether a gene has a very high or very low level of expression, the magnitude 
of change from “control” is more easily detected.  
 
In terms of the quality of the samples used for analysis, other than the inherently 
increased risk of nuclease action normally problematic in clinical specimens, there 
was a time difference between the completion of the qPCR arrays and the 
validation qPCRs. The same RNA lysates were used for separate cDNA 
preparations for the qPCR arrays and qPCR validations. As the validations were 
performed 2-6 months after the original extractions were completed, despite 
following the standard procedures for long-term storage of RNA (at -80°C, with 
minimal freeze-thaw cycles), it is possible that the RNA integrity was reduced in 
the period of time between cDNA preparations. This may have further affected the 
validation qPCRs, and might explain why most of the genes re-analysed were not 
statistically significantly different. 
 
For the qPCR validation assays, primer sequences were individually designed and 
therefore different to those used in the qPCR arrays, as another validation 
measure. Added to this, a combination of two reference genes were selected from 
the qPCR array data, and used for data normalization of the validation qPCR 
assays, to further minimise any error. The reference genes HPRT and B2M had 
shown the most stable level of expression across all tissue samples, making them 
the best choices. By making these changes to the original methodology, the aim 
was to add an extra level of stringency to the validation process, thereby aiming to 
exclude any false positives that might have occurred during the qPCR array 
analyses. Overall, the aim was to minimize inconsistent and inaccurate reporting of 
gene expression data, by following as many of the published MIQE (Minimum 
Information Necessary for Quantitative Real-Time PCR Experiments) guidelines as 
 194 
deemed fit for purpose in this thesis (Johnson et al., 2014, Dheda et al., 2005, 
Bustin et al., 2010, Bustin, 2010).  
 
4.3.1.2 Statistical analyses 
Whilst assessing appropriate analysis of qPCR data, it is also important to consider 
the statistical analysis and any post-hoc tests used. Most small to medium-scale 
gene expression analyses, such as in this chapter, are subjected to a simple 
unpaired Student’s T-test, for each gene, comparing “test” to “control” samples. For 
a single test, the assumption is that the data follow a normal distribution, and with 
a threshold set at 5%, a significant difference in gene expression between test and 
control would be indicated with a p value of 0.05 or less. This shows that there is a 
5% or less probability that this difference would occur purely by chance, and is not 
related to the experimental parameters (Motulsky, 2014).  
 
In the case of studies where multiple comparisons are being made within the same 
system, interpreting multiple p values becomes more complicated. With a 5% 
threshold, the probability that at least one comparison will be significantly 
different becomes much higher than 5% (Motulsky, 2014, Berry, 2007). The larger 
the number of tests, the easier it becomes to identify rare events (p<0.05), making 
it more likely that errors will be made. Various degrees of stringency in correcting 
for multiple comparisons have been developed and are applied depending on the 
study requirements and the number of multiplicities (Berry, 2007, Rothman, 1990, 
Herve, 2007). However, it is a fine balance between maximizing the possibility of 
identifying significant results, and making sure the more stringent corrections do 
not overlook real effects taking place (Herve, 2007). In my qPCR analyses, no 
correction for multiplicities was made, due to the relatively small number of tests 
being performed, in the context of gene expression studies. Additionally, one major 
aim of this analysis is to generate new hypotheses to test further, rather than 
simply prove or disprove an existing hypothesis. The overall gene expression 
patterns observed in this chapter were considered within the wider context of the 
functions of those genes, the pathways and other molecules they interact with, 
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rather than simply restricting research into only those specific genes (Saville, 
1990). 
 
4.3.2 Extracellular matrix and adhesion molecules  
4.3.2.1 ECM structural molecules - Collagens 
As described in Chapter 1, the collagen functions range from providing tissue 
structure, aiding cell adhesion and migration, to tissue repair and remodelling 
(Gordon and Hahn, 2010, Kadler et al., 2007, Ricard-Blum, 2011). The most 
abundant form of collagen in the body is fibril-forming collagen type I, which 
provides structure and tensile strength to tissues (Gelse et al., 2003).  In keloid 
scarring (and fibrosis as a whole), it is well established that increased levels of 
collagen I make up the bulk of the fibrotic scar tissue (Jumper et al., 2015). The 
increased levels of collagen type I and fibronectin 1 gene expression seen in this 
chapter, along with the increased levels of mature collagen I protein expression 
discussed in Chapter 3, confirm the fibrotic state of the tissues (Babu et al., 1989).  
 
Collagens V and VI have all been previously noted as overexpressed in keloid 
tissue and isolated cells, via microarray gene expression studies (Huang et al., 
2013a). These collagens are known to interact with collagen type I, thereby 
affecting their gene expression levels. Collagen V filaments are often buried inside 
the triple helical collagen I structures (Birk, 2001, Fichard et al., 1995, Gelse et al., 
2003), but have also been noted near the basement membrane in skin (Birk et al., 
1986, Gay et al., 1981). Here, fine collagen V filaments may interact with collagen 
types IV and VI (Chanut-Delalande et al., 2004, Chanut-Delalande et al., 2001), both 
of which play an important role in the basement membrane, connecting the 
epidermis to the dermis (Gordon and Hahn, 2010, Ricard-Blum, 2011).  
 
Out of the FACIT (fibril-associated collagens with interrupted triple helices) 
collagen types XII, XIV and XVI, which were significantly overexpressed in my data, 
collagens XII and XVI have previously been reported to be overexpressed in whole 
keloid tissue (Huang et al., 2013a, Chen et al., 2003). In normal skin, collagens XII 
and XIV crosslink with collagen I fibrils (Amenta et al., 2005, Gelse et al., 2003, 
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Ricard-Blum, 2011), whereas collagen XVI integrates itself into fibrillin1-
containing microfibrils in the papillary dermis (Kassner et al., 2003). In a mouse 
model of bleomycin-induced pulmonary fibrosis, collagens XII and XIV were 
implicated in the fibrotic tissue development (Tzortzaki et al., 2003). Over the 12-
week bleomycin treatment period, collagen XII was at its highest during weeks 4-8, 
whereas collagen XIV showed an increased expression from 4 to 12 weeks, 
suggesting distinct roles for each of these collagens during fibrosis (Tzortzaki et al., 
2003). The same group confirmed this observation in pulmonary fibrosis patients, 
and showed that collagen XII in particular co-localised with collagen I nodules in 
the granulation tissue (Tzortzaki et al., 2006). 
 
4.3.2.2 Tissue remodelling - MMPs 
There is clearly a high level of ECM production taking place in keloid tissues, as 
demonstrated by the gene up-regulation of several collagens. As for ECM-
degrading molecules, MMPs 1, 2, 3, 13, 14 and 16 gene expressions were all 
significantly up-regulated in keloid tissue compared to normal skin, in my PCR 
array findings. MMP1 in particular showed the highest gene expression level, 
though also had a very high standard error. This was due to the wide variance 
between individual keloid patients, ranging from 12-fold to 67-fold increased 
expression of MMP1. Protein expression patterns established in Chapter 3 reflect 
the MMP13 overexpression, however the extremely high gene expression of MMP1 
is not reflective of the almost no difference in protein levels observed in Chapter 3. 
Previous studies confirm the MMP13 overexpression in keloids, however MMP1 
and MMP3 have shown to be under-expressed in keloid tissues and fibroblast 
cultures (Huang et al., 2013a, Smith et al., 2008). One study showed how the lack of 
MMP1-mediated degradation of Collagen I in keloids could be due to TIMP1 
blocking MMP1 action. When TIMP1 was knocked down by siRNA in keloid 
fibroblasts, collagen I degradation increased, thought to be due to MMP1 and 
MMP2 action (Aoki et al., 2014).  
 
MMP2 showed the highest levels of protein expression in section 3.2.4. of 
Chapter 3, however did not show any significant difference in gene expression 
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here. This is in contrast to previous studies which have found MMP2 to be 
overexpressed at the gene level (Huang et al., 2013a). In my findings, MMP14 gene 
expression was increased in keloid samples compared to normal skin, reflecting 
the increase in protein expression observed in Chapter 3. Previous microarray 
studies have also shown an increased MMP14 expression in both keloid and 
hypertrophic scars (Huang et al., 2013a). As discussed in Chapter 3, MMP14 
enables the activation of pro-MMP2, therefore suggesting that the increased 
MMP14 expression could signify an increase in MMP2 activity. Other than the 
differences in detection methods between previous studies and the work 
presented in this thesis (discussed earlier), this discrepancy could be due to the 
differences in source material used. Added to this, it has long been debated 
whether in vitro experimentation on MMP biology is truly reflective of their actual 
function in vivo (Giannandrea and Parks, 2014, Parks et al., 2004). 
 
4.3.2.3 ECM mineralisation-associated factors (SPARC, SPP1) 
Osteogenesis- and chondrogenesis-associated genes have previously been 
identified as significantly increased in a keloid microarray study. These included 
POSTN (periostin), OGN (osteoglycin), cadherin 11, and HTRA1 (serine protease 
11, IGF binding) (Naitoh et al., 2005). In hypertrophic scars, two other osteogenic 
factors, SPARC (osteonectin) and SPP1 (osteopontin), have been reported to be 
significantly overexpressed compared to normal skin (Wu et al., 2004a). In my 
findings, both SPARC and SPP1 were overexpressed in the keloid specimens, 
compared to normal tissue, despite revealing a high level of inter-patient 
variability in terms of the magnitude of overexpression (see Figure 4-8). This was 
especially reflected in the validation qPCRs, where one keloid even showed a small 
down-regulation of SPARC and another showed a small down-regulation of SPP1 
(see Figure 4-7). Both SPARC and SPP1 are best known for their roles in bone 
formation, and bone ECM assembly (Sodek et al., 2000). Very little is known about 
the expression patterns and functions of SPARC and SPP1 in keloid scarring, 
however there are a number of studies reporting their effects in other types of 
fibrosis and in the context of wound repair (Chavez-Muñoz et al., 2012, Wu et al., 
2012, Hunter et al., 2012, Goldsmith et al., 2013, Sodek et al., 2000).  
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SPARC is an ECM protein, known to directly affect pro-collagen processing and 
therefore influence collagen stability and assembly (Goldsmith et al., 2013). It has 
been proposed that SPARC in fact acts as a collagen molecular chaperone in the 
endoplasmic reticulum (ER), and together with heat-shock protein 47 (HSP47), 
ensures that no misfolded procollagen molecules exit from the ER (Martinek et al., 
2007). An interesting study on hypertrophic scarring, showed how stratifin (SFN, 
also known as 14-3-3σ) interaction with SPARC may have implications for ECM 
regulation in dermal fibroses such as hypertrophic and keloid scars (Chavez-
Muñoz et al., 2012). The SPARC/SFN complex was identified in normal 
keratinocyte-conditioned media (KCM), which when applied to normal fibroblasts, 
decreased pro-collagen type I gene expression in the fibroblasts. In human 
hypertrophic scar tissue SPARC was increased and SFN decreased, leading to a 
greater expression of collagen I. (Chavez-Muñoz et al., 2012) 
 
In myocardial fibrosis, a lack of SPARC in myocardial fibroblasts led to an 
increased detection of collagen I, compared to wild-type fibroblasts, though most 
of the collagen was fully matured (Harris et al., 2011). The role of SPARC in 
collagen assembly was further elucidated in vivo, where a SPARC-null mouse study 
revealed significantly reduced collagen fibril formation and impaired collagen 
maturation (Schellings et al., 2009, Bradshaw et al., 2009). Taken together, these 
studies suggest that when SPARC is absent, the rate of collagen maturation is 
greatly reduced within the myocardium (Goldsmith et al., 2013). Regulating SPARC 
expression and action on ECM remodeling could help to attenuate excessive scar 
tissue growth.  
 
SPP1 is a secreted phosphoprotein (Craig et al., 1989), which interacts with αvβ3-
integrin, CD44, and other ECM molecules such as fibronectin (O'Regan and 
Berman, 2000, Liaw et al., 1995, Denhardt and Guo, 1993). It is functionally very 
diverse, and expressed in many different tissues, including bone, dentin, kidney, 
brain, vascular tissues, ganglia of the inner ear, the epithelia of mammary, salivary 
and sweat glands, distal renal tubes, activated macrophages and lymphocytes, as 
well as fibroblastic cells (Buback et al., 2009, Wang and Denhardt, 2008, Sodek et 
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al., 2000, Anborgh et al., 2011, Rittling, 2011). In fact, SPP1 is thought to be 
required for fibroblast differentiation into myofibroblasts (Lenga et al., 2008), as 
well as osteoblast differentiation (Zohar et al., 1997). SPP1 stimulates cell 
signalling pathway activation, via phosphorylation of a range of extracellular 
receptors at the cell-ECM interface (Denhardt et al., 2001, Sodek et al., 2000, Lopez 
et al., 1995), and has been linked to multiple processes including inflammation, 
cancer metastasis, apoptosis inhibition, wound healing, and ECM remodelling 
(particularly bone remodelling) (O'Regan and Berman, 2000, Denhardt et al., 2001, 
Hunter et al., 2012).  
 
The pro-fibrotic effect of SPP1 has been shown in pulmonary fibrosis (Takahashi et 
al., 2001, Pardo et al., 2005), kidney fibrosis (Persy et al., 2003), and dermal 
fibrosis within systemic sclerosis (Wu et al., 2012, Gardner et al., 2006). In 
idiopathic pulmonary fibrosis patients, SPP1 gene expression was increased, and 
thought to promote fibroblast and epithelial cell proliferation and migration 
(Hunter et al., 2012, Pardo et al., 2005). In dermal wound studies, SPP1-null mice 
demonstrated a haphazardly organised ECM in the dermis, with collagen fibrils 
being reduced in size and number, compared to wild-type mice (Liaw et al., 1998). 
In a mouse model of bleomycin-induced dermal fibrosis, SPP1 knockouts were less 
fibrotic, and expressed decreased TGF-β1 levels, as compared to wild-types (Wu et 
al., 2012). In an equine model of wound healing, SPP1 gene expression appeared at 
its highest throughout the duration of wound closure, but maintained a low-level 
expression after wound closure was complete, and showed no expression in 
normal skin (Miragliotta et al., 2014). The same study found SPP1 protein 
expression, as tested by IHC, was increased in human keloid samples, compared to 
normal skin, particularly in the epidermis (Miragliotta et al., 2014). 
 
4.3.3 Signalling pathways 
Looking more closely at the significantly altered signal transduction pathway 
target genes in this sample group, it appears that there is no single signalling 
pathway apparently linked to these keloids. It is clear that TGF-β/Smad signalling 
is taking place, with a number of target genes from this pathway having shown 
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altered expression in the qPCR data of this chapter: other than collagen type I and 
α-SMA, ID1 (inhibitor of differentiation 1), MMP2, and Wnt target WISP1 (WNT1 
inducible signalling pathway protein 1) were all overexpressed in the keloid scars. 
The up-regulation of HEY1 (hairy/enhancer-of-split related with YRPW motif 1), 
WISP1, and VEGFA (vascular endothelial growth factor A) suggests an activation of 
the Wnt and Notch pathways playing a role in cell survival and development (Su et 
al., 2002, Xu et al., 2000, Murphy and Fitzgerald, 2001). Cell proliferation and 
survival-linked gene EGFR was shown to be under-expressed. Although one study 
showed a greater growth response to EGF in keloid fibroblasts (Kikuchi et al., 
1995), another study showed the opposite effect (Satish et al., 2004). Additionally, 
Satish et al. found that there was no real difference in EGFR expression in keloid 
fibroblasts (Shih and Bayat, 2010b). These genes all play a role in mediating 
myofibroblast activation, as well as being downstream targets of TGF-β/Smad (He 
and Dai, 2015, Phanish et al., 2006, Liu, 2010).  
 
SORBS1 (sorbin and SH3 domain containing 1) is a CBL-associated protein which 
is linked to insulin receptor signalling (Yang et al., 2003). In keloid biology, the 
expression or role of SORBS1 has not been reported to date. I found SORBS1 was 
down-regulated in keloid tissues, suggesting an effect on signalling through the 
PPAR (peroxisome proliferator-activated receptor) (Chen et al., 2012) and IR 
(insulin receptor) (Yang et al., 2003) pathways. An under-expression of SORBS1 
could suggest a reduction of insulin-stimulated glucose transport (Chen et al., 
2012, Yang et al., 2003), thereby affecting cell proliferation. This could be 
indicative of the reported higher levels of apoptosis seen in the central keloid 
regions. 
 
The down-regulation of BMP2 and BMP4 (bone morphogenetic proteins 2 and 4) 
could mean an inhibition of the Hedgehog pathway, which would impact parts of 
TGF-β and Wnt signalling. The observed downregulation of BCL2 (B-cell 
lymphoma 2) suggests a decrease in apoptotic pathway activity (Wei et al., 2008). 
SPP1 has shown to prevent apoptosis by activating NFκB (nuclear factor kappa B) 
in endothelial cells (Scatena et al., 1998), maintaining membrane integrity, and 
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preventing Bcl-x cellular redistribution (a Bcl-2 family member thought to block 
procaspase activation) (Sodek et al., 2000, Denhardt and Noda, 1998). 
 
Overall, conflicting conclusions can be made from the signalling pathway target 
gene expression patterns observed in this chapter. It seems numerous studies 
looking at cell proliferation and apoptosis-related genes also show conflicting 
results (Shih and Bayat, 2010b). This is most likely due in large part to the source 
materials used, i.e. the keloid characteristics, and which lesional regions were 
analysed. Also, experimental design is highly variable between studies, making it 
difficult to deduce which targets show a true correlation to keloid pathogenesis. 
 
In the next chapter, a first level of validation of the targets identified above, which 
were significantly altered in keloids, are examined in keloid-derived cell cultures. 
Both fibroblast and keratinocyte cultures are analysed.  
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5 Target validation in 
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5.1 Introduction 
A variety of cell culture systems have been used over the last three decades, to 
investigate the growth of keloid fibroblasts, and to define their characteristics in 
comparison to normal fibroblasts (Luo et al., 2001, van den Broek et al., 2014). Cell 
growth kinetic studies have shown keloid and normal fibroblasts do not differ 
significantly, when cultured in the presence of fetal calf serum (Russell and Witt, 
1976, Diegelmann et al., 1979). Cell size, and density-dependent growth inhibition 
were similar between keloid and normal fibroblasts (Russell and Witt, 1976). 
However, when grown in serum-free conditions, keloid fibroblasts demonstrated a 
lower dependence on growth factors than normal cells (Russell et al., 1988). 
Additionally, keloid fibroblasts showed an increased growth response to TGF-β 
(Bettinger et al., 1996) and PDGF (Haisa et al., 1994) treatments, suggesting that 
keloid fibroblasts could have a higher growth potential than normal fibroblasts. 
Luo et al. showed that there were varying levels of proliferative and apoptotic 
fibroblasts, depending on the region of the keloid. The fibroblasts found in the 
deeper layers of the dermis appeared to be the least apoptotic, though all keloid 
fibroblast fractions (from the papillary and reticular dermis) were still at least 2-
fold less apoptotic than normal control fibroblasts (Luo et al., 2001).  
 
Keloid keratinocytes have mainly been studied in relation to fibroblasts, showing 
their effect on fibroblast behaviour. A variety of cell culture methods have been 
employed, whereby there is an interaction between keratinocytes and fibroblasts, 
such as: treating fibroblasts with keratinocyte conditioned media (Ghaffari et al., 
2009b, Mukhopadhyay et al., 2005); co-culturing the two cell types using a trans-
well system (Xia et al., 2004, Lim et al., 2002b, Lim et al., 2001); or using collagen 
gels for organotypic 3D cultures (Butler et al., 2008). Keloid keratinocytes have 
been shown to increase collagen I synthesis in both normal and keloid fibroblasts 
(Ghaffari et al., 2009b, Mukhopadhyay et al., 2005, Lim et al., 2002b), as well as 
promote fibroblast growth (Lim et al., 2001), and reduce fibroblast apoptosis 
(Funayama et al., 2003). Keloid keratinocytes have been shown to modulate 
cytokine secretion by fibroblasts, such as CTGF (connective tissue growth factor) 
(Khoo et al., 2006), IL6, IL8, MCP1 (monocyte chemoattractant protein-1), VEGF, 
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and others (Lim et al., 2009). When cultured together, both keloid keratinocytes 
and keloid fibroblasts displayed an increased expression of TGF-β1 and TGF-βRI, 
while the fibroblasts also had increased levels of TGF-β2 and Smad2 (a 
downstream target of the TGF-β pathway) (Xia et al., 2004). This TGF-β related 
overexpression was seen both in total and active forms of the proteins (Xia et al., 
2004). Overall, it is clear that the epithelial-mesenchymal interaction is important 
for signalling processes in both cell-types, impacting on their growth, expansion 
and turnover.  
 
Investigations on keloid keratinocyte monolayer cultures have not been widely 
documented. One gene expression profiling study compared monolayer cultured 
keloid fibroblasts and keratinocytes against whole keloid scar tissue (Hahn et al., 
2013). Their microarray analysis found a small subset of genes with significantly 
altered expression in both keloid fibroblasts and keratinocytes, as well as in the 
original tissues, compared to their normal counterparts. Periostin (POSTN), an 
osteogenic factor, showed the highest gene up-regulation in tissue and fibroblasts, 
but not keratinocytes. Whereas transforming growth factor β receptor III (TGFβ-
RIII) showed a significant down-regulation in tissue and keratinocytes, but not in 
fibroblasts (Hahn et al., 2013). 
 
In terms of keloid regional differences, a small number of studies have shown 
differential expression of proliferative and anti-apoptotic genes being expressed in 
the central, marginal or adjacent normal skin of keloid biopsies. However, the 
same studies often failed to verify the same expression patterns in isolated 
fibroblasts and keratinocytes. Shih et al. found 10 genes to be significantly 
differentially expressed by at least 2-fold between keloid margin and adjacent 
normal skin, while the same 10 genes showed no statistically significant difference 
between fibroblast populations of the same keloid regions (Shih et al., 2010b). 
Despite this, the trend seen in cultured fibroblasts was the same as in the original 
biopsy data in 7 out of the 10 identified genes. The authors suggested that the cell 
culture methodology used was the most likely cause for the lack of statistical 
significance (Shih et al., 2010b), though the high inter-patient variability observed 
was potentially another contributing factor. Importantly, the related keloid 
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keratinocytes were not examined in this study, which might have helped to explain 
the difference in results between biopsies and cultured cells. 
 
The culture system chosen for target validation of genes identified from whole 
tissue in Chapter 4 was a monolayer culture of fibroblasts and keratinocytes from 
keloids. One of the keloids from which matching fibroblasts and keratinocytes 
were isolated, was also part of the analysis in both Chapters 3 and 4.  This simple 
and relatively shorter protocol was selected in favour of a co-culture system, so as 
to be able to increase the number of patient samples being used. A more complex 
co-culture or organotypic culture system would restrict the sample number, due to 
project time constraints. Both fibroblast and keratinocyte populations were 
cultured from keloid and normal tissue, and expression analysis was performed on 
passage 3 or 4 of all cultures. Taking into account the high level of bias in defining 
the boundaries of each keloid margin without first looking at the histological 
features (discussed in Chapter 3), an equal proportion of keratinocytes or 
fibroblasts from each scar region was combined to reflect the whole scar tissue. 
This way, the gene expression data in keloid cells would also be comparable to the 
whole tissue data.  
 
5.1.1 Aim 
The primary aim of this chapter was to examine a selection of the gene targets 
previously validated in keloid whole tissue in Chapter 4, in primary cultures of 
fibroblasts and keratinocytes isolated from keloid and normal tissue. Both 
fibroblasts and keratinocytes were cultured as a single layer, and examined in 
isolation from each other, in order to examine the differences between keloid and 
normal cells. All cultures were first assessed for any difference in rate of growth, 
and basic morphology. Finally, a verification of the most significantly altered target 
was made by IHC-IF on the original patient specimens. 
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5.2 Results 
Primary cultures from keloid and normal tissues, were established for both 
fibroblast and keratinocyte cell populations. Section 2.3, Chapter 2 describes the 
full procedure of cell isolation and expansion. A total of six keloid patients and four 
normal skin donors were used for the propagation of fibroblast and keratinocyte 
cultures. Patient 36 was the only keloid which was analysed in full throughout this 
thesis in terms of the IHC in Chapter 3, both gene expression qPCR arrays in 
Chapter 5, and the analyses described below in both fibroblasts and keratinocytes. 
Patient 34 tissue was also fully characterised (Chapter 3), analysed in the qPCR 
arrays (Chapter 4), but only the fibroblasts were available for gene expression 
analysis below. Similarly, only Normal Skin 6 was fully examined throughout this 
thesis. Most of the remaining fibroblast and keratinocyte cultures were isolated 
from tissues, which were characterised in Chapter 3, but not analysed in the qPCR 
arrays of Chapter 4. Refer to Tables 2-1 and 2-2 in Chapter 2 for full information 
on which samples were used for which analyses. 
 
Below, a calculation of the rate of growth of each patient’s cells is presented. This is 
followed by an evaluation of whether the targets, previously found to be altered in 
whole tissue, continue to show similar gene expression patterns in cultured cells. 
Both cell types were grown as single layer cultures, and patient matched cells (i.e. 
both fibroblasts and keratinocytes from the same patient) were used wherever 
possible. In order to reflect the analyses thus far, where whole keloid tissues were 
used, inclusive of the central, edge and adjacent normal regions, the isolated 
fibroblasts and keratinocytes were similarly taken from all three regions of the 
keloid. The only difference here is that the epidermal and dermal cells were 
examined separately.   
 
5.2.1 Cell morphology and growth of primary cultured cells  
5.2.1.1 Primary fibroblasts 
Primary fibroblast morphology was similar between normal and keloid fibroblasts. 
The cells had a typical elongated spindle shape, and once they reached a 
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confluence of higher than 50%, they began to align into parallel clusters. Both 
keloid and normal fibroblasts appeared very similar to each other in morphology 
and cell-shape. Figure 5-1 shows representative images from primary fibroblast 
cultures. 
 
The rate of growth was determined by two methods: using the Alamar Blue assay, 
and by population doubling. In the fibroblast population, cells were propagated 
from 6 keloid patients, and from 4 healthy controls. The Alamar Blue assay was 
carried out over 7 days, with measurements taken at days 1, 3, 5 and 7. Population 
doubling times were quantified over seven passages carried out over a 28 day 
period. There was some variation between individuals, but overall no significant 
difference in growth rate was found between the keloid and the normal groups, as 
tested by a 2-way ANOVA (Figure 5-2). In the first two passages the population 
doubling time, for all fibroblasts was between 1.5-2 population doublings per 
week. This rose a little to an average of 2.5-3.5 population doublings per week, at 
later passages.  
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Figure 5-1 Fibroblast cell morphology 
Representative images from keloid and normal fibroblast populations, imaged at 
approximately 70% confluence. Cells were elongated and spindle-shaped in both 
keloid and normal groups, with very little difference between them. Some areas of 
keloid fibroblast cultures showed a higher proportion of larger, more spread cells 
compared to normal cultures, however this was not deemed to be significant. 
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Figure 5-2 Cell growth rate of keloid and normal fibroblasts, by Alamar Blue assay and Population Doubling time calculation 
Primary cultured fibroblasts were plated at passage 2 or 3, and the rate of growth measured by Alamar Blue assay (A) on days 1, 3, 5 and 7 of 
culture. Population Doubling levels (B) were investigated by propagating fibroblasts for 28 days through six passages, and their rate of cell 
doubling calculated at each passage. Fibroblasts were isolated from a total of 6 keloid patients and 4 healthy controls. No significant difference 
was found, as analysed using a 2-way ANOVA. Error bars represent the standard error of the mean (SEM) 
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5.2.1.2 Primary keratinocytes 
All primary keratinocytes presented the typical “cobblestone” morphology, though 
there were some differences between keloid and normal cells. Primary keloid 
keratinocytes appeared larger, and more spread than normal keratinocytes. Both 
keloid and normal keratinocytes grew in colonies.  However, those of normal cells 
were much more compact, with the individual cells looking smaller. In the keloid 
group, there were more cases of single cells growing outside of their colonies, 
compared to the normal group, particularly with increasing passage number. This 
would suggest that the keloid keratinocytes were undergoing differentiation at an 
earlier stage compared to normal keratinocytes. Figure 5-3 shows representative 
images of keloid and normal keratinocytes under serum-free culture conditions. 
 
The rate of growth was calculated by two methods: using the Alamar Blue assay, 
and by population doubling. In the keratinocyte population, cells were expanded 
from 4 keloid scars and 3 healthy controls. The Alamar Blue assay was carried out 
over 8 days, with measurements taken at days 1, 3, 5 and 8. Population doubling 
times were measured over four passages carried out over a 20 day period. There 
was a high level of variation in cell growth rate, particularly in the Alamar Blue 
assay, which showed no significant difference between keloid and normal cell 
cultures (as tested using a 2-way ANOVA). In the population doubling 
measurements however, a statistically significantly lower rate of growth was 
recorded for the keloid keratinocyte population (Figure 5-4). In the first passage 
of measuring population doubling time, keloid keratinocytes showed 0.2-0.5 
population doublings per week. This rose a little in the next passage to 0.8-1.7 
population doublings per week, but then fell down to 0.1, and even -0.6 population 
doublings per week in one case. This suggested that after passage 4 or 5, keloid 
keratinocytes were starting to differentiate and exiting the exponential growth 
phase. Normal keratinocytes, on the other hand, showed an initial population 
doubling rate of 0.5-2 per week, which went up slightly to 1-2 population 
doublings per week by passage 5. Overall, the total population doubling levels of 
the normal keratinocytes were statistically significantly higher than the keloid 
keratinocytes, suggesting a faster rate of growth.  
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Figure 5-3 Keratinocyte cell morphology 
Representative images from keloid and normal keratinocyte populations, imaged at 
approximately 60% confluence. Both keloid and normal keratinocytes showed a 
“cobblestone” morphology, though keloid cells were larger and more spread out. Also, 
keloid keratinocytes showed less compact colony formation, with many more single 
cells growing outside the colony formations, as compared to normal keratinocytes.  
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Figure 5-4 Cell growth rate of keloid and normal keratinocytes, by Alamar Blue assay and Population Doubling time calculation. 
Primary cultured keratinocytes were plated at passage 2 or 3, and the rate of growth measured by Alamar Blue assay (A) at 1, 3, 5 and 8 days 
of culture. Population Doubling levels (B) were investigated by propagating keratinocytes for 20 days through 4 passages, and their rate of cell 
doubling calculated at each passage. Keratinocytes were isolated from a total of 4 keloid patients and 3 healthy controls. Keloid keratinocytes 
showed a statistically significantly decreased rate of growth at days 11 and 20, as measured by population doubling levels (B), calculated using 
a 2-way ANOVA. Error bars represent the standard error of the mean (SEM) 
 
* 
* 
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5.2.2 Expression profiles of altered genes in primary cells 
5.2.2.1 Primary fibroblasts 
The 18 GOIs (genes of interest) selected from the qPCR arrays on whole tissue, and 
which were subsequently validated in the same tissues, using individually 
designed qPCR assays (relative standard curve method), were examined in the 
keloid and normal primary fibroblasts described so far in this chapter. Even 
though only four genes (EGFR, SORBS1, BCL2, and BMP2) continued to show 
statistically significant differences in expression between keloid and normal 
tissues, described in Chapter 4, all 18 genes were tested in the single layer cell 
cultures, to examine whether the cells retained the same general trends as the 
original tissues.  
 
The fold-changes in expression of the 18 genes are shown in Figure 5-5 and Table 
5-1. Every point within each gene on the graph represents one patient’s 
fibroblasts. Most of the genes revealed very little variance between patient cells. 
However MMP3, MMP13, BMP4 and GATA3 showed varying levels of expression 
between patients. When the Student’s t-test was carried out, only SPP1 showed a 
statistically significant over-expression in keloid fibroblasts compared to normal 
fibroblasts (p=0.026). By contrast, all of the selected genes (except for MMP2 and 
SFN) had shown to be statistically significantly different in the original qPCR 
arrays, using the same statistical test. It was noted that SFN was almost statistically 
significantly different with (p= 0.0502) and similarly WISP1 with (p=0.052). 
 
In Figure 5-6, the original tissue data from the qPCR validation assays is compared 
side by side with the fibroblast qPCR data. Even though the same levels of change 
in gene expression were not directly reproduced in the validation, the fold-changes 
for most genes were similarly altered, i.e. both array and validation results 
showing an up- or down-regulation.  The exceptions were MMPs 1, 2 and 3, and 
TNC, where the whole tissue data showed an up-regulation in keloids, whereas the 
fibroblast culture results displayed a down-regulation. Similarly, SFN, EGFR and 
GATA3 all displayed a down-regulation in keloid whole tissue, though keloid 
fibroblasts showed an up-regulation for all three. 
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Figure 5-5 Gene expression profile in primary fibroblasts 
Real Time qPCR (relative standard curve method) was performed on 18 GOIs and 2 
reference genes, selected from the targets found to be differentially expressed in 
whole tissue (see Chapter 4). The majority of the genes showed a small difference 
between keloid and normal fibroblasts, with only SPP1 demonstrating a significant 
increase in keloid fibroblasts, as tested by the Student’s t-test. [* = p<0.05]. Fibroblasts 
were isolated from n=6 keloid, n=4 control patients. Error bars represent the SD. 
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Table 5-1 Fold-changes in genes expression, in keloid primary fibroblasts. n=6 
keloids; n=4 normal controls; In blue, statistically significantly altered in keloid vs 
normal (p<0.05). This data is plotted in Figure 5-5. 
Gene 
symbol 
Mean          
fold-changes 
St. Deviation of 
mean 
P value (Student’s t-
test) 
SFN 2.558 1.865 0.0502 
SPP1  2.390 1.743 0.026 
WISP1 2.090 2.269 0.052 
MMP13 1.842 12.895 0.178 
GATA3 1.487 4.102 0.105 
COL1A1 1.434 1.826 0.163 
MMP14 1.280 2.584 0.181 
SPARC 1.265 1.637 0.298 
VEGFA 1.218 0.482 0.448 
EGFR 1.167 1.119 0.335 
BCL2 -0.035 1.258 0.768 
MMP2 -1.082 2.366 0.569 
BMP2 -1.138 1.183 0.270 
MMP3 -1.261 5.947 0.752 
HEY1 -1.291 1.488 0.356 
SORBS1 -1.414 0.936 0.309 
TNC -1.561 1.347 0.064 
MMP1 -2.775 2.453 0.129 
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Figure 5-6 Gene expression pattern in primary fibroblasts, compared to whole tissue 
The gene expression profiles in primary fibroblasts did not necessarily match the 
pattern of expression observed in whole tissue (tissue data represents validation 
qPCRs from section 4.2.3). MMPs 1, 2 and 3, SFN, TNC, EGFR, and GATA3 all showed 
opposite gene regulation, between whole tissue and isolated fibroblasts, whereas the 
rest of the genes showed similar gene expression trends between the two sample 
types. Data was taken from Figures 4-7 (in Chapter 4) and 5-5, for clearer comparison. 
Error bars represent the SD. 
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5.2.2.2 Primary keratinocytes  
The fold-changes in expression of the 18 GOIs in primary keratinocytes are shown 
in Figure 5-7 and Table 5-2. Every point within each gene on the graph 
represents one patient’s keratinocytes. Many of the genes revealed a high level of 
variance between patient cells, including MMPs 1, 2, 3, 13, and 14, SPARC, SPP1, 
SORBS1, and WISP1. In fact, almost all of these genes showed variable expression 
in keloids with both up-regulation and down-regulation of expression. When the 
Student’s t-test was carried out, no genes showed any significant difference in 
keloid compared to normal keratinocytes (Table 5-2).  
 
In Figure 5-8, the original validation qPCR data is compared alongside with the 
keratinocyte qPCR data, as the exact same qPCR assays and statistical analyses had 
been used on both sets of data, making them more comparable. Even though the 
same levels of change in gene expression were not directly reproduced in the 
isolated keratinocytes, the fold-changes for most genes were similarly altered, i.e. 
both array and validation results showing an up- or down-regulation.  The 
exceptions were MMPs 2, 3, 13, where the array data showed an up-regulation in 
keloid tissues, and a down-regulation in the keratinocyte culture results. Similarly, 
SFN and BCL2 showed a down-regulation in whole tissue, and an up-regulation in 
isolated keratinocytes. 
 
Finally, the original validation qPCR data was compared against both the isolated 
fibroblast and keratinocyte data in parallel (Figure 5-9). A small number of genes 
still showed opposite effects in whole tissue to isolated keloids cells, including 
MMP2, MMP3, SFN and BCL2. Other genes showed consistently similar regulation 
between whole tissue and keloid cells, such as COL1A1, MMP14, SPARC, SPP1, 
BMP2, SORBS1, VEGFA, and WISP1. The remaining genes MMPs 1, 13, TNC, EGFR, 
and GATA3 showed an interesting pattern whereby one of the cell types linked in 
with the whole tissue data, and the other cell type showed the opposite. For 
example, MMP13 was overexpressed in both whole tissue and fibroblasts, but 
under-expressed in keratinocytes. By contrast, TNC showed an up-regulation in 
whole tissue and keratinocytes, but a down-regulation in keloid fibroblasts. 
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Figure 5-7 Gene expression profile in primary keratinocytes  
Real Time qPCR (relative standard curve method) was performed on 18 GOIs and 2 
reference genes, selected from the targets found to be differentially expressed in 
whole tissue (see Chapter 4). All genes showed a small difference between keloid and 
normal keratinocytes, with no genes demonstrating a statistically significant 
difference, as tested by the Student’s t-test. Many genes including all the MMPs, 
SPARC, SPP1, SORBS1 and WISP1, showed varied expression levels between patients. 
Keratinocytes were isolated from n=4 keloid, n=3 control patients. Error bars represent 
the Standard Deviation (SD)  
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Table 5-2 Fold-changes in gene expression, in keloid primary keratinocytes. (n=6) 
This data is plotted in Figure 5-7 
Gene 
symbol 
Mean             
fold-changes 
St. Deviation of 
mean 
P value    
(Student’s t-test) 
SPP1 5.234 1.283 0.209 
SPARC 4.208 1.237 0.158 
BCL2 1.959 2.005 0.237 
MMP14 1.914 1.454 0.428 
VEGFA 1.193 1.184 0.738 
TNC 1.104 1.282 0.811 
SFN 1.098 1.686 0.762 
WISP1 1.074 4.329 0.455 
HEY1 -0.005 1.395 0.707 
MMP1 -0.464 2.005 0.549 
COL1A1 -0.719 2.488 0.850 
MMP3 -1.017 2.029 0.804 
MMP13 -1.224 1.244 0.699 
EGFR -1.630 1.359 0.129 
BMP2 -1.752 1.551 0.154 
GATA3 -2.181 1.337 0.052 
SORBS1 -5.100 1.355 0.117 
MMP2 -5.536 34.765 0.656 
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Figure 5-8 Gene expression pattern in primary keratinocytes, compared to whole 
tissue 
The gene expression profiles in primary keratinocytes did not necessarily match the 
pattern of expression observed in whole tissue (tissue data represents validation 
qPCRs from section 4.2.3. in Chapter 4). MMPs 2, 3 and 13, SFN, and BCL2 all showed 
opposite gene regulation, between whole tissue and isolated fibroblasts, whereas the 
rest of the genes showed similar gene expression trends between the two sample 
types. Data was taken from Figures 4-7 (Chapter 4) and 5-7, for clearer comparison. 
Error bars represent the SD. 
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Figure 5-9 Comparing differences in gene expression patterns between whole tissue, primary fibroblasts and primary keratinocytes.  
Summary of data already presented in Figures 4-7 (in Chapter 4), 5-6 and 5-8. For the majority of these genes, at least one cell-type reflected 
the gene regulation pattern in whole tissue. The exceptions were MMP2, MMP3, SFN, and BCL2, which displayed the same gene regulation 
pattern between fibroblasts and keratinocytes, but were in contrast to the trend seen in whole tissue. Error bars represent the SD. 
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5.2.3 SPP1 protein expression in tissue 
As SPP1 gene expression appeared to be consistently up-regulated in whole tissue 
and primary keloid fibroblasts and keratinocytes, described in both the previous 
and current chapters, it was of interest to examine whether SPP1 protein levels 
were also increased in keloid scars, compared to normal tissue. For this, 3 keloid 
specimens, along with a hypertrophic scar and 2 control normal specimens (fully 
characterised in Chapter 3) were analysed by IHC-immunofluorescence. SPP1 
protein expression is visible in red, and DAPI nuclear stain is in blue (Figures       
5-10, 5-11 and 5-12). 
 
In normal skin, there was some variability observed in the intensity of SPP1 
protein expression in the dermal compartments, with patient 4 showing a higher 
level of SPP1 than patient 6, particularly in the reticular dermis (Figure 5-10). 
Increased expression was seen in all skin appendages such as hair follicle bulbs, 
sweat glands and sebaceous glands. In the epidermis, SPP1 expression was 
consistent across both specimens, and along the length of the entire tissues, being 
restricted mainly to the upper layers of the epidermis. There was very little SPP1 
expression in the basal epidermis. Also, it appeared that SPP1 was present both in 
secreted form in amongst the ECM of the dermis, as well as intracellular form - 
particularly noticeable in the epidermis. 
 
In keloid scars, there was some variability in SPP1 expression between scar 
regions, which appeared consistently across the 3 keloids tested here (Figures     
5-11 and 5-12). Dermal expression of SPP1 was comparable to normal skin in the 
papillary dermis, though appeared increased in the deeper dermal layers. In 
particular, the regions containing thickened collagen nodules previously identified 
in Chapter 3, showed increased levels of SPP1 protein expression (Figures 5-11 
and 5-12). Additionally, in regions of high inflammatory invasion, notably in the 
edge dermal region of patients 34 (Figure 5-11) and 55 (Figure 5-12), SPP1 
protein levels were at their highest. The hypertrophic scar showed a similar 
pattern of dermal expression to the keloid specimens. The papillary dermis had a 
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relatively low level of expression, though the more collagenous, myofibroblast-rich 
reticular dermis revealed an increased level of expression.  
 
In the hypertrophic and keloid epidermis, SPP1 protein expression was noted 
across the whole length of the lesions, with the basal epidermal layer showing the 
most intense signal. In this case, SPP1 is mostly seen to be intracellular, in contrast 
to the dermis where most of the protein is in the secreted form. Overall, it is clear 
that these keloids and hypertrophic scar tissue show an increased SPP1 
expression, compared to normal skin. 
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Figure 5-10 SPP1 protein expression by immunofluorescence, in normal skin and 
tissue controls. 
SPP1 protein expression was present in the reticular dermis of normal skin, with some 
variability in intensity between subjects. Epidermal expression was mainly 
concentrated in the upper layers of the epidermis.  The positive (+ve) and negative      
(-ve) controls were performed on human stomach cancer tissue, as directed by the 
antibody manufacturer. SPP1 is shown in red; DAPI nuclear stain is shown in blue. 
Scale bars represent 100μm. SPP1 was examined in n=3 keloids, n=1 hypertrophic scar, 
and n=2 normal skin in total. 
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Figure 5-11 SPP1 protein expression by immunofluorescence, in keloid scars. 
SPP1 protein expression was present in the papillary dermis of the central scar and 
adjacent normal tissue of the keloids, with increased levels noted in the collagenous 
nodules of the keloid centre in patient 36 (Centre d. = centre dermis). An intense 
dermal expression of SPP1 was observed in a region of inflammatory invasion, at the 
keloid edge of patient 34 (yellow arrow). Across the whole keloid scar, epidermal 
expression was increased in the lower layers, especially near the basement membrane, 
as compared to normal skin (Figure 5-10). SPP1 is shown in red; DAPI nuclear stain is 
shown in blue. Scale bars represent 100μm; Centre ep. = Centre epidermis. SPP1 was 
examined in n=3 keloids, n=1 hypertrophic scar, and n=2 normal skin in total. 
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Figure 5-12 SPP1 protein expression by immunofluorescence, in keloid and 
hypertrophic scars 
SPP1 protein expression was present across the whole dermis of patient 55, which did 
not have a clear central region (refer to Figure 3- 27 and section 3.2.3.4 in Chapter 3). 
An increased level of SPP1 was noted in areas of inflammatory invasion (yellow 
arrow), and across the whole epidermis, as compared to normal skin (Figure 5-10). The 
hypertrophic scar showed a similar pattern of SPP1 expression as in keloid scars, with 
increased levels of in the basal epidermis and nodular collagenous region of the 
reticular dermis (RD) – also noted in patient 36 centre (Figure 5-11). SPP1 is shown in 
red; DAPI nuclear stain is shown in blue. Scale bars represent 100μm; PD = papillary 
dermis. SPP1 was examined in n=3 keloids, n=1 hypertrophic scar, and n=2 normal skin 
in total. 
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5.3 Discussion 
In this chapter, I have examined the basic cell morphology and growth rate of 
keloid-derived fibroblasts and keratinocytes, compared against primary 
fibroblasts and keratinocytes from normal control skin. There was no difference in 
growth rate and cell morphology between keloid and normal fibroblasts. Keloid 
keratinocytes however showed a statistically significant decrease in growth rate, 
compared to normal keratinocytes. Also, keloid keratinocytes appeared larger, 
more spread out, and their colonies were less tight than their normal counterparts. 
 
Out of the 18 selected and validated GOIs from Chapter 4, only SPP1 showed a 
statistically significantly different expression in keloid cells, and only within the 
fibroblast population. A high level of inter-patient variability was observed in the 
gene expression data, particularly in the keratinocyte population – a factor likely to 
have contributed to the lack of statistical significance found in the results. Despite 
this, some interesting trends were noted in the gene expression profiles, when 
compared against the original whole tissue data. In particular, MMPs 1, 13, TNC, 
EGFR, and GATA3 showed somewhat complementary gene expression profiles in 
the fibroblast and keratinocyte expression profiles, where only one cell type 
matched up with the same trend of gene expression difference as observed in 
whole tissue, and the other cell type showed the opposite trend.  
 
Finally, SPP1 protein expression appeared to be increased in regions of the 
expanding keloid dermis, as well as in the basal epidermal layers of the whole 
keloid scar tissue. This may implicate osteogenic processes (Sodek et al., 2000) 
with keloid scarring. 
 
5.3.1 Keloid-derived fibroblasts 
As described earlier in section 5.1, it has been shown that cell morphology 
(Chipev et al., 2000) and growth rates appear to be similar between keloid and 
normal fibroblast cultures (Russell and Witt, 1976). Though under serum-
starvation conditions, keloid fibroblasts appear not to require as many growth 
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factors to propagate successfully, as are required by normal fibroblasts (Russell et 
al., 1988). This supports my findings, where keloid and normal fibroblasts showed 
no differences in cell morphology or rate of growth, as tested by the Alamar Blue 
assay and population doubling levels. Collagen type I gene expression was not 
significantly altered between keloid and normal fibroblasts, even though there was 
a trend of increased COL1A1 expression in the keloid fibroblasts (section 5.2.2.1). 
This is most likely due to the culture system used in this chapter. It has been 
demonstrated that collagen type I expression is decreased in primary keloid 
fibroblasts grown as a monolayer, as the cell passage number increases (Syed et al., 
2011). In the original tissue, regional differences in the collagen I/III ratio were 
also observed, with the keloid edge showing the highest level of collagen I/III. 
However, by passage 3 of monolayer fibroblast cultures, the differences between 
keloid regions were no longer significant (Syed et al., 2011). Despite this drawback 
to using monolayer fibroblast cultures as models to study keloid pathogenesis, 
multiple research groups have used them to deduce a whole range of gene (Smith 
et al., 2008, Seifert et al., 2010) and protein expression profiling patterns (Aoki et 
al., 2014, Bettinger et al., 1996, Bran et al., 2010, Chin et al., 2000), signalling 
pathway analysis (Chua et al., 2011, Fujiwara et al., 2005b, Satish et al., 2004), as 
well as to test the effectiveness of potential new keloid treatments (Wendling et al., 
2003, Syed et al., 2013, Sadick et al., 2008). 
 
During the gene expression analysis on keloid fibroblasts in this chapter SPP1 was 
the only gene to show a statistically significant difference. SPP1 was overexpressed 
by 2.4-fold in keloid compared to normal fibroblasts. The same trend was observed 
in both whole tissue (see sections 4.2.1.2 in Chapter 4), and in keloid 
keratinocytes (see section 5.2.2.2) – though the result was not statistically 
significant for the keratinocyte population. The rest of the genes analysed showed 
no statistically significant changes, as tested by a Student’s t-test for each gene.  
 
A decreased expression of MMPs 1, 2 and 3 was noted in keloid fibroblasts, even 
though the opposite trend was seen in whole tissue (refer to Figure 5-6). In 
previous studies, MMPs 1 and 3 have been reported as down-regulated in keloid 
tissues and fibroblast cultures (Huang et al., 2013a, Smith et al., 2008). 
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Nevertheless, my MMP gene expression data in cultured cells was not statistically 
significant, and the lack of consistency in the literature on the MMP family 
supports the ongoing debate as to whether in vitro examination of MMP expression 
and activity is truly reflective of physiological MMP function (Giannandrea and 
Parks, 2014, Parks et al., 2004). 
 
5.3.2 Keloid-derived keratinocytes 
As already mentioned, the fibroblast and myofibroblast has been the main focus of 
research in fibrosis and keloid scarring, due to its key role in ECM synthesis. 
Although comparatively limited, research on the role of the epidermis and the 
keratinocyte cell-type in keloid pathogenesis is increasingly showing their 
importance in the disease (Menon et al., 2012, Xia et al., 2004). Most studies 
looking at the role of keloid keratinocytes are based on co-culture or 3D culture 
systems. In normal skin cells, simply co-culturing normal keratinocytes with 
normal fibroblasts significantly increases fibroblast proliferation, compared to 
when the fibroblasts are cultured as a monolayer (Funayama et al., 2003). The 
effect is increased when co-culturing keloid keratinocytes with normal fibroblasts, 
and even further increased when co-culturing keloid keratinocytes with keloid 
fibroblasts (Funayama et al., 2003, Lim et al., 2001). Furthermore, keloid 
keratinocytes had the strongest effect on reducing apoptosis of both normal and 
keloid fibroblasts (Funayama et al., 2003). These effects have been noted, 
regardless of whether the culture system used was inclusive (Phan et al., 2002) or 
not (Funayama et al., 2003) of fetal calf serum. Interestingly, keloid keratinocytes 
were shown to induce normal fibroblasts to secrete collagen type I in the same 
manner as keloid fibroblasts (Lim et al., 2002b, Phan et al., 2002). Even simply 
adding keratinocyte conditioned media to dermal fibroblasts increases the level of 
collagen production in the fibroblasts (Ghaffari et al., 2009b). This suggests that 
keloid keratinocytes have an important role in the mesenchymal differentiation 
status, and therefore in the fibrogenic nature of keloid scars (Lim et al., 
2002b)(Lim et al., 2002b)(Lim et al., 2002b)(Lim et al., 2002b)(Lim et al., 
2002b)(Lim et al., 2002b)(Lim et al., 2002b). 
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It has been shown that the microenvironment surrounding the keloid scars is often 
ischemic and hypoxic (Kischer and Brody, 1981), and regions within the keloid 
scar itself are hypoxic (Steinbrech et al., 1999, Zhang et al., 2003, Zhang et al., 
2004). Increased hypoxia leads to an accumulation of HIF1α (hypoxia-inducible 
factor-1α) in scar tissue (Zhang et al., 2003, Wu et al., 2004b), which is thought to 
promote fibrogenesis through epithelial-to-mesenchymal transition (EMT), and 
excessive ECM production (Sun et al., 2009, Higgins et al., 2007). During EMT, 
epithelial cells lose their polarity and cell-cell adhesions, and acquire a migratory 
behavior, enabling them to transform into mesenchymal cells (Yin et al., 2013, 
Savagner and Arnoux, 2009, Yan et al., 2010). Ma et al. postulate that keloid 
keratinocytes adopt a fibroblast-like appearance through EMT, thereby enhancing 
their capacity to invade beyond the original wound margin, and expanding the 
keloid scar (Ma et al., 2015).  
 
Keloid keratinocyte monolayer cultures appeared to form loose colonies in 
comparison to normal keratinocytes, and were more widely dispersed, with an 
increased level of motility, as tested by a scratch assay (Hahn et al., 2013). 
Subsequent microarray analysis revealed an up-regulation of genes related to cell 
adhesion, the ECM, and motility; while they showed a down-regulation of genes 
involved in cell differentiation, cell junctions, and EGFR signalling (Hahn et al., 
2013). My findings fit in very closely with these previous studies. The keloid-
derived keratinocytes showed a statistically significant decrease in growth rate, 
and morphologically they appeared larger and more spread than normal 
keratinocytes. Together with the apparent up-regulation of anti-apoptotic gene 
BCL2, and the down-regulation of EGFR noted in the gene expression analysis 
(section 5.2.2.2), this data tentatively supports the literature above with the 
notion that keloid keratinocytes are more invasive, perhaps more mesenchymal-
like than their normal counterparts.  
 
The gene expression analysis of keratinocyte cultures above revealed no 
significant differences between keloid and normal cells. The levels of gene 
expression was inconsistent between patients in almost half of the genes tested, 
reflecting the nature of the disorder.  Overall, when comparing the three sets of 
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gene expression data (whole tissue, fibroblasts and keratinocytes), 4 out of 18 
genes showed completely different trends in cell cultures vs tissue; 8 out of 18 
genes showed consistently similar trends in all three sample groups; and 5 out 18 
genes showed a mixture of trends, whereby at least one cell type was consistent 
with the whole tissue data (section 5.2.2.2). In the last group of genes, TNC and 
EGFR are of potential interest. TNC showed an increased expression in whole 
tissue and cultured keratinocytes, but a decreased expression in keloid fibroblasts 
(Figure 5-9). This hexameric glycoprotein is thought to potentially influence 
fibronectin activity, as it appears at the same time during the early phases of 
wound healing (Shrestha et al., 1996, Halper and Kjaer, 2014). TNC overexpression 
has previously been linked to fibrosis, including scleroderma (Lacour et al., 1992) 
and other hyperproliferative skin conditions (Schalkwijk et al., 1991). Little is 
known about TNC in relation to keloid scarring, though it has been found to be 
diffusely expressed in the keloid dermis, especially around the large collagen 
bundles of the keloid reticular dermis (Dalkowski et al., 1999, Jumper et al., 2015, 
Sidgwick and Bayat, 2012). TNC gene expression patterns in isolated keloid cells 
have not been reported, and my findings show an underexpression in the dermal 
cells.  
 
5.3.3 SPP1 expression as a marker of invasiveness 
SPP1 was the only target to appear as significantly altered between keloids and 
normal skin, shown in whole tissue as well as in isolated fibroblasts and 
keratinocytes, at both the gene and protein level. As discussed in Chapter 4, SPP1 
is an osteogenic factor, which has been found to be overexpressed in hypertrophic 
scars (Wu et al., 2004a), and other types of fibrosis (Pardo et al., 2005, Persy et al., 
2003, Gardner et al., 2006). It has been suggested that SPP1 promotes fibrosis-
related signalling, through myofibroblast activation (Lenga et al., 2008). This 
would fit in with my findings, where SPP1 protein expression was more intense in 
the densely collagenous nodules of the keloid reticular dermis. By comparing the 
localisation of SPP1 protein expression (Figures 5-11 and 5-12) and the α-SMA 
expression (Figures 3-10, 3-16, 3-20 and 3-28 in Chapter 3) in the same keloid 
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and hypertrophic scar tissues, it becomes plausible that SPP1 is linked with 
myofibroblast expression.  
 
It is well established that SPP1 is involved in cell adhesion and cell migration. It 
can bind to certain integrins (mainly αv β3), and affect cell migration via interaction 
with CD44 and activation of the EGFR pathway (Sodek et al., 2000). In fact, SPP1 
can stimulate cell activity through a range of extracellular receptors at the cell-
ECM interface, including αv β3 integrin, EGFR, and VEGFR, affecting a range of 
functions, such as cytoskeletal organisation through PI3-kinase signalling, 
promoting cell proliferation through MAPK/Ras signalling, and preventing 
apoptosis by activating NFκB (Sodek et al., 2000, Lopez et al., 1995, Denhardt and 
Guo, 1993). 
  
The strong epidermal expression of SPP1 in my keloid tissues is supported by 
Miregliotta et al., who showed a strong SPP1 expression in the epidermis of keloid 
lesions, though there was no clear comparison to normal healthy skin (Miragliotta 
et al., 2014). In psoriasis, the intensity of SPP1 expression in the lesional epidermis 
was associated with severity of the condition, where increased SPP1 expression 
was found with increased disease severity (Abdou et al., 2012). In oral squamous 
cell carcinoma, SPP1 expression has been proposed for use as a biomarker of 
disease invasion, but not as a predictive marker of progression from dysplasia to 
malignant transformation (Routray et al., 2013). In cancer biology in general, SPP1 
has been linked to metastasis, and research into targeting this molecule as an anti-
cancer therapy or as a biomarker for predicting metastasis is extensive (Jain et al., 
2007, Kiss et al., 2015, Anborgh et al., 2015, Yan et al., 2015, Huang et al., 2015, 
Hou et al., 2015).  
 
On this basis, further research into the feasibility of using SPP1 as a biomarker of 
keloid scarring, would be of interest. The current literature on SPP1 expression 
and its diverse functionality across tissue types and disorders, plus its established 
connection to promoting cell migration, would lead to the hypothesis that SPP1 
might be a useful marker of keloid scar severity. Further detail on potential future 
work is described in the following chapter. 
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6 Conclusion and future 
work 
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6.1 Overall conclusions 
The research presented in this thesis suggests that SPP1 could be a useful 
biomarker for keloid scarring. Based on the gene expression data, targets linked to 
the TGF-β/Smad, BMP, and Wnt pathways were altered, supporting some previous 
reports. Taken together, there is an indication of osteogenic and chondrogenic-
related signalling taking place.  
 
In Chapter 3, the keloid and control tissues used throughout the thesis were 
characterised in terms of whole tissue morphology, collagen fibre formation, cell 
proliferation, myofibroblast expression, and collagenase and gelatinase expression.  
I found that all the keloid scars showed an increased level of myofibroblast 
expression, which mainly corresponded with areas containing “keloidal collagen” 
in the fibrotic reticular dermis. Surrounding these regions, MMP2 and MMP14 
expression in particular appeared increased, as tested by IHC. Overall, the edge 
scar regions showed increased levels of proliferation, increased inflammatory 
infiltration, and evidence of increased scar tissue formation, compared to the 
remaining scar regions, and unaffected normal skin. One key observation was that 
the degree of myofibroblast expression and amount of dense collagenous nodules 
present in each keloid was variable, making it challenging to define clear 
boundaries between central, edge and adjacent normal sites.  For this reason, the 
ensuing gene expression investigations were carried out on whole tissue biopsies, 
incorporating epidermal and dermal compartments, as well as all scar regions. 
 
In Chapter 4, a total of 168 genes associated with the ECM microenvironment and 
a selection of well-studied signalling pathways were examined in n=5 keloid n=5 
control tissues. Out of these, a total of 31 genes demonstrated a statistically 
significant difference of expression in keloid scars compared to normal tissues. A 
selection of 18 genes were then validated in the same tissues, using an alternative 
qPCR method, which revealed only four genes (BCL-2, BMP2, SORBS1, and EGFR) 
remained statistically significantly altered in keloids compared to normal skin. 
Additional genes to take into account, despite the lack of statistical significance, 
were COL1, MMP2 and GATA3 as these were approximately statistically significant 
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at the p<0.05 level (p= 0.0513, 0.0598 and 0.0538 respectively); as well as SPP1, 
SPARC, and HEY1, as these genes showed the largest expression fold-change (+5.0, 
+3.3, and -7.7 respectively).  
 
Based on these results, in Chapter 5 I then investigated if these altered gene 
expression patterns were retained in vitro, in the isolated fibroblast and 
keratinocyte populations from the same cohort of tissues characterised in Chapter 
3. One keloid, Patient 36, was analysed in all investigations, Patient 34 was 
analysed in all but the cultured keratinocyte experiments, and the rest of the 
keloid-derived cells used in Chapter 5 were not matched to those used in the gene 
expression data of Chapter 4. The keloid keratinocytes showed a significantly 
lower rate of growth compared to normal keratinocytes, though the fibroblasts 
showed no difference between keloid and normal cells. In the gene expression 
analysis, the results were varied between patients, particularly in the keratinocyte 
population, leading to very little statistical significance being reached in the final 
analyses. SPP1 showed a strong statistically significant up-regulation in keloid 
fibroblasts, while SFN and WISP1 showed a near-statistically significant up-
regulation in keloid fibroblasts, and GATA3 showed a near-statistically significant 
down-regulation in keloid keratinocytes. When comparing the gene expression 
analyses from this thesis to published datasets (outlined in section 4.1.1 and 
Table 4-1, in Chapter 4) (Shih and Bayat, 2010b, Huang et al., 2013a), 15 genes 
were investigated in both cases. Ten out of these confirmed the altered gene 
expression in keloid material, reported in literature (Table 6-1). Among the 5 
genes that showed a different result to the literature, were JAG-1, MMPs 1, 2 and 3, 
and TNC, of which the MMPs demonstrated varied gene expression patterns 
between whole tissue, primary fibroblasts or primary keratinocytes. The high 
similarity in my data compared to previous reports, taking into account the 
different methodologies, research teams, and patient material, provides an extra 
level of confidence in my research. Finally, SPP1 protein expression was increased 
in keloid tissue, compared to normal skin biopsies. In particular, the basal 
epidermal layers and “keloidal collagen” regions of the dermis within the keloid 
scars displayed the most intense expression.  
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Table 6-1 List of genes reported to be up- or down-regulated in at least two 
microarray studies (see Table 4-1), compared to the data presented in this thesis.  
Gene 
code 
Gene full name 
Gene Up/ Down 
regulation: 
Literature Thesis 
A2M Alpha-2-macroglobulin UP - 
ACAN Aggrecan UP - 
ADIPOQ Adiponectin, C1Q and collagen domain 
binding 
UP - 
ANXA1 Annexin-A1 UP - 
BMP6 Bone morphogenetic protein 6 UP - 
COL1A1 Collagen I alpha1 UP UP 
COL1A2 Collagen I alpha2 UP - 
COL4A2 Collagen IV alpha2 UP UP 
COL5A2 Collagen V alpha2 UP - 
COL6A1 Collagen VI alpha1 UP UP 
COL15A1 Collagen XV alpha1 UP UP 
DCN Decorin  UP - 
EGFR  Epidermal growth factor receptor DOWN DOWN 
FAP Fibroblast activation protein alpha UP - 
FN1 Fibronectin 1 UP UP 
HIF-1A Hypoxia-inducible factor alpha subunit 1 UP - 
IGFBP7 Insulin-like growth factor binding protein 7 UP - 
JAG-1 Jagged-1 UP DOWN 
JUP  Junction plakoglobin DOWN - 
MMP1  Matrix Metalloproteinase1 (collagenase 1 DOWN UP (down in 
fibroblasts) 
MMP2 Matrix Metalloproteinase2 (gelatinase A) UP UP (down in 
fibroblasts & 
keratinocytes 
MMP3  Matrix Metalloproteinase3 (stromelysin 1) DOWN UP (down in 
fibroblasts & 
keratinocytes 
MMP14 Matrix Metalloproteinase 14 (MT1-MMP) UP UP 
NERP Neuronal regeneration related protein UP - 
NRP1  Neuropilin 1 DOWN - 
OGN Osteoglycin UP - 
POSTN Periostin, osteoblast specific factor UP - 
SERPINF1  Serpin peptidase inhibitor, clade F DOWN - 
TGF-β1 Transforming growth factor beta 1 UP UP 
TGF-βRIII  Transforming growth factor beta receptor III DOWN - 
THBS2  Thrombospondin 2 DOWN UP 
THBS4 Thrombospondin 4 UP - 
TNC  Tenascin C DOWN UP 
VCAN Versican UP UP 
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Overall, the trends identified in my research suggest involvement of more than one 
signalling pathway in keloid scarring. It is likely that there is cross-talk between 
signalling pathways. The TGF-β/BMP pathway is involved in a wide range of 
processes, and has shown to regulate cell proliferation, differentiation, migration, 
apoptosis and ECM remodelling among others (Guo and Wang, 2009). TGF-β has a 
particularly large number of transcriptional and non-transcriptional targets, plus 
multiple components, which make direct and dynamic contacts with other proteins 
(Guo and Wang, 2009). This gives rise to an enormous complexity, and flexibility of 
TGF-β/BMP functions. Interactions between the TGF-β/BMP, Wnt, Hedgehog, 
Notch, and MAPK pathways among others, are key to appropriate growth and 
tissue homeostasis (Guo and Wang, 2009). Alterations in these pathways have 
been identified in the development of various diseases, including  in cancer 
development and fibrosis (Massagué, 2008, Mishra et al., 2005, Attisano and 
Labbé, 2004, Sumi et al., 2008). Within the MAPK pathway, RTKs (receptor 
tyrosine kinases) such as EGFR (epithelial growth factor receptor), FGFR 
(fibroblast growth factor receptor), IGFR (insulin-like growth factor receptor), 
PDGFR (platelet-derived growth factor receptor) and insulin receptor, can induce 
activation via Ras. EGFR signalling activates both the MAPK and 
phosphatidylinositol-3 kinase (PI3K)/Akt pathways, but also communicates with 
TGF-β/Smad in mammary epithelial cells, which is important in the context of 
breast cancer development (Siegel et al., 2003, Ueda et al., 2004, Janda et al., 2002, 
Wang et al., 2008, Seton-Rogers and Brugge, 2004). The contact between the 
EGFR/MAPK and TGF-β pathways often also leads to growth factor release, such as 
TGF-β and PDGF, which can lead to increased cell invasion and differentiation 
(Lehmann et al., 2000, Oft et al., 1996, Yue and Mulder, 2000). Cell proliferation 
and differentiation is also affected by TGF-β/Wnt signalling. These two pathways 
act synergistically at the nuclear, cytosolic and ligand binding levels, making it a 
truly diverse cross-talk (Guo and Wang, 2009).  Another interesting signalling 
pathway with growing interest is the Hippo pathway, which has shown cross-talk 
with the  TGF-β/BMP and Wnt pathways (Piccolo et al., 2014). The main 
transcriptional regulators of Hippo signalling are YAP/TAZ (yes-associated 
protein), and their activity are key for whole organ growth, and tissue renewal and 
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regeneration. These regulators act as sensors of cell structure, shape and polarity, 
as well as responding to growth factor signals being initiated by the Wnt pathway 
(Piccolo et al., 2014). This pathway has not been studied in relation to keloid 
scarring, and has minimal reports on other forms of fibrosis (Liu et al., 2015). 
Given the pathway interaction however, this would be another interesting cascade 
to study. 
 
Finally, throughout Chapters 4 and 5, the consistent up-regulation of SPP1 
observed in whole tissue, keloid keratinocytes and keloid fibroblasts, at both the 
gene and protein level has not been previously reported. This target has the 
potential to act as a biomarker of keloid invasiveness, especially with its increased 
expression noted at the keloid scar margin. 
 
6.2 Suggested Future Research 
A prevailing feature throughout the thesis was a high inter-patient variability 
affecting the statistical analyses of gene and protein expression patterns being 
examined. One disadvantage with investigating the whole scar tissue, inclusive of 
the different regions, means that sometimes the dynamics between the established 
centre and the expanding edge are not taken into consideration. For this reason, an 
obvious next step would be to investigate much more extensively the pathways 
and targets identified in this thesis, in the separate keloid regions. As the 
boundaries can be difficult to define, laser capture microdissection could be used 
to selectively isolate different regions of interest: the nodular regions of the 
reticular and scar margin dermis; the papillary dermis of the central scar, the 
dermis in the adjacent normal tissue; as well as the corresponding epidermal 
portions. Based on previous studies as discussed in earlier chapters, namely Bayat 
and his team, it is likely that the largest differences in gene regulation could be 
found between the expanding margin and the rest of the keloid.  
  
As has been discussed in Chapter 4, previous gene expression studies on keloid 
whole tissue or cells have shown conflicting results. This is most likely due the use 
of different methodologies and source materials by different research groups. The 
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source materials range from whole tissue biopsies to keloid-derived primary cells; 
containing marginal and extralesional regions, or not; retrieved from different 
ethnic populations. Keloid scarring is clearly a complex, multi-faceted disorder, 
which is affected by much more than just two cell types and excessive collagen I 
production. With the aim to model a disease process in vitro, so that basic 
mechanisms can be investigated in much more detail, a simple experimental 
design can be very effective at elucidating which genes and proteins are 
constitutively dysregulated, regardless of their 3D environment or interaction with 
neighbouring cells. Once such biomarkers are identified, the related signalling 
processes and mechanisms of action can be further investigated in more complex 
disease models, where multiple parameters can be more effectively elaborated. 
 
6.2.1 Characterisation of identified targets 
A first line of future work would be to establish to potential use of SPP1 as a 
biomarker for keloid invasiveness/ aggressiveness. This would be a longer-term 
project, whereby a large number of keloids covering different body regions, patient 
ethnicities, and individual treatment histories would be examined for SPP1 protein 
expression. This could be compared against an equally extensive number of 
hypertrophic and normotrophic scar tissues, and if there is a strong link between 
SPP1 and scar invasiveness, this could be used to stratify patients for a more 
personalised treatment strategy. 
 
Another line of further research would be to extensively characterise the pathways 
identified as altered in my gene expression data. The protein expression levels and 
phosphorylation status of key mediators within the TGF-β/Smad, BMP, and Wnt 
pathways, should first be analysed in the original keloid tissues, by Western Blot 
and IHC-IF. Alongside this, further protein expression and activity patterns of the 
osteogenic factors SPP1, SPARC and SFN across the keloid regions, and the 
differences between the epidermal and dermal compartments could be carried out. 
The isolated keratinocytes and fibroblasts from keloid and normal tissues could 
then be cultured in a transwell system or in a 3D culture system, with the aim to 
elucidate how the epidermal and dermal compartments influence each other. This 
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could be extended to examine the effect of say, the marginal keloid keratinocytes, 
on normal fibroblasts, and therefore investigate whether keratinocytes from 
different keloid regions have different fibrogenic-enhacing capabilites. The 
identified targets above would be analysed by Western Blot and ELISA, as well as 
ICC (immunocytochemistry) where appropriate. 
 
The advantage of using these in vitro models over clinical samples is that the 
targets of interest can then be knocked down or suppressed by siRNA or drug 
treatment, or alternatively they can be manipulated to overexpress in the cultured 
cells. The effects on fibrogenesis could then be evaluated. A prolonged culture 
using these more comprehensive systems would also be interesting to carry out, as 
it is likely that the fibrogenic phenotype is enhanced over time, as the synthesised 
ECM accumulates, and the cells begin to differentiate and stratify. This would also 
help to elucidate the reason for the non appearance of statistical significance in my 
in vitro data – whether it is due to the lack of epithelial-mesechymal interaction, or 
whether it is due to the lack of 3D environmental cues. 
 
6.2.2 Familial genetics 
As discussed in Chapter 1, a small number of genome-wide studies (GWAS) have 
been carried out on families displaying a hereditary form of keloid scarring. These 
studies were performed on families of Chinese, Japanese and African-American 
origin, and the prevailing mode of inheritance was autosomal dominant with 
incomplete penetrance. Some overlap in their results has suggested potential 
polymorphisms to exist within the EGFR and SMAD2/3 genes (Velez Edwards et 
al., 2014, Nakashima et al., 2010b, Shih and Bayat, 2010b, Chen et al., 2006).  
 
As the patient profile in our clinic has a large proportion of patients with African-
Caribbean origin, we selected five families which displayed the above mode of 
inheritance in keloid scarring. To date, full exome sequencing has been completed 
on 1 to 2 family members from each family, who present keloid formation. This 
approach was chosen over the GWAS analysis, so as to focus on the protein-coding 
genes only. Based on the very small sample number of 9 individuals, 3 genes have 
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been initially identified as containing disease-specific polymorphisms. These 
results will need to first be validated by full sequencing of those genes, on a larger 
number of keloid samples, before the gene and associated protein functions can be 
investigated in vitro (as in section 6.2.1). 
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Appendix A: Complete Gene List for ECM & Adhesion Molecule qPCR array (Chapter 2) 
A total of 84 genes of interest were tested, with 5 reference genes (ACTB, B2M, GAPDH, HPRT1, and RPLP0), and 7 internal assay controls. 
Plate 
Position 
UniGene code RefSeq code Gene Symbol Gene Description Alternative Gene Names 
A01 Hs.643357 NM_006988 ADAMTS1 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 1 
C3-C5, KIAA1346, METH1 
A02 Hs.131433 NM_139025 ADAMTS13 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 13 
C9orf8, DKFZp434C2322, FLJ42993, 
MGC118899, MGC118900, TTP, 
VWFCP, vWF-CP 
A03 Hs.271605 NM_007037 ADAMTS8 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 8 
ADAM-TS8, FLJ41712, METH2 
A04 Hs.502328 NM_000610 CD44 CD44 molecule (Indian blood group) 
CDW44, CSPG8, ECMR-III, HCELL, 
HUTCH-I, IN, LHR, MC56, MDU2, 
MDU3, MGC10468, MIC4, Pgp1 
A05 Hs.461086 NM_004360 CDH1 
Cadherin 1, type 1, E-cadherin 
(epithelial) 
Arc-1, CD324, CDHE, ECAD, LCAM, UVO 
A06 Hs.476092 NM_003278 CLEC3B 
C-type lectin domain family 3, 
member B 
DKFZp686H17246, TN, TNA 
A07 Hs.143434 NM_001843 CNTN1 Contactin 1 F3, GP135 
A08 Hs.523446 NM_080629 COL11A1 Collagen, type XI, alpha 1 CO11A1, COLL6, STL2 
A09 Hs.101302 NM_004370 COL12A1 Collagen, type XII, alpha 1 BA209D8.1, COL12A1L, DJ234P15.1 
A10 Hs.409662 NM_021110 COL14A1 Collagen, type XIV, alpha 1 UND 
A11 Hs.409034 NM_001855 COL15A1 Collagen, type XV, alpha 1 FLJ38566 
A12 Hs.368921 NM_001856 COL16A1 Collagen, type XVI, alpha 1 447AA 
B01 Hs.172928 NM_000088 COL1A1 Collagen, type I, alpha 1 OI4 
B02 Hs.508716 NM_001846 COL4A2 Collagen, type IV, alpha 2 DKFZp686I14213, FLJ22259 
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B03 Hs.210283 NM_000093 COL5A1 Collagen, type V, alpha 1 - 
B04 Hs.474053 NM_001848 COL6A1 Collagen, type VI, alpha 1 OPLL 
B05 Hs.420269 NM_001849 COL6A2 Collagen, type VI, alpha 2 DKFZp586E1322, FLJ46862, PP3610 
B06 Hs.476218 NM_000094 COL7A1 Collagen, type VII, alpha 1 EBD1, EBDCT, EBR1 
B07 Hs.654548 NM_001850 COL8A1 Collagen, type VIII, alpha 1 C3orf7, MGC9568 
B08 Hs.591346 NM_001901 CTGF Connective tissue growth factor 
CCN2, HCS24, IGFBP8, MGC102839, 
NOV2 
B09 Hs.534797 NM_001903 CTNNA1 
Catenin (cadherin-associated 
protein), alpha 1, 102kDa 
CAP102, FLJ36832, FLJ52416 
B10 Hs.476018 NM_001904 CTNNB1 
Catenin (cadherin-associated 
protein), beta 1, 88kDa 
CTNNB, DKFZp686D02253, FLJ25606, 
FLJ37923 
B11 Hs.166011 NM_001331 CTNND1 
Catenin (cadherin-associated 
protein), delta 1 
CAS, CTNND, KIAA0384, P120CAS, 
P120CTN, p120, p120(CAS), p120(CTN) 
B12 Hs.314543 NM_001332 CTNND2 
Catenin (cadherin-associated 
protein), delta 2 (neural plakophilin-
related arm-repeat protein) 
GT24, NPRAP 
C01 Hs.81071 NM_004425 ECM1 Extracellular matrix protein 1 - 
C02 Hs.203717 NM_002026 FN1 Fibronectin 1 
CIG, DKFZp686F10164, 
DKFZp686H0342, DKFZp686I1370, 
DKFZp686O13149, ED-B, FINC, FN, FNZ, 
GFND, GFND2, LETS, MSF 
C03 Hs.57697 NM_001523 HAS1 Hyaluronan synthase 1 HAS 
C04 Hs.643447 NM_000201 ICAM1 Intercellular adhesion molecule 1 BB2, CD54, P3.58 
C05 Hs.644352 NM_181501 ITGA1 Integrin, alpha 1 CD49a, VLA1 
C06 Hs.482077 NM_002203 ITGA2 
Integrin, alpha 2 (CD49B, alpha 2 
subunit of VLA-2 receptor) 
BR, CD49B, GPIa, VLA-2, VLAA2 
C07 Hs.265829 NM_002204 ITGA3 Integrin, alpha 3 (antigen CD49C, CD49C, FLJ34631, FLJ34704, GAP-B3, 
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alpha 3 subunit of VLA-3 receptor) GAPB3, MSK18, VCA-2, VL3A, VLA3a 
C08 Hs.694732 NM_000885 ITGA4 
Integrin, alpha 4 (antigen CD49D, 
alpha 4 subunit of VLA-4 receptor) 
CD49D, IA4, MGC90518 
C09 Hs.505654 NM_002205 ITGA5 
Integrin, alpha 5 (fibronectin 
receptor, alpha polypeptide) 
CD49e, FNRA, VLA5A 
C10 Hs.133397 NM_000210 ITGA6 Integrin, alpha 6 
CD49f, DKFZp686J01244, FLJ18737, 
ITGA6B, VLA-6 
C11 Hs.524484 NM_002206 ITGA7 Integrin, alpha 7 FLJ25220 
C12 Hs.171311 NM_003638 ITGA8 Integrin, alpha 8 - 
D01 Hs.174103 NM_002209 ITGAL 
Integrin, alpha L (antigen CD11A 
(p180), lymphocyte function-
associated antigen 1; alpha 
polypeptide) 
CD11A, LFA-1, LFA1A 
D02 Hs.172631 NM_000632 ITGAM 
Integrin, alpha M (complement 
component 3 receptor 3 subunit) 
CD11B, CR3A, MAC-1, MAC1A, 
MGC117044, MO1A, SLEB6 
D03 Hs.436873 NM_002210 ITGAV 
Integrin, alpha V (vitronectin 
receptor, alpha polypeptide, antigen 
CD51) 
CD51, DKFZp686A08142, MSK8, VNRA 
D04 Hs.643813 NM_002211 ITGB1 
Integrin, beta 1 (fibronectin 
receptor, beta polypeptide, antigen 
CD29 includes MDF2, MSK12) 
CD29, FNRB, GPIIA, MDF2, MSK12, VLA-
BETA, VLAB 
D05 Hs.375957 NM_000211 ITGB2 
Integrin, beta 2 (complement 
component 3 receptor 3 and 4 
subunit) 
CD18, LAD, LCAMB, LFA-1, MAC-1, 
MF17, MFI7 
D06 Hs.218040 NM_000212 ITGB3 
Integrin, beta 3 (platelet 
glycoprotein IIIa, antigen CD61) 
CD61, GP3A, GPIIIa 
D07 Hs.632226 NM_000213 ITGB4 Integrin, beta 4 CD104 
 246 
D08 Hs.536663 NM_002213 ITGB5 Integrin, beta 5 FLJ26658 
D09 Hs.521869 NM_000216 KAL1 Kallmann syndrome 1 sequence ADMLX, HHA, KAL, KALIG-1, KMS 
D10 Hs.270364 NM_005559 LAMA1 Laminin, alpha 1 LAMA, S-LAM-alpha 
D11 Hs.200841 NM_000426 LAMA2 Laminin, alpha 2 LAMM 
D12 Hs.436367 NM_000227 LAMA3 Laminin, alpha 3 BM600, E170, LAMNA, LOCS, lama3a 
E01 Hs.650585 NM_002291 LAMB1 Laminin, beta 1 CLM, MGC142015 
E02 Hs.497636 NM_000228 LAMB3 Laminin, beta 3 
BM600-125KDA, FLJ99565, LAM5, 
LAMNB1 
E03 Hs.609663 NM_002293 LAMC1 Laminin, gamma 1 (formerly LAMB2) LAMB2, MGC87297 
E04 Hs.83169 NM_002421 MMP1 
Matrix metallopeptidase 1 
(interstitial collagenase) 
CLG, CLGN 
E05 Hs.2258 NM_002425 MMP10 
Matrix metallopeptidase 10 
(stromelysin 2) 
SL-2, STMY2 
E06 Hs.143751 NM_005940 MMP11 
Matrix metallopeptidase 11 
(stromelysin 3) 
SL-3, ST3, STMY3 
E07 Hs.1695 NM_002426 MMP12 
Matrix metallopeptidase 12 
(macrophage elastase) 
HME, ME, MGC138506, MME, MMP-12 
E08 Hs.2936 NM_002427 MMP13 
Matrix metallopeptidase 13 
(collagenase 3) 
CLG3, MANDP1 
E09 Hs.2399 NM_004995 MMP14 
Matrix metallopeptidase 14 
(membrane-inserted) 
1, MMP-14, MMP-X1, MT-MMP, MT-
MMP 1, MT1-MMP, MT1MMP, 
MTMMP1 
E10 Hs.80343 NM_002428 MMP15 
Matrix metallopeptidase 15 
(membrane-inserted) 
MT2-MMP, MTMMP2, SMCP-2 
E11 Hs.546267 NM_005941 MMP16 
Matrix metallopeptidase 16 
(membrane-inserted) 
C8orf57, DKFZp761D112, MMP-X2, MT-
MMP2, MT-MMP3, MT3-MMP 
E12 Hs.513617 NM_004530 MMP2 Matrix metallopeptidase 2 CLG4, CLG4A, MMP-II, MONA, TBE-1 
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(gelatinase A, 72kDa gelatinase, 
72kDa type IV collagenase) 
F01 Hs.375129 NM_002422 MMP3 
Matrix metallopeptidase 3 
(stromelysin 1, progelatinase) 
CHDS6, MGC126102, MGC126103, 
MGC126104, MMP-3, SL-1, STMY, 
STMY1, STR1 
F02 Hs.2256 NM_002423 MMP7 
Matrix metallopeptidase 7 
(matrilysin, uterine) 
MMP-7, MPSL1, PUMP-1 
F03 Hs.161839 NM_002424 MMP8 
Matrix metallopeptidase 8 
(neutrophil collagenase) 
CLG1, HNC, MMP-8, PMNL-CL 
F04 Hs.297413 NM_004994 MMP9 
Matrix metallopeptidase 9 
(gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) 
CLG4B, GELB, MANDP2, MMP-9 
F05 Hs.503878 NM_000615 NCAM1 Neural cell adhesion molecule 1 CD56, MSK39, NCAM 
F06 Hs.514412 NM_000442 PECAM1 
Platelet/endothelial cell adhesion 
molecule 
CD31, FLJ34100, FLJ58394, PECAM-1 
F07 Hs.89546 NM_000450 SELE Selectin E CD62E, ELAM, ELAM1, ESEL, LECAM2 
F08 Hs.728756 NM_000655 SELL Selectin L 
CD62L, LAM1, LECAM1, LEU8, LNHR, 
LSEL, LYAM1, PLNHR, TQ1 
F09 Hs.73800 NM_003005 SELP 
Selectin P (granule membrane 
protein 140kDa, antigen CD62) 
CD62, CD62P, FLJ45155, GMP140, 
GRMP, LECAM3, PADGEM, PSEL 
F10 Hs.371199 NM_003919 SGCE Sarcoglycan, epsilon DYT11, ESG 
F11 Hs.111779 NM_003118 SPARC 
Secreted protein, acidic, cysteine-
rich (osteonectin) 
ON 
F12 Hs.185597 NM_003119 SPG7 
Spastic paraplegia 7 (pure and 
complicated autosomal recessive) 
CAR, CMAR, FLJ37308, MGC126331, 
MGC126332, PGN, SPG5C 
G01 Hs.313 NM_000582 SPP1 Secreted phosphoprotein 1 BNSP, BSPI, ETA-1, MGC110940, OPN 
G02 Hs.369397 NM_000358 TGFBI Transforming growth factor, beta- BIGH3, CDB1, CDG2, CDGG1, CSD, 
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induced, 68kDa CSD1, CSD2, CSD3, EBMD, LCD1 
G03 Hs.164226 NM_003246 THBS1 Thrombospondin 1 THBS, THBS-1, TSP, TSP-1, TSP1 
G04 Hs.371147 NM_003247 THBS2 Thrombospondin 2 TSP2 
G05 Hs.169875 NM_007112 THBS3 Thrombospondin 3 MGC119564, MGC119565, TSP3 
G06 Hs.522632 NM_003254 TIMP1 TIMP metallopeptidase inhibitor 1 CLGI, EPA, EPO, FLJ90373, HCI, TIMP 
G07 Hs.633514 NM_003255 TIMP2 TIMP metallopeptidase inhibitor 2 CSC-21K 
G08 Hs.644633 NM_000362 TIMP3 TIMP metallopeptidase inhibitor 3 HSMRK222, K222, K222TA2, SFD 
G09 Hs.143250 NM_002160 TNC Tenascin C 
150-225, GMEM, GP, HXB, JI, 
MGC167029, TN, TN-C 
G10 Hs.109225 NM_001078 VCAM1 Vascular cell adhesion molecule 1 
CD106, DKFZp779G2333, INCAM-100, 
MGC99561 
G11 Hs.643801 NM_004385 VCAN Versican 
CSPG2, DKFZp686K06110, ERVR, GHAP, 
PG-M, WGN, WGN1 
G12 Hs.2257 NM_000638 VTN Vitronectin V75, VN, VNT 
H01 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
H02 Hs.534255 NM_004048 B2M Beta-2-microglobulin - 
H03 Hs.592355 NM_002046 GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
G3PD, GAPD, MGC88685 
H04 Hs.412707 NM_000194 HPRT1 
Hypoxanthine 
phosphoribosyltransferase 1 
HGPRT, HPRT 
H05 Hs.546285 NM_001002 RPLP0 Ribosomal protein, large, P0 
L10E, LP0, MGC111226, MGC88175, P0, 
PRLP0, RPP0 
H06 N/A SA_00105 HGDC 
Human Genomic DNA 
Contamination 
HIGX1A 
H07 N/A SA_00104 RTC Reverse Transcription Control RTC 
H08 N/A SA_00104 RTC Reverse Transcription Control RTC 
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H09 N/A SA_00104 RTC Reverse Transcription Control RTC 
H10 N/A SA_00103 PPC Positive PCR Control PPC 
H11 N/A SA_00103 PPC Positive PCR Control PPC 
H12 N/A SA_00103 PPC Positive PCR Control PPC 
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 Appendix B: Complete Gene List for Signal Transduction PathwayFinder qPCR array (Chapter 2) 
A total of 84 genes of interest were tested, with 5 reference genes (ACTB, B2M, GAPDH, HPRT1, and RPLP0), and 7 internal assay controls. 
Plate 
Position 
UniGene 
code 
RefSeq code 
Gene 
Symbol 
Gene Description Alternative Gene Names 
A01 Hs.655772 NM_004457 ACSL3 
Acyl-CoA synthetase long-chain 
family member 3 
ACS3, FACL3, PRO2194 
A02 Hs.268785 NM_004458 ACSL4 
Acyl-CoA synthetase long-chain 
family member 4 
ACS4, FACL4, LACS4, MRX63, MRX68 
A03 Hs.11638 NM_016234 ACSL5 
Acyl-CoA synthetase long-chain 
family member 5 
ACS2, ACS5, FACL5 
A04 Hs.441047 NM_001124 ADM Adrenomedullin AM 
A05 Hs.632446 NM_001668 ARNT 
Aryl hydrocarbon receptor nuclear 
translocator 
HIF-1-beta, HIF-1beta, HIF1-beta, HIF1B, 
HIF1BETA, TANGO, bHLHe2 
A06 Hs.496487 NM_001675 ATF4 
Activating transcription factor 4 (tax-
responsive enhancer element B67) 
CREB-2, CREB2, TAXREB67, TXREB 
A07 Hs.156527 NM_004655 AXIN2 Axin 2 
AXIL, DKFZp781B0869, MGC10366, 
MGC126582 
A08 Hs.624291 NM_004324 BAX BCL2-associated X protein BCL2L4 
A09 Hs.467020 NM_014417 BBC3 BCL2 binding component 3 FLJ42994, JFY1, PUMA 
A10 Hs.150749 NM_000633 BCL2 B-cell CLL/lymphoma 2 Bcl-2 
A11 Hs.227817 NM_004049 BCL2A1 BCL2-related protein A1 ACC-1, ACC-2, BCL2L5, BFL1, GRS, HBPA1 
A12 Hs.516966 NM_138578 BCL2L1 BCL2-like 1 
BCL-XL, S, BCL2L, BCLX, BCLXL, BCLXS, Bcl-X, 
DKFZp781P2092, bcl-xL, bcl-xS 
B01 Hs.127799 NM_001165 BIRC3 Baculoviral IAP repeat containing 3 
AIP1, API2, CIAP2, HAIP1, HIAP1, MALT2, 
MIHC, RNF49, c-IAP2 
B02 Hs.73853 NM_001200 BMP2 Bone morphogenetic protein 2 BMP2A 
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B03 Hs.68879 NM_130851 BMP4 Bone morphogenetic protein 4 BMP2B, BMP2B1, MCOPS6, OFC11, ZYME 
B04 Hs.519162 NM_006763 BTG2 BTG family, member 2 MGC126063, MGC126064, PC3, TIS21 
B05 Hs.63287 NM_001216 CA9 Carbonic anhydrase IX CAIX, MN 
B06 Hs.514821 NM_002985 CCL5 Chemokine (C-C motif) ligand 5 
D17S136E, MGC17164, RANTES, SCYA5, 
SISd, TCP228 
B07 Hs.523852 NM_053056 CCND1 Cyclin D1 BCL1, D11S287E, PRAD1, U21B31 
B08 Hs.376071 NM_001759 CCND2 Cyclin D2 KIAK0002, MGC102758 
B09 Hs.370771 NM_000389 CDKN1A 
Cyclin-dependent kinase inhibitor 1A 
(p21, Cip1) 
CAP20, CDKN1, CIP1, MDA-6, P21, SDI1, 
WAF1, p21CIP1 
B10 Hs.238990 NM_004064 CDKN1B 
Cyclin-dependent kinase inhibitor 1B 
(p27, Kip1) 
CDKN4, KIP1, MEN1B, MEN4, P27KIP1 
B11 Hs.440829 NM_005195 CEBPD 
CCAAT/enhancer binding protein 
(C/EBP), delta 
C, EBP-delta, CELF, CRP3, NF-IL6-beta 
B12 Hs.705379 NM_000098 CPT2 Carnitine palmitoyltransferase 2 CPT1, CPTASE 
C01 Hs.591402 NM_000757 CSF1 
Colony stimulating factor 1 
(macrophage) 
MCSF, MGC31930 
C02 Hs.481980 NM_001343 DAB2 
Disabled homolog 2, mitogen-
responsive phosphoprotein 
(Drosophila) 
DOC-2, DOC2, FLJ26626 
C03 Hs.488293 NM_005228 EGFR Epidermal growth factor receptor ERBB, ERBB1, HER1, PIG61, mENA 
C04 Hs.707901 NM_001423 EMP1 Epithelial membrane protein 1 CL-20, EMP-1, TMP 
C05 Hs.2303 NM_000799 EPO Erythropoietin EP, MGC138142, MVCD2 
C06 Hs.380135 NM_001443 FABP1 Fatty acid binding protein 1, liver FABPL, L-FABP 
C07 Hs.244139 NM_000043 FAS 
Fas (TNF receptor superfamily, 
member 6) 
ALPS1A, APO-1, APT1, CD95, FAS1, FASTM, 
TNFRSF6 
C08 Hs.465778 NM_002002 FCER2 Fc fragment of IgE, low affinity II, CD23, CD23A, CLEC4J, FCE2, IGEBF 
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receptor for (CD23) 
C09 Hs.283565 NM_005438 FOSL1 FOS-like antigen 1 FRA, FRA1, fra-1 
C10 Hs.645560 NM_002032 FTH1 Ferritin, heavy polypeptide 1 FHC, FTH, FTHL6, MGC104426, PIG15, PLIF 
C11 Hs.80409 NM_001924 GADD45A 
Growth arrest and DNA-damage-
inducible, alpha 
DDIT1, GADD45 
C12 Hs.110571 NM_015675 GADD45B 
Growth arrest and DNA-damage-
inducible, beta 
DKFZp566B133, GADD45BETA, MYD118 
D01 Hs.524134 NM_002051 GATA3 GATA binding protein 3 HDR, MGC2346, MGC5199, MGC5445 
D02 Hs.654465 NM_001498 GCLC 
Glutamate-cysteine ligase, catalytic 
subunit 
GCL, GCS, GLCL, GLCLC 
D03 Hs.315562 NM_002061 GCLM 
Glutamate-cysteine ligase, modifier 
subunit 
GLCLR 
D04 Hs.271510 NM_000637 GSR Glutathione reductase MGC78522 
D05 Hs.146393 NM_014685 HERPUD1 
Homocysteine-inducible, 
endoplasmic reticulum stress-
inducible, ubiquitin-like domain 
member 1 
HERP, KIAA0025, Mif1, SUP 
D06 Hs.250666 NM_005524 HES1 
Hairy and enhancer of split 1, 
(Drosophila) 
FLJ20408, HES-1, HHL, HRY, bHLHb39 
D07 Hs.57971 
NM_00101092
6 
HES5 
Hairy and enhancer of split 5 
(Drosophila) 
bHLHb38 
D08 Hs.234434 NM_012258 HEY1 
Hairy/enhancer-of-split related with 
YRPW motif 1 
BHLHb31, CHF2, HERP2, HESR1, HRT-1, 
MGC1274, OAF1 
D09 Hs.144287 NM_012259 HEY2 
Hairy/enhancer-of-split related with 
YRPW motif 2 
CHF1, GRIDLOCK, GRL, HERP1, HESR2, HRT2, 
MGC10720, bHLHb32 
D10 Hs.472566 NM_014571 HEYL 
Hairy/enhancer-of-split related with 
YRPW motif-like 
HEY3, HRT3, MGC12623, bHLHb33 
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D11 Hs.517581 NM_002133 HMOX1 Heme oxygenase (decycling) 1 HO-1, HSP32, bK286B10 
D12 Hs.643447 NM_000201 ICAM1 Intercellular adhesion molecule 1 BB2, CD54, P3.58 
E01 Hs.504609 NM_002165 ID1 
Inhibitor of DNA binding 1, dominant 
negative helix-loop-helix protein 
ID, bHLHb24 
E02 Hs.856 NM_000619 IFNG Interferon, gamma IFG, IFI 
E03 Hs.7879 NM_001550 IFRD1 
Interferon-related developmental 
regulator 1 
PC4, TIS7 
E04 Hs.436061 NM_002198 IRF1 Interferon regulatory factor 1 IRF-1, MAR 
E05 Hs.728907 NM_000214 JAG1 Jagged 1 
AGS, AHD, AWS, CD339, HJ1, JAGL1, 
MGC104644 
E06 Hs.2795 NM_005566 LDHA Lactate dehydrogenase A GSD11, LDH1, LDHM 
E07 Hs.159142 
NM_00104016
7 
LFNG 
LFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase 
SCDO3 
E08 Hs.655559 NM_052972 LRG1 Leucine-rich alpha-2-glycoprotein 1 FLJ45787, HMFT1766, LRG 
E09 Hs.632486 NM_021960 MCL1 
Myeloid cell leukemia sequence 1 
(BCL2-related) 
BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, 
MGC104264, MGC1839, Mcl-1, TM, bcl2-L-
3, mcl1, EAT 
E10 Hs.2256 NM_002423 MMP7 
Matrix metallopeptidase 7 
(matrilysin, uterine) 
MMP-7, MPSL1, PUMP-1 
E11 Hs.202453 NM_002467 MYC 
V-myc myelocytomatosis viral 
oncogene homolog (avian) 
MRTL, bHLHe39, c-Myc 
E12 Hs.495473 NM_017617 NOTCH1 Notch 1 TAN1, hN1 
F01 Hs.406515 NM_000903 NQO1 NAD(P)H dehydrogenase, quinone 1 DHQU, DIA4, DTD, NMOR1, NMORI, QR1 
F02 Hs.412484 NM_002543 OLR1 
Oxidized low density lipoprotein 
(lectin-like) receptor 1 
CLEC8A, LOX1, LOXIN, SCARE1, SLOX1 
F03 Hs.728886 NM_182649 PCNA Proliferating cell nuclear antigen MGC8367 
 254 
F04 Hs.696032 NM_006238 PPARD 
Peroxisome proliferator-activated 
receptor delta 
FAAR, MGC3931, NR1C2, NUC1, NUCI, 
NUCII, PPARB 
F05 Hs.494538 NM_000264 PTCH1 Patched 1 
BCNS, FLJ26746, FLJ42602, HPE7, NBCCS, 
PTC, PTC1, PTCH, PTCH11 
F06 Hs.408528 NM_000321 RB1 Retinoblastoma 1 OSRC, RB, p105-Rb, pRb, pp110 
F07 Hs.414795 NM_000602 SERPINE1 
Serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator 
inhibitor type 1), member 1 
PAI, PAI-1, PAI1, PLANH1 
F08 Hs.656699 NM_005094 SLC27A4 
Solute carrier family 27 (fatty acid 
transporter), member 4 
ACSVL4, FATP4, IPS 
F09 Hs.473721 NM_006516 SLC2A1 
Solute carrier family 2 (facilitated 
glucose transporter), member 1 
DYT17, DYT18, GLUT, GLUT1, GLUT1DS, 
MGC141895, MGC141896, PED 
F10 Hs.527973 NM_003955 SOCS3 Suppressor of cytokine signalling 3 
ATOD4, CIS3, Cish3, MGC71791, SOCS-3, 
SSI-3, SSI3 
F11 Hs.38621 NM_006434 SORBS1 Sorbin and SH3 domain containing 1 
CAP, DKFZp451C066, DKFZp586P1422, 
FLAF2, FLJ12406, KIAA1296, R85FL, SH3D5, 
SH3P12, SORB1 
F12 Hs.437277 NM_003900 SQSTM1 Sequestosome 1 A170, OSIL, PDB3, ZIP3, p60, p62, p62B 
G01 Hs.642990 NM_007315 STAT1 
Signal transducer and activator of 
transcription 1, 91kDa 
DKFZp686B04100, ISGF-3, STAT91 
G02 Hs.241570 NM_000594 TNF Tumor necrosis factor DIF, TNF-alpha, TNFA, TNFSF2 
G03 Hs.478275 NM_003810 TNFSF10 
Tumor necrosis factor (ligand) 
superfamily, member 10 
APO2L, Apo-2L, CD253, TL2, TRAIL 
G04 Hs.435136 NM_003329 TXN Thioredoxin DKFZp686B1993, MGC61975, TRX, TRX1 
G05 Hs.728817 NM_003330 TXNRD1 Thioredoxin reductase 1 GRIM-12, MGC9145, TR, TR1, TRXR1, TXNR 
G06 Hs.73793 NM_003376 VEGFA Vascular endothelial growth factor A MGC70609, MVCD1, VEGF, VPF 
G07 Hs.492974 NM_003882 WISP1 WNT1 inducible signalling pathway CCN4, FLJ14388, WISP1c, WISP1i, WISP1tc 
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protein 1 
G08 Hs.248164 NM_005430 WNT1 
Wingless-type MMTV integration 
site family, member 1 
INT1 
G09 Hs.258575 NM_004185 WNT2B 
Wingless-type MMTV integration 
site family, member 2B 
WNT13, XWNT2 
G10 Hs.336930 NM_033131 WNT3A 
Wingless-type MMTV integration 
site family, member 3A 
MGC119418, MGC119419, MGC119420 
G11 Hs.696364 NM_003392 WNT5A 
Wingless-type MMTV integration 
site family, member 5A 
hWNT5A 
G12 Hs.29764 NM_006522 WNT6 
Wingless-type MMTV integration 
site family, member 6 
- 
H01 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
H02 Hs.534255 NM_004048 B2M Beta-2-microglobulin - 
H03 Hs.592355 NM_002046 GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
G3PD, GAPD, MGC88685 
H04 Hs.412707 NM_000194 HPRT1 
Hypoxanthine 
phosphoribosyltransferase 1 
HGPRT, HPRT 
H05 Hs.546285 NM_001002 RPLP0 Ribosomal protein, large, P0 
L10E, LP0, MGC111226, MGC88175, P0, 
PRLP0, RPP0 
H06 N/A SA_00105 HGDC 
Human Genomic DNA 
Contamination 
HIGX1A 
H07 N/A SA_00104 RTC Reverse Transcription Control RTC 
H08 N/A SA_00104 RTC Reverse Transcription Control RTC 
H09 N/A SA_00104 RTC Reverse Transcription Control RTC 
H10 N/A SA_00103 PPC Positive PCR Control PPC 
H11 N/A SA_00103 PPC Positive PCR Control PPC 
H12 N/A SA_00103 PPC Positive PCR Control PPC 
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Appendix C: Full data for ECM and Adhesion Molecule qPCR array (Chapter 4) 
The results above were estimated with the data analysis template provided by Qiagen  (http://www.sabiosciences.com/PCRArrayPlate.php)  
Full description of the genes are in Appendix A. 
Gene Symbol Well 
Average ΔCt 
(Ct(GOI) - Avg Ct (REF)) 
2(-ΔCt) Fold Change 
(KEL / NS) 
Fold Up- or 
Down- 
Regulation 
P value 
(Student’s T-
test) KELOID NORMAL KELOID NORMAL 
ADAMTS1 A01 7.18 5.08 6.9E-03 2.9E-02 0.23 -4.28 0.391261 
ADAMTS13 A02 12.29 11.90 2.0E-04 2.6E-04 0.76 -1.31 0.869222 
ADAMTS8 A03 10.80 10.22 5.6E-04 8.4E-04 0.67 -1.50 0.743437 
CD44 A04 1.90 1.29 2.7E-01 4.1E-01 0.66 -1.52 0.077257 
CDH1 A05 2.22 2.64 2.2E-01 1.6E-01 1.34 1.34 0.230413 
CLEC3B A06 5.25 2.87 2.6E-02 1.4E-01 0.19 -5.20 0.007131 
CNTN1 A07 3.80 5.72 7.2E-02 1.9E-02 3.78 3.78 0.056307 
COL11A1 A08 3.14 9.79 1.1E-01 1.1E-03 100.50 100.50 0.152714 
COL12A1 A09 3.91 7.43 6.7E-02 5.8E-03 11.44 11.44 0.041628 
COL14A1 A10 0.96 3.08 5.1E-01 1.2E-01 4.33 4.33 0.032894 
COL15A1 A11 3.17 3.98 1.1E-01 6.3E-02 1.76 1.76 0.063871 
COL16A1 A12 2.42 4.88 1.9E-01 3.4E-02 5.50 5.50 0.019857 
COL1A1 B01 -3.39 1.24 1.1E+01 4.2E-01 24.84 24.84 0.013361 
COL4A2 B02 3.61 4.79 8.2E-02 3.6E-02 2.27 2.27 0.030212 
COL5A1 B03 2.39 6.58 1.9E-01 1.0E-02 18.26 18.26 0.013699 
COL6A1 B04 0.84 3.08 5.6E-01 1.2E-01 4.73 4.73 0.026889 
COL6A2 B05 1.20 3.38 4.3E-01 9.6E-02 4.52 4.52 0.036823 
COL7A1 B06 4.71 4.95 3.8E-02 3.2E-02 1.18 1.18 0.737516 
COL8A1 B07 9.28 12.75 1.6E-03 1.4E-04 11.09 11.09 0.155489 
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CTGF B08 1.47 1.12 3.6E-01 4.6E-01 0.79 -1.27 0.969107 
CTNNA1 B09 2.86 2.77 1.4E-01 1.5E-01 0.94 -1.06 0.723164 
CTNNB1 B10 4.39 5.72 4.8E-02 1.9E-02 2.53 2.53 0.049249 
CTNND1 B11 4.06 3.79 6.0E-02 7.2E-02 0.83 -1.20 0.338003 
CTNND2 B12 11.58 10.78 3.3E-04 5.7E-04 0.57 -1.74 0.533543 
ECM1 C01 1.96 2.60 2.6E-01 1.7E-01 1.55 1.55 0.269241 
FN1 C02 -1.12 2.09 2.2E+00 2.3E-01 9.28 9.28 0.018301 
HAS1 C03 12.62 9.53 1.6E-04 1.4E-03 0.12 -8.51 0.188207 
ICAM1 C04 5.53 4.95 2.2E-02 3.2E-02 0.67 -1.50 0.222020 
ITGA1 C05 4.64 5.38 4.0E-02 2.4E-02 1.66 1.66 0.086869 
ITGA2 C06 4.11 3.91 5.8E-02 6.6E-02 0.87 -1.14 0.410996 
ITGA3 C07 4.97 4.55 3.2E-02 4.3E-02 0.75 -1.34 0.175365 
ITGA4 C08 6.02 7.60 1.5E-02 5.1E-03 3.01 3.01 0.050691 
ITGA5 C09 4.97 5.42 3.2E-02 2.3E-02 1.37 1.37 0.309134 
ITGA6 C10 3.66 3.57 7.9E-02 8.4E-02 0.94 -1.06 0.640923 
ITGA7 C11 7.70 7.51 4.8E-03 5.5E-03 0.88 -1.14 0.787563 
ITGA8 C12 7.51 6.70 5.5E-03 9.6E-03 0.57 -1.75 0.376324 
ITGAL D01 10.02 9.89 9.6E-04 1.1E-03 0.92 -1.09 0.626094 
ITGAM D02 8.30 7.67 3.2E-03 4.9E-03 0.65 -1.54 0.281092 
ITGAV D03 2.59 3.48 1.7E-01 9.0E-02 1.85 1.85 0.061350 
ITGB1 D04 0.77 2.09 5.9E-01 2.4E-01 2.50 2.50 0.049593 
ITGB2 D05 6.33 6.31 1.2E-02 1.3E-02 0.99 -1.01 0.932733 
ITGB3 D06 6.47 6.70 1.1E-02 9.6E-03 1.17 1.17 0.798189 
ITGB4 D07 5.67 5.03 2.0E-02 3.1E-02 0.64 -1.56 0.064969 
ITGB5 D08 4.04 4.74 6.1E-02 3.8E-02 1.62 1.62 0.140738 
KAL1 D09 4.36 6.42 4.9E-02 1.2E-02 4.16 4.16 0.091676 
LAMA1 D10 10.85 13.12 5.4E-04 1.1E-04 4.81 4.81 0.008354 
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LAMA2 D11 4.92 5.24 3.3E-02 2.6E-02 1.25 1.25 0.372134 
LAMA3 D12 5.52 4.03 2.2E-02 6.1E-02 0.36 -2.80 0.010269 
LAMB1 E01 2.71 3.83 1.5E-01 7.0E-02 2.16 2.16 0.052244 
LAMB3 E02 6.51 5.48 1.1E-02 2.2E-02 0.49 -2.04 0.041922 
LAMC1 E03 1.95 2.15 2.6E-01 2.3E-01 1.15 1.15 0.371435 
MMP1 E04 7.59 13.28 5.2E-03 1.0E-04 51.78 51.78 0.002595 
MMP10 E05 11.13 12.53 4.5E-04 1.7E-04 2.64 2.64 0.289883 
MMP11 E06 5.64 9.57 2.0E-02 1.3E-03 15.25 15.25 0.079780 
MMP12 E07 8.57 8.43 2.6E-03 2.9E-03 0.90 -1.11 0.700688 
MMP13 E08 7.91 12.52 4.2E-03 1.7E-04 24.34 24.34 0.000502 
MMP14 E09 4.92 6.86 3.3E-02 8.6E-03 3.85 3.85 0.046886 
MMP15 E10 12.50 13.01 1.7E-04 1.2E-04 1.43 1.43 0.439033 
MMP16 E11 5.60 7.97 2.1E-02 4.0E-03 5.18 5.18 0.049611 
MMP2 E12 1.02 1.75 4.9E-01 3.0E-01 1.66 1.66 0.182191 
MMP3 F01 8.08 11.29 3.7E-03 4.0E-04 9.22 9.22 0.029302 
MMP7 F02 6.54 6.19 1.1E-02 1.4E-02 0.78 -1.28 0.280388 
MMP8 F03 12.69 11.53 1.5E-04 3.4E-04 0.45 -2.23 0.453450 
MMP9 F04 7.75 7.19 4.6E-03 6.9E-03 0.68 -1.48 0.778497 
NCAM1 F05 9.96 9.52 1.0E-03 1.4E-03 0.74 -1.35 0.458615 
PECAM1 F06 3.58 4.71 8.4E-02 3.8E-02 2.20 2.20 0.346497 
SELE F07 7.38 7.82 6.0E-03 4.4E-03 1.35 1.35 0.767086 
SELL F08 8.92 10.44 2.1E-03 7.2E-04 2.86 2.86 0.278719 
SELP F09 7.29 8.42 6.4E-03 2.9E-03 2.18 2.18 0.072656 
SGCE F10 3.90 4.30 6.7E-02 5.1E-02 1.32 1.32 0.744538 
SPARC F11 -1.58 1.63 3.0E+00 3.2E-01 9.24 9.24 0.033400 
SPG7 F12 7.16 7.17 7.0E-03 6.9E-03 1.00 1.00 0.923552 
SPP1 G01 6.27 11.15 1.3E-02 4.4E-04 29.59 29.59 0.032033 
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TGFBI G02 0.69 1.88 6.2E-01 2.7E-01 2.28 2.28 0.042894 
THBS1 G03 3.54 4.81 8.6E-02 3.6E-02 2.40 2.40 0.142607 
THBS2 G04 1.02 3.21 4.9E-01 1.1E-01 4.58 4.58 0.016805 
THBS3 G05 10.10 10.44 9.1E-04 7.2E-04 1.27 1.27 0.252470 
TIMP1 G06 4.97 5.89 3.2E-02 1.7E-02 1.89 1.89 0.048601 
TIMP2 G07 1.89 2.30 2.7E-01 2.0E-01 1.34 1.34 0.278459 
TIMP3 G08 2.16 0.91 2.2E-01 5.3E-01 0.42 -2.39 0.132625 
TNC G09 0.94 3.48 5.2E-01 8.9E-02 5.85 5.85 0.007962 
VCAM1 G10 3.40 4.25 9.5E-02 5.3E-02 1.81 1.81 0.085035 
VCAN G11 1.73 4.12 3.0E-01 5.8E-02 5.23 5.23 0.051174 
VTN G12 12.87 11.85 1.3E-04 2.7E-04 0.49 -2.03 0.115585 
ACTB H01 0.26 0.64 8.3E-01 6.4E-01 1.30 1.30 0.681253 
B2M H02 -2.00 -2.41 4.0E+00 5.3E+00 0.75 -1.33 0.162935 
GAPDH H03 0.87 1.52 5.5E-01 3.5E-01 1.57 1.57 0.176600 
HPRT1 H04 4.98 4.98 3.2E-02 3.2E-02 1.00 1.00 0.959250 
RPLP0 H05 -3.85 -4.10 1.4E+01 1.7E+01 0.84 -1.19 0.383135 
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Appendix D: Full data for Signal Transduction PathwayFinder qPCR array (Chapter 4) 
The results above were estimated with the data analysis template provided by Qiagen  (http://www.sabiosciences.com/PCRArrayPlate.php)  
Full description of the genes are in Appendix B 
Gene Symbol Well 
Average  ΔCt 
(Ct(GOI) - Avg Ct (REF)) 
2(-ΔCt) Fold Change 
KEL / NS 
Fold Up- or 
Down- 
Regulation 
P value 
(Student’s T-
test) KELOID NORMAL KELOID NORMAL 
ACSL3 A01 2.97 3.35 1.3E-01 9.8E-02 1.30 1.30 0.216806 
ACSL4 A02 4.12 4.24 5.7E-02 5.3E-02 1.08 1.08 0.764788 
ACSL5 A03 5.48 6.30 2.2E-02 1.3E-02 1.77 1.77 0.217011 
ADM A04 5.74 4.59 1.9E-02 4.1E-02 0.45 -2.22 0.083592 
ARNT A05 7.36 7.07 6.1E-03 7.4E-03 0.82 -1.22 0.372955 
ATF4 A06 1.38 1.52 3.9E-01 3.5E-01 1.10 1.10 0.574682 
AXIN2 A07 5.11 4.50 2.9E-02 4.4E-02 0.66 -1.52 0.068553 
BAX A08 4.11 4.41 5.8E-02 4.7E-02 1.23 1.23 0.188123 
BBC3 A09 7.90 7.78 4.2E-03 4.6E-03 0.92 -1.09 0.997460 
BCL2 A10 6.57 4.93 1.1E-02 3.3E-02 0.32 -3.12 0.002738 
BCL2A1 A11 7.86 8.93 4.3E-03 2.1E-03 2.10 2.10 0.257681 
BCL2L1 A12 5.88 5.37 1.7E-02 2.4E-02 0.70 -1.43 0.046001 
BIRC3 B01 5.96 5.28 1.6E-02 2.6E-02 0.63 -1.60 0.119844 
BMP2 B02 9.20 6.86 1.7E-03 8.6E-03 0.20 -5.04 0.019109 
BMP4 B03 7.21 5.33 6.8E-03 2.5E-02 0.27 -3.67 0.010352 
BTG2 B04 7.41 7.10 5.9E-03 7.3E-03 0.81 -1.24 0.930445 
CA9 B05 9.71 8.34 1.2E-03 3.1E-03 0.39 -2.58 0.646662 
CCL5 B06 4.97 5.86 3.2E-02 1.7E-02 1.85 1.85 0.088517 
CCND1 B07 3.95 2.62 6.4E-02 1.6E-01 0.40 -2.52 0.064827 
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CCND2 B08 3.03 3.58 1.2E-01 8.4E-02 1.46 1.46 0.135709 
CDKN1A B09 2.21 2.53 2.2E-01 1.7E-01 1.25 1.25 0.554369 
CDKN1B B10 4.60 4.03 4.1E-02 6.1E-02 0.67 -1.48 0.183205 
CEBPD B11 6.28 5.17 1.3E-02 2.8E-02 0.46 -2.16 0.319870 
CPT2 B12 6.67 6.86 9.8E-03 8.6E-03 1.14 1.14 0.602308 
CSF1 C01 5.86 5.46 1.7E-02 2.3E-02 0.76 -1.32 0.088254 
DAB2 C02 5.11 5.84 2.9E-02 1.7E-02 1.66 1.66 0.168331 
EGFR C03 3.43 2.27 9.3E-02 2.1E-01 0.45 -2.23 0.009781 
EMP1 C04 0.44 0.26 7.3E-01 8.3E-01 0.88 -1.13 0.275246 
EPO C05 12.47 12.41 1.8E-04 1.8E-04 0.96 -1.04 0.505581 
FABP1 C06 12.05 11.62 2.4E-04 3.2E-04 0.74 -1.35 0.382597 
FAS C07 3.08 3.12 1.2E-01 1.2E-01 1.03 1.03 0.898058 
FCER2 C08 12.76 12.03 1.4E-04 2.4E-04 0.61 -1.65 0.413576 
FOSL1 C09 7.42 8.32 5.8E-03 3.1E-03 1.86 1.86 0.816903 
FTH1 C10 -2.06 -1.73 4.2E+00 3.3E+00 1.25 1.25 0.219272 
GADD45A C11 8.80 8.40 2.2E-03 3.0E-03 0.76 -1.31 0.689107 
GADD45B C12 3.34 4.14 9.9E-02 5.7E-02 1.74 1.74 0.064647 
GATA3 D01 8.36 6.70 3.1E-03 9.6E-03 0.32 -3.15 0.023721 
GCLC D02 4.06 3.61 6.0E-02 8.2E-02 0.73 -1.36 0.166876 
GCLM D03 5.08 5.84 3.0E-02 1.7E-02 1.70 1.70 0.139488 
GSR D04 9.20 8.16 1.7E-03 3.5E-03 0.48 -2.06 0.192992 
HERPUD1 D05 4.04 4.37 6.1E-02 4.8E-02 1.26 1.26 0.361058 
HES1 D06 4.79 4.55 3.6E-02 4.3E-02 0.85 -1.18 0.900575 
HES5 D07 9.33 7.71 1.6E-03 4.8E-03 0.33 -3.06 0.075277 
HEY1 D08 5.30 6.69 2.5E-02 9.7E-03 2.62 2.62 0.032749 
HEY2 D09 4.82 7.35 3.5E-02 6.1E-03 5.78 5.78 0.079819 
HEYL D10 9.29 9.84 1.6E-03 1.1E-03 1.47 1.47 0.203567 
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HMOX1 D11 5.06 5.25 3.0E-02 2.6E-02 1.14 1.14 0.526496 
ICAM1 D12 5.49 5.92 2.2E-02 1.6E-02 1.35 1.35 0.097339 
ID1 E01 2.44 3.95 1.8E-01 6.5E-02 2.84 2.84 0.032846 
IFNG E02 10.20 10.91 8.5E-04 5.2E-04 1.64 1.64 0.344414 
IFRD1 E03 4.56 4.55 4.2E-02 4.3E-02 0.99 -1.01 0.872188 
IRF1 E04 5.27 5.10 2.6E-02 2.9E-02 0.89 -1.12 0.562025 
JAG1 E05 1.36 0.92 3.9E-01 5.3E-01 0.74 -1.36 0.251756 
LDHA E06 0.24 0.30 8.5E-01 8.1E-01 1.05 1.05 0.766327 
LFNG E07 5.63 4.40 2.0E-02 4.7E-02 0.42 -2.35 0.120184 
LRG1 E08 6.37 6.71 1.2E-02 9.5E-03 1.27 1.27 0.867053 
MCL1 E09 0.72 0.45 6.1E-01 7.3E-01 0.83 -1.21 0.453196 
MMP7 E10 6.68 6.39 9.7E-03 1.2E-02 0.82 -1.23 0.684311 
MYC E11 1.96 1.11 2.6E-01 4.6E-01 0.55 -1.81 0.179182 
NOTCH1 E12 7.51 7.41 5.5E-03 5.9E-03 0.93 -1.08 0.847396 
NQO1 F01 5.59 5.70 2.1E-02 1.9E-02 1.08 1.08 0.631394 
OLR1 F02 11.25 12.50 4.1E-04 1.7E-04 2.37 2.37 0.171092 
PCNA F03 3.27 3.49 1.0E-01 8.9E-02 1.16 1.16 0.251301 
PPARD F04 6.29 6.11 1.3E-02 1.5E-02 0.88 -1.13 0.837181 
PTCH1 F05 11.52 10.30 3.4E-04 8.0E-04 0.43 -2.33 0.080442 
RB1 F06 3.92 3.80 6.6E-02 7.2E-02 0.92 -1.09 0.410839 
SERPINE1 F07 6.31 6.65 1.3E-02 9.9E-03 1.27 1.27 0.267068 
SLC27A4 F08 4.90 5.36 3.4E-02 2.4E-02 1.37 1.37 0.315273 
SLC2A1 F09 3.50 3.85 8.8E-02 6.9E-02 1.27 1.27 0.271907 
SOCS3 F10 5.94 6.94 1.6E-02 8.1E-03 2.01 2.01 0.327575 
SORBS1 F11 5.78 3.79 1.8E-02 7.2E-02 0.25 -3.97 0.016236 
SQSTM1 F12 2.70 2.49 1.5E-01 1.8E-01 0.86 -1.16 0.771592 
STAT1 G01 3.50 3.84 8.9E-02 7.0E-02 1.27 1.27 0.154955 
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TNF G02 8.12 9.25 3.6E-03 1.6E-03 2.20 2.20 0.576176 
TNFSF10 G03 2.84 3.31 1.4E-01 1.0E-01 1.38 1.38 0.383086 
TXN G04 0.32 -0.19 8.0E-01 1.1E+00 0.71 -1.42 0.385635 
TXNRD1 G05 4.87 4.75 3.4E-02 3.7E-02 0.92 -1.09 0.450042 
VEGFA G06 4.51 5.55 4.4E-02 2.1E-02 2.06 2.06 0.019082 
WISP1 G07 4.38 7.72 4.8E-02 4.7E-03 10.10 10.10 0.043855 
WNT1 G08 12.90 12.72 1.3E-04 1.5E-04 0.88 -1.13 0.786171 
WNT2B G09 4.91 4.12 3.3E-02 5.8E-02 0.58 -1.74 0.316136 
WNT3A G10 11.79 10.51 2.8E-04 6.8E-04 0.41 -2.42 0.333833 
WNT5A G11 5.45 7.77 2.3E-02 4.6E-03 5.00 5.00 0.107835 
WNT6 G12 11.33 10.30 3.9E-04 8.0E-04 0.49 -2.05 0.191243 
ACTB H01 -0.75 -0.63 1.7E+00 1.6E+00 1.09 1.09 0.497115 
B2M H02 -2.24 -2.69 4.7E+00 6.5E+00 0.73 -1.37 0.051859 
GAPDH H03 0.81 1.11 5.7E-01 4.6E-01 1.23 1.23 0.336504 
HPRT1 H04 4.88 4.89 3.4E-02 3.4E-02 1.01 1.01 0.979106 
RPLP0 H05 -3.45 -3.32 1.1E+01 1.0E+01 1.10 1.10 0.480909 
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